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I. Abstract 
 
Lamina-associated polypeptide 2α (LAP2α) is a mammalian nucleoplasmic protein 
implicated in cell cycle regulation through its interaction with A-type lamins and the retinoblastoma 
protein (pRb). Mutations in lamin A/C and LAP2α cause a variety of pathological human conditions, 
collectively termed laminopathies. One of the tissues most frequently affected by changes in genes 
encoding lamin A/C and LAP2α is striated muscle. To elucidate the molecular mechanisms 
underlying these severe conditions and study the role of LAP2α in striated muscle tissue, I 
analyzed the structural and functional properties of heart and skeletal muscle in complete and 
conditional tissue-specific LAP2α knockout mice.  
Similar to the human condition caused by a mutation in LAP2α, complete knockout of the 
gene impaired heart function in mice and rendered the myocardium more susceptible to fibrosis 
with advancing age. At the molecular level, loss of LAP2α caused a deregulation of major cardiac 
transcription factors GATA4 and MEF2c, as well as their tissue-specific target genes. Activation of 
compensatory pathways in LAP2α-deficient hearts resulted in downregulation of β-adrenergic 
receptor signaling and reduced responsiveness of the myocardium to chronic β-adrenergic 
stimulation, stalling the progression from cardiac hypertrophy towards heart failure. On the other 
hand, dystrophin deficiency in an Mdx background resulted in a transient rescue of the Lap2α-/- 
phenotype.  
Skeletal muscle of LAP2α-deficient mice showed no overt defects in muscle morphology, 
function and regeneration in vivo. Nevertheless, the absence of LAP2α caused an increase in the 
murine myofiber-associated muscle stem cell pool, which showed an enhanced stem cell-like 
phenotype and delayed myogenic differentiation in vitro. In addition, loss of LAP2α shifted the 
myofiber type ratios of adult slow muscles towards fast fiber types. 
Altogether, these data suggest a novel role of LAP2α in maintenance of cardiac function 
under normal and stress conditions and demonstrate a dual function of the protein in skeletal 
muscle tissue, namely in satellite cell maintenance and early myogenic differentiation, as well as 
myofiber type-specification and muscle remodeling. 
  
iii 
 
II. Zusammenfassung 
 
Lamina-assoziiertes Polypeptid 2α (LAP2α) ist ein nucleoplasmatisches Protein, welches 
spezifisch in Säugerzellen expremiert wird. Durch die Interaktion mit A-Typ Laminen und dem 
Retinoblastoma Protein ist es in die Regulation des Zellzyklus involviert. Mutationen in Lamin A/C 
und LAP2α können zu Krankheiten im Menschen führen, die Laminopathien genannt werden und 
bei welchen am häufigsten die quergestreifte Muskulatur betroffen ist. Ich habe die strukturellen 
und funktionellen Eigenschaften von Herz-und Skelettmuskulatur in kompletten sowie 
gewebsspezifisch-konditionellen LAP2α knockout Mäusen analysiert, um einen Einblick in die 
molekularen Mechanismen zu bekommen, die den Erkrankungen zu Grunde liegen. 
Das Fehlen von LAP2α in Mäusen verursachte einen ähnlichen Phenotyp, wie die Mutation 
des Genes im Menschen. Die Mäuse weisen eine verminderte Funktionalität des Herzens und eine 
erhöhte Anfälligkeit für Fibrose im Myokard im vorangeschrittenen Alter auf. Auf molekularer Ebene 
führte das Fehlen von LAP2α zu einer Deregulation der für die Herzentwicklung wichtigen 
Transkriptionsfaktoren GATA4 und MEF2c, sowie deren Zielgene. Die Aktivierung von 
Kompensationsmechanismen im Herz der Lap2α-/- Maus hatte eine verminderte Aktivität des β-
adrenergen Rezeptors zur Folge. Die dadurch herbeigeführte reduzierte β-adrenerge 
Stimulationsfähigkeit des Myokards verhinderte eine weitere Progression der Hypertrophie, welche 
andernfalls zum Versagen der Herztätigkeit geführt hätte. Andererseits führte eine Dystrophin-
Defizienz in einem genetischen “Mdx“ Hintergrund zu einer transienten Aufhebung des LAP2α-null 
Phenotyps. 
Die Morphologie, Funktion und Regeneration der Skelettmuskulatur in der Lap2α-/- Maus 
zeigte in vivo keine offensichtlichen Veränderungen. Nichtsdestotrotz führte das Fehlen von LAP2α 
zu einer erhöhten Anzahl von Muskelfaser-assoziierten Stammzellen, welche eine verzögerte 
myogene in vitro Differenzierung aufwiesen. Zusätzlich verschob sich durch die Abwesenheit von 
LAP2α das Verhältnis der unterschiedlichen Muskelfasertypen von langsamen zu schnellen 
Fasertypen. 
Zusammenfassend weisen diese Ergebnisse auf eine neue Rolle von LAP2α in der 
Erhaltung der physiologischen Funktionen des Herzens unter Stress- und Normalbedingungen hin. 
Im Weiteren zeigen die erhaltenen Daten eine weitere Funktion von LAP2α in der 
Skelettmuskulatur, speziell in der Homöostase der Satellitenzellen und der frühen myogenen 
Differenzierung, sowie in der Determinierung des Muskelfasertyps und der Muskelremodellierung. 
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1.1 The nuclear envelope 
 
 
During the course of evolution, the lipid bilayer enclosing the genetic material of eukaryotic 
cells developed into a complex membrane structure called the nuclear envelope (NE). In higher 
eukaryotes, the nuclear envelope comprises three distinct membrane domains – the outer, the 
inner and the nuclear pore membrane (Figure 1). The pore membrane contains and associates 
with protein components of nuclear pore complexes (NPCs), the channel-type structures that allow 
diffusion of small and active transport of large molecules in- and out of the nucleus. The outer 
nuclear membrane (ONM), which is linked to the rough endoplasmic reticulum and therefore often 
coated with ribosomes, contains proteins involved in positioning of the nucleus within the cell by 
mediating contacts with the cytoskeleton. The inner nuclear membrane (INM) contains a subset of 
integral and peripheral membrane proteins that interact with the adjacent nuclear lamina and are 
implicated in maintenance and dynamics of the underlying chromatin structure (reviewed in [1]). 
1.1.1 The nuclear lamina 
 
The nuclear lamina is a filamentous meshwork formed underneath the inner nuclear 
membrane of metazoan cells which, by providing mechanical stability for the nuclear envelope, 
maintains the integrity of the nucleus and supports nuclear function through the interactions with 
chromatin and numerous components of the nucleoplasm (reviewed in [2]). The major building 
blocks of the nuclear lamina are lamins – the nuclear type V intermediate filament (IF) proteins 
(reviewed in [3]). The IF family comprises numerous proteins (keratins, vimentin, desmin, synemin, 
syncoilin, peripherin, neurofilament proteins, nestin, α-internexin, glial fibrillary acid protein and 
ER
Outer nuclear
membrane
Inner nuclear
membrane
Nuclear pore
complex
Chromatin
Nuclear
Lamina
Integral NE 
proteins
Ribosomes
Figure 1. Schematic representation of a eukaryotic nucleus 
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lamins) which, despite of their different expression and localization patterns, all share a similar 
structural organization, with a ~45 nm long central α-helical rod region flanked by non-α-helical N-
terminal head and C-terminal tail domains (Figure 2) (reviewed in [1, 3, 4]). In contrast to cytoplasmic 
IF proteins, lamins have extra 42 residues in their coil 1B and a highly conserved 108 amino acid 
long C-terminal immunoglobulin fold structure3, 5. Additionally, the tail domain of lamins harbors the 
nuclear localization signal (NLS) and, in most cases, an iso-prenylation and carboxy-methylation 
motif called the CaaX-box (C, cysteine; a, aliphatic; X, any amino acid), which is modified by 
farnesylation in several sequential steps and mediates the interaction of lamins with the INM 
(reviewed in [3]). Although a precise assembly mechanism of these IF proteins is still elusive, the 
proposed models predict head-to-tail assembly of homodimers, formed by parallel alignment of 
single lamin molecules via the coiled coil-helix interactions, into protofilaments, which in turn align 
laterally to form a complex scaffold able to withstand the mechanical forces imposed upon the 
nucleus6. 
Lamin-encoding genes are absent from plant, as well as yeast cells and their evolution is 
considered to coincide with the appearance of open mitosis in animal kingdom (reviewed in [7]). 
Whereas primitive metazoans possess a single lamin polypeptide, seven lamin variants, encoded 
by 3 genes (LMNA, LMNB1 and LMNB2), have been found in vertebrate nuclei and, based on their 
biochemical properties and expression patterns, organized into two major groups named A-type 
and B-type lamins (reviewed in [8]). 
Figure 2. Lamins and cytoplasmic intermediate-filament proteins share the basic structural 
composition. 1A/B and 2A/B represent the α-helical coiled coil domains. Modified according to C.J. 
Hutchinson and H.J. Worman, Nature Cell Biology, 2004. 
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1.1.1.1 A-type lamins 
 
A-type lamins (A, A∆10, C and C2) are products of the alternatively spliced LMNA gene 
located on the human chromosome 1 q21.2-q21.3 (Chr 3 (42.6 cM) in the mouse). The LMNA 
spans 57.6 kb organized into 12 exons which encode the largest A-type variant, a 664 amino acid 
long protein named lamin A. Lamin C (572 aa) is a shorter isoform arising from the use of an 
alternative splicing site inside intron 10, which has no CaaX box, but contains 6 unique residues at 
its C-terminal end instead. The meiotic lamin C2 posesses only a short sequence of 6 aa 
substituting the complete N-terminal end and a part of the central rod domain of somatic lamins. A 
deletion of the LMNA exon 10 results in a 90 bp smaller variant named lamin A∆108-11.  
The production of the mature lamin A protein includes several posttranslational 
modifications and endoproteolytic cleavages (Figure 3)8, 12. The primary translational product of the 
lamin A mRNA, called prelamin A, bears the C-terminal CaaX box which is subject to farnesylation 
at the cysteine residue by a protein farnesyltransferase (FTase). In the second step, the -aaX 
residue is cleaved by an endopeptidase (Ras-converting enzyme (RCE1) or Zmpste24) before an 
isoprenyl carboxymethyl transferase (Icmt) places a carboxymethyl moiety onto the terminal 
cysteine. Such a product is then additionally cut by Zmpste24 15 residues upstream of the terminal 
farnesyl- and carboxymethylated cysteine to yield a mature lamin A protein, which has now lost the 
farnesyl moiety and its ability to integrate tightly into the INM8, 12.  
Although the majority of A-type lamins localizes to the nuclear periphery, a distinct portion 
of these proteins can also be found inside the nucleoplasm where it is thought to serve specific 
nuclear functions13. 
Figure 3. The maturation process of lamin A. Adapted according to A.E. Rusiñol and M.S. Sinensky, 
Journal of Cell Science, 2006. 
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The expression of A-type lamins is developmentally regulated and appears asynchronously 
in various tissues. During mouse development, their expression starts at about E9 within the 
visceral endoderm and the trophoblast14, whereas all pre-implantation stage embryonic cells, as 
well as post-natal stem cells in the immune and hematopoietic system, cells of the neuroendocrine 
system and pancreatic island cells do not express A-type lamins or do so at very low levels15. 
 
1.1.1.2 B-type lamins 
 
B-type lamins (B1, B2 and B3) are ubiquitously expressed at all developmental stages of 
an organism and the presence of at least one variant is essential for cell viability1, 16. Two B-type 
lamin genes have been described in mammalian cells: LMNB1, found on human chromosome 5 
q23.3-q31.1 (mouse Chr 18 (29.0 cM)), encoding lamin B1 and LMNB2, maped to chromosome 19 
p13.3 in human and chromosome 10 in mouse (43.0 cM), which encodes for lamin B2 and a 
smaller, male germline-specific lamin B3 variants8. All B-type lamins possess a terminal CaaX 
motif and are therefore subject to posttranslational isoprenylation8. In contrast to lamin A, B-type 
lamins do not go through the last enzymatic processing step (cleavage of the C-terminal 15 aa 
long peptide) and remain stably farnesylated. This permanent farnesylation of B-type lamins 
enables their association with the INM and restricts their subcellular localization to the nuclear 
periphery8. 
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1.1.2 The lamin interactome 
 
Lamins are not merely structural components of the nuclear lamina mechanically stabilizing 
the nucleus. Through the constantly growing number of interaction partners, they are implicated in 
various cellular processes, such as large scale chromatin organization, positioning of the nucleus, 
spacing of the nuclear pore complexes, nuclear reassembly after mitosis, DNA replication, RNA 
polymerase II-dependent gene expression and cell cycle control17.  
The LEM-domain protein family represents a major group of lamin-interacting factors. The 
LEM-domain (LAP2, Emerin, MAN1) is a structural motif of approximately 40 amino acids 
organized into two loop-connected parallel α-helices, which defines a growing family of unrelated 
nucleoplasmic and inner nuclear membrane-associated proteins, including several lamina-
associated polypeptide (LAP2) isoforms, emerin, MAN1, LEM2/5, ANKLE1/2, as well as 
Drosophila-specific proteins otefin and Bocksbeutelα/β (Figure 4)18. The special characteristic of 
the LEM-domain is the ability to bind a chromatin-associated protein conserved in multicellular 
organisms from flies to human called barrier-to-autointegration factor (BAF), which has been shown 
to cross-link double stranded DNA and function as a transcriptional co-repressor 18, 19. 
LL LEM
LL LEM
LL LEM
LL LEM
LL LEM
LL LEMLAP2α
LAP2β
LAP2ε
LAP2δ
LAP2γ
LAP2ζ
ANK LEMANKLE1
LEM ANKANKLE2
LEMEmerin
RRMLEMMAN1
LEMLEM2
LEMLEMD1
LEM
LEM
ANK LEMCe-Lem3
Ce-LEM2
Ce-emerin
LEM
LEM
LEM
otefin
Bocksbeutel-α
Bocksbeutel-β
Figure 4. Schematic diagram of the LEM-domain protein family. LEM – LEM-motif, LL – LEM-like motif, 
ANK – ankyrin repeats, RRM – RNA recognition motif. The α-specific region of LAP2α is depicted in violet, 
the common C-terminal LAP2 domains in shades of green and white, and the transmembrane regions of all 
proteins in dotted-black. 
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The LAP2 protein family comprises six alternatively spliced products of the LAP2 gene 
designated LAP2α, β, γ, δ, ε, and ζ20. All isoforms, except LAP2α and LAP2ζ, are inner nuclear 
membrane proteins characterized by the highly conserved 186 residues long N-terminal region 
which contains two globular chromatin-binding motifs – the BAF-interacting LEM and the DNA-
associated LEM-like domain21. The C-terminal tails of nearly all LAP2 members are closely related 
and, in addition to the transmembrane sequence, contain a lamin B-binding region21. With its 693 
amino acids, LAP2α represents the largest and the most distantly related nucleoplasmic LAP2 
isoform which, instead of the membrane spanning domain, possesses a unique C-terminal 
chromatin-interacting segment and therefore differs from the other members in terms of 
expression, cellular localization, binding preference and supposed functions21-23. The high 
resolution structure of full length LAP2α has not been resolved yet. Although its N-terminal 
constant region seems to be monomeric, some studies predict a preference for the formation of 
full-length protein oligomers24, 25. The α-specific C-terminal tail, organized into 6 helices, has been 
shown to dimerize and thereby form an unusual structure with a central four-stranded coiled-coil, 
representing a previously unseen polypeptide fold (Figure 5)25. 
Figure 5. The structure of LAP2α C-terminal domain dimer. The central four-stranded coiled-coil of the 
dimer is formed by monomer helices (A-F) shown in orange and green. Modified according to C.M. Bradley 
et al., Structure, 2007. 
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So far, LAP2α has been found only in mammalian cells, whereas other isoforms exist also 
in other vertebrate classes26, 27. Together with the β-isoform, LAP2α is predominantly expressed in 
highly proliferating tissues and growing cultures, while LAP2γ seems to be up-regulated only in 
differentiating tissues28. Biological functions and expression patterns of smaller LAP2 isoforms are 
still largely unknown. In contrast to other LAP2 members which interact with both types of lamins, 
LAP2α preferentially binds to the nucleoplasmic pool of lamin A/C via its specific C-terminal tail – 
the residues 616-693 of LAP2α interact specifically with lamin A/C tail residues 319-57222. The 
complex of LAP2α/lamin A/C has been shown to bind the major cell cycle regulator and 
differentiation factor – the retinoblastoma protein (pRb) in its active, hypophosphorylated form and 
thus regulate cell cycle progression and differentiation in an E2F/pRb-dependent manner29-31. 
LAP2α complexes might even be directly acting on transcription of E2F target-genes, since they 
have been found associated with promoters of endogenous E2F/pRb-responsive sequences30. In 
addition, targeting of pRb for proteosomal degradation in LMNA knockout fibroblasts implies a role 
of LAP2α/lamin A/C complexes in nuclear anchorage and preservation of pRb stability31. Recently, 
LAP2α has been found to control the balance between proliferation and differentiation of transient 
amplifier cells during skin and hematopoietic tissue homeostasis by affecting pRb stability32. 
Other potential roles of LAP2α derive from studies on retroviral life cycle, where it was 
found essential for retroviral DNA integration into the host genome, as a cellular component of 
retroviral preintegration complexes, and replication of the Moloney murine leukemia virus 
(MMLV)33. However, the exact molecular mechanisms of these processes still remain unclear. Heat 
shock proteins Hsp70 and Hsc70 have also been found associated with LAP2α in vivo, suggesting 
a role of the protein in stress resistance34. As Hsp70 is thought to regulate the enzymatic activities 
of DNA base excision repair in human cells35 and its loss leads to increased genomic instability in 
mouse36, LAP2α might also be involved in DNA damage response. 
LAP2β is a 451 residues long integral membrane protein that preferentially binds lamins at 
the nuclear periphery and is involved in the regulation of transcription37. It associates with germ 
cell-less (GCL), a factor that takes away the DP3 subunit from the DP3-E2F complexes and 
therefore represses E2F-mediated transcription38. Previous studies have introduced the possibility 
of a more general function of LAP2β in transcriptional repression of various members of the E2F 
protein family, as well as signaling pathways like p53 and NFK-κB. What is more, its repressive 
activity seems to be regulated through the intraction with HDAC3 (class I histone deacethylase)39. 
Overexpression of LAP2β induces deacethylation of histone H4 in vivo and in vitro, supporting the 
idea that membrane-anchored LEM proteins might directly be involved in large scale chromatin 
organization and transcriptional regulation at the nuclear periphery (reviewed in [18]). Interestingly, 
GCL knock out mice, although viable, exhibit nuclear abnormalities in various tissues and impaired 
sperm development40, supporting the link between nuclear stability and regulation of gene 
expression. LAP2β also associates with the chromatin protein HA95 and thus contributes to the 
initiation of DNA replication by stabilizing cell-division-cycle protein-6 (cdc6), an important 
component of pre-replication complexes41.  
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LAP2ζ, with its 224 residues, represents the smallest member of the LAP2 family. In 
contrast to the other isoforms, it lacks the membrane spanning domain as well as the nuclear 
localization signal, and is therefore predominantly found in the cytoplasm20, 42. A recent study 
showed that LAP2ζ, in excess, is able to relieve the chromatin of BAF-mediated repression by 
binding BAF and retaining this mainly nuclear protein in the cytoplasm. In addition, co-expression 
of LAP2ζ with either LAP2β or HDAC3 resulted in suppression of the inhibitory activity of the later 
two factors, which lead to the conclusion that LAP2ζ might present a transcriptional regulator, 
exerting its function through inhibition of BAF- and LAP2β-mediated gene silencing42. 
MAN1 is a ubiquitously expressed inner nuclear membrane-associated LEM-domain 
protein that interacts with both types of lamins43. In addition to the N-terminal LEM sequence, it 
possesses a C-terminal tail with two membrane-spanning domains and a RNA recognition motif 
(RRM), which directly binds to receptor-regulated Smads (R-Smad) and, by anchoring them at the 
nuclear periphery, inhibits the downstream path of the bone morphogenic protein (BMP)-induced 
signaling18. Overexpression of MAN1 was also shown to decrease receptor-mediated 
phosphorylation and oligomerization of the R-Smads, as well as influence the BMP and TGFβ 
signaling pathway in Xenopus development44, 45. The support for the MAN1-Smad interaction 
hypothesis came with the analysis of MAN1∆/∆ mice that lack the C-terminal Smad-reacting 
domain46. The homozygous embryos died during development due to defects in TGF-β-dependent 
vascular remodeling. According to the predicted model the upregulation of R-Smad2/3 signaling in 
MAN1∆/∆ mice could have caused an increase in deposition of extracellular matrix, which in turn 
could have lead to impaired migration of endothelial cells during angiogenesis46. 
Another member of the LEM-domain protein family is a small (254 aa), ubiquitously 
expressed integral membrane protein called emerin47. It was first discovered as a product of the 
human EMD gene mutated in Emery-Dreifuss muscular dystrophy47. Both emerin and MAN1 
interact in vitro with several gene expression regulators, including GCL, BAF, as well as the 
apoptosis-promoting factor Btf, and probably have some overlapping functions48. In addition, 
emerin has been implicated in the regulation of the Wnt signaling49, which controls various cellular 
processes such as proliferation, differentiation and apoptosis50. One of the Wnt signaling 
mediators, β-catenin, accumulates at adherens junctions and, upon activation of the Wnt cascade, 
transiently localizes to the nucleus to influence target gene expression50. Emerin has been shown 
to bind β-catenin and, by tethering it to the nuclear periphery or promoting its nuclear export, inhibit 
its transcriptional activity49. The retention of emerin at the nuclear periphery depends on the 
presence of either lamin A or C. While LMNA knockout cells show its re-localization to the 
endoplasmatic reticulum (ER)51, lamin C-only cells and Lmna-/- cells ectopically expressing lamin A 
exhibit normal emerin distribution at the NE52, 53. This interaction indirectly involves lamins in the 
regulation of Wnt-mediated gene expression.  
In addition, emerin was implicated in the regulation of actin dynamics by capping the 
pointed ends and stabilizing the polymeric filamentous F-actin in vitro54. It was also found in 
complexes with a specific nuclear form of αII-spectrin, a filamentous protein that binds to F-actin54. 
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Despite the growing group of interaction partners and proposed functions, the physiological role of 
emerin and mechanistic details of its molecular interactions remain to be elucidated. 
Lamin A and emerin have been found to associate with nuclear isoforms of the nesprin 
family, which comprises multiple alternatively spliced products of the human SYNE1 and SYNE2 
genes55. Members of this protein family contain a spectrin-repeat rod domain linked to a C-terminal 
transmembrane KASH (Klarsicht-ANC-Syne-Homology) sequence, which mediates nuclear 
membrane localization, and/or N-terminal paired calponin-homology region that binds actin56. 
Nesprins are found in multiple sub-cellular compartments, such as the INM, ONM, mitochondria, 
Golgi apparatus, sarcoplasmic reticulum, muscle sarcomere and the plasma membrane, where 
they form networks which link these structures to the actin cytoskeleton56. The localization of 
specific, INM-bound isoforms like Nesprin 1α is dependent on their binding to lamin A55. Nesprins 
in the ONM interact with the SUN (Sad1/UNC-84 homology)-domain containing proteins (UNC-84, 
UNC-83, Ce-matefin) in the perinuclear space. These Nesprin-SUN-domain protein complexes, 
also called LINC complexes, bridge the luminal space between the INM and ONM and 
mechanically connect microtubules, actin and cytoplasmic intermediate filaments with the nuclear 
lamina, providing a structural link between the cytoskeleton and nucleoskeleton57. 
Lamin A and C have been found to bind and sequester cFos, a component of the AP1 
complex that regulates transcription, differentiation, apoptosis and cell cycle progression in 
mammalian cells, and therefore inhibit its activity58. Constituents of the AP1 complex – cFos and 
Jun – are able to form heterodimers with unrelated DNA binding proteins like NFAT, Smads and 
bHLH transcription factors59, thereby implicating lamins in the control of gene expression. 
The immature form of lamin A – the pre-lamin A – has been shown to bind the adipocyte-
specific transcription factor SREBP1 and, through its sequestration at the nuclear periphery, inhibit 
adipogenesis by preventing SREBP1-mediated activation of the peroxisome proliferator activator 
receptor gamma (PPARγ)60. 
Through their association with a range of nuclear bodies61, as well as a constantly growing 
cohort of interaction partners such as LAP1, histon H2A or H2B dimers, monomeric actin, MOK2 
and DNA, A-type lamins can be connected to almost all nuclear processes within a eukaryotic 
cell17, 26. 
One of the most prominent B-type lamin binding partners is the lamin B receptor (LBR), an 
integral membrane protein which also links lamins to organization of peripheral chromatin62. LBR 
interacts with double stranded DNA (in vitro), histone H3-H4 tetramers, chromatin associated 
protein HA95 and heterochromatin protein-1 (HP1), shown to bind the epigenetic mark of silent 
genes (unmethylated histone 3 at lysine 9)63. Mutations in LBR cause an autosomal dominant 
phenotype called Pelger-Huët anomaly, characterized by abnormal chromatin organization and 
decreased lobulation of white-blood-cell nuclei64, providing further support for its role in chromatin 
organization. The membrane-embedded domain of LBR has a special sterol-reductase activity. A 
mutation affecting this region of LBR has also been linked to a severe human condition with 
impaired cholesterol biosynthesis called the Greenberg skeletal dysplasia65. However, the exact 
role of this enzyme activity and its relation to chromatin structure regulation remains unclear. Mice 
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with mutations in Lbr gene, called the ichtyosis locus, develop alopecia, variable syndactyly, 
hydrocephalus and abnormal granulocyte nuclear morphology66, emphasizing the significance of 
this factor for normal mammalian cell function. 
Lamin B1 in somatic cells binds the POU domain repressor protein Oct-1 which regulates 
the expression of collagenase genes67, 68, implicating B-type lamins in the maintenance of 
extracellular matrix. Interestingly, MAN1, which also binds B-type lamins, was first identified by 
autoantibodies from a patient with collagen vascular disease43.  
Although the lamin interactome is extensive and intensively studied, the molecular details 
and physiological relevance of these networks remain to be discovered. 
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1.2 NE breakdown – mitosis time 
 
In contrast to single-cell eukaryotes like S. cerevisiae whose nuclei retain their integrity 
during mitosis, the complex nuclear envelope of higher eukaryotes has to disassemble between 
prophase and prometaphase stages of the cell cycle to allow engagement of chromosomes with 
the cytoplasmic mitotic spindle (reviewed in [7]). In the process of opened mitosis, the NE 
breakdown is triggered by Polo-like kinase 1 (Plk1)-mediated phosphorylation of the G2-phase 
specific cyclin B1 (reviewed in [69]). Together with its binding partner Cdk1, Cyclin B1 forms the so 
called mitosis promoting factor (MPF), which shuttles between the nucleus and the cytoplasm 
during the G2 phase of the cell cycle. Phosphorylation of cyclin B causes the accumulation of MPF 
inside of the nucleus and enables the Cdk1 component to trigger phosphorylation of nucleoporins, 
lamins, integral INM proteins, as well as many other nuclear proteins, finally resulting in NE 
disassembly (reviewed in [7]). 
In vertebrate cells, two specific serine residues (S22 and S392), which symmetrically flank 
the lamin rod domain, serve as substrates for a variety of protein kinases like PKC, PKA, MAPK 
and casein kinase II in the process of filament breakdown70, 71. LAP2α has up to seven serines 
clustered in its chromatin binding region, whose phosphorylation is necessary for dissociation of 
the protein from the chromatin during mitosis72. Binding of LAP2β to lamins and/or chromatin is 
also regulated by its phosphorylation by Cdk173.  
Phosphorylated nucleoporins leave the NPCs early in mitosis. Subsequently, a subset of 
them associates with kinetochores forming holes in the NE and leading to the loss of NE barrier 
function. The phosphorylated lamin filaments and NE membranes are subsequently transported on 
spindle microtubules towards the centrosomes by dynein motors. In mammalian cells, A-type 
lamins dissociate from the nuclear lamina at early prophase, whereas B-type lamins do so only 
later. Following its dissociation from chromatin, the NE becomes completely disassembled and, 
according to the current models, its membranes either form special vesicles that are reused at the 
end of mitosis for reassembly, or fuse with the ER network (reviewed in [7]). 
During final stages of mitosis, the NE reassembles around the segregated chromosomes in 
a highly regulated temporal fashion to form new daughter nuclei. Individual nucleoskeletal proteins 
initially targeted to the chromosomal surface attract the membranes, which fuse before the NPCs 
are able to assemble. The newly formed NPCs paw the way for import of lamins and the full 
reassembly of the nuclear lamina (reviewed in [7]). In the process of NE-reassembly, LAP2α and 
BAF initially accumulate at chromosomal telomeric regions during anaphase and form the, so 
called, core structures adjacent to the spindle pole and mid-spindle area74. Since these two 
proteins have been found to co-localize with the telomeric protein TRF2 at core structures, it was 
suggested that LAP2α might transiently serve to anchor telomeres to defined stable regions in the 
reforming nuclei74. Slightly after LAP2α and BAF, other proteins like emerin, LAP2β and a sub-
fraction of lamin C, are targeted to the core regions (reviewed in [7]). LBR, in contrast, is initially 
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detectable at more peripheral chromatin regions indicating a different type of interaction with the 
chromatin75.  
B-type lamins can be detected on chromosomes shortly after LAP2β and, as they stay 
associated with the membranes during the NE breakdown, they could initially be targeted to 
chromosomes together with membrane structures. However, their assembly into a stable lamina 
occurs in subsequent stages at the inner surface of the newly formed membrane (reviewed in [7]). 
In contrast, A-type lamins are transported through the NPCs and redistribute inside the nucleus 
during telophase/G1 transition74. Consistent with this idea, inhibition of B-type lamin polymerization 
at the end of mitosis does not interfere with the assembly of A-type lamins. At early G1 phase the 
intact NE again fully encloses the chromatin which becomes decondensed during the nuclear 
growth (reviewed in [7]). 
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1.3 The nuclear envelope from a medical point of view 
 
Mutations in genes encoding nuclear envelope proteins cause a group of pathological 
conditions in human called the nuclear envelopathies. At present, disease-causing mutations have 
been reported for 14 genes: EDM (STA), LMNA, LMNB1, LMNB2, FACE-1 (ZMPSTE24), LBR, 
MAN1, LAP2, AAAS, TOR1A, LIS1, SYNE1, SYNE2 and NUP155 (Figure 6) (reviewed in [76-78]). 
Although symptoms caused by changes in proteins encoded by these genes vary greatly in 
severity and tissue type affected, many of them include nuclear dismorphology, as well as 
alteration in chromatin organization and gene expression. 
Lamin A/C
Tissue specific:
• muscle – EDMD, LGMD, 
L-CMD, DCM-CD, HSS-S
• nerve – AR & AD CMT2
• fat – FPLD, POS
Systemic:
• MAD, AWS, HGPS, LILLRC,
RD, LFA 
Nesprin-1 & 2
EDMD, Cerebellar 
ataxia
NUP155
AF
Figure 6. Schematic diagram of the nuclear envelope including pathological conditions caused by 
mutations in NE-associated proteins. RD – restrictive dermopathy; HGPS – Hutchinson-Gilford progeria 
syndrome; PHA – Pelger-Huët anomaly; EDMD – Emery-Dreifuss muscular dystrophy; ADLD – adult-onset 
autosomal dominant leukodystrophy; LGMD – limb girdle muscular dystrophy; DCM-DC – dilated 
cardiomyopathy with conduction system disease; CMT – Charcot-Marie-Tooth disorder; FPLD – familial 
partial lipodystrophy; MAD – mandibuloacral dysplasia; AWS – atypical Werner syndrome; POS – polycystic 
ovary syndrome; LFA – lethal foetal akinesia; L-CMD – lamin-associated congenital muscular dystrophy; 
HSS-S – heart-hand syndrome of Slovenian type; LILLRC - LIRLLC syndrome; AR – autosomal dominant; 
AD autosomal recessive; PLD – partial lipodystrophy; AAA – achalasia-addisonianism-alacrima; AF – atrial 
fibrillation. Modified according to H.J. Worman and G. Bonne, Experimental Cell Research, 2007. 
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1.3.1 Laminopathies 
 
With more than 250 mutations reported so far, LMNA is the most frequently altered 
member of the nuclear envelope protein-encoding gene group linked to a disease (reviewed in [76]). 
Diseases caused by changes in lamin A/C protein or Zmpste24, one of the enzymes involved in 
lamin maturation, form a major subclass of envelopathies named laminopathies. Specific tissues 
selectively affected in primary laminopathies (caused by mutations in LMNA) include striated 
muscle, peripheral nerves and adipose tissue. Premature ageing syndromes and their related 
disorders, characterized by defects in multiple tissues, are classified as systemic laminopathies, 
although an increasing number of published LMNA-linked conditions with mixed symptoms 
suggests an overlapping continuum within different types of laminopathies (reviewed in [8]). 
Figure 7. LMNA disease-causing mutations are spread along lamin A/C molecules. Dominant and 
recessive disorders are depicted on top and bottom of the scheme respectively. Numbers in parentheses in 
black indicate numbers of reported affected individuals carrying the specific mutation. Adapted according to 
H.J. Worman and G. Bonne, Experimental Cell Research, 2007.  
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1.3.1.1 Striated muscle laminopathies 
 
LMNA mutations linked to striated muscle disorders are spread along the gene with no firm 
relation between the pathological phenotype, the type, and/or the localization of the mutation 
(Figure 7) (reviewed in [79]). Striated muscle defects account for ~60-70% of laminopathies and, 
according to their symptoms, fall into 5 distinct categories: 
 
1.3.1.1.1 Limb-girdle muscular dystrophy type 1B (LGMD1B) 
 
LGMD presents a clinically and genetically heterogeneous group of muscular disorders 
inherited in a dominant (LGMD1) or recessive (LGMD2) manner, which are characterized by slowly 
progressive weakness and wasting of the pelvic girdle. Additional age-related atrioventricular 
cardiac conduction disturbances and dilated cardiomyopathy distinguish a special subgroup of 
these disorders caused by mutations in LMNA, classified as LGMD1B80, 81.  
 
1.3.1.1.2 Emery-Dreifuss muscular dystrophy 
 
EDMD is a rare pathological striated muscle condition characterized by early contractures 
of elbows, Achilles tendons and postcervical muscles, slowly progressive muscle weakness and 
wasting, initiating in the humeroperoneal region, as well as life-threatening cardiomyopathy with 
conduction blocks. It is linked to mutations in two genes: a) emerin-encoding EMD, which is passed 
on in an X-linked (XL-EDMD) fashion and b) LMNA inherited as autosomal dominant (AD-EDMD) 
or autosomal recessive (AR-EDMD) trait47, 82. 
 
1.3.1.1.3 Congenital muscular dystrophy (L-CMD) 
 
Congenital muscular dystrophies are genetic myopathies specified by dystrophic features 
on muscle biopsy, as well as hypotonia, weakness, or delayed motor development from the first 
few months of life83. Mutations in 12 different genes and 2 loci have been associated with the 
currently recognized nine clinical subtypes of CMD84. Congenital muscular dystrophies share some 
symptoms with EDMD, such as spinal rigidity, hyperCKemia and contractures of elbows and 
Achilles tendons. However, the main feature of LMNA-related CMD (L-CMD) – the selective deficit 
of head support or axial muscle weakness – is not present in EDMD. Cardiac involvement in L-
CMD is rarely observed, probably owing to the young age of most of the diagnosed patients. L-
CMD presents a severe end of the spectrum of striated muscle laminopathies, as it develops within 
1-18 Introduction 
the first year of life, in contrast to EDMD and LGMD1B, which have a later onset between mid-
childhood and adulthood respectively84. 
 
1.3.1.1.4 Dilated cardiomyopathy with conduction system disease (DCM-CD) 
 
Cardiac dilation and reduced systolic function are the two major characteristics of the 
largely heterogeneous group of inherited and acquired disorders classified as dilated 
cardiomyopathy (DCM). Among more than 20 candidates, LMNA and β-myosin heavy chain gene 
are the two most frequently mutated genes linked to the familial form of DCM (reviewed in [79]). 
Patients carrying a LMNA mutation are presented with the worst prognosis of all DCM cases and 
are at greater risk of sudden death.  
A recent study identified new DCM-mutational hot spots in LMNA, affecting the lamin A/C 
coil 1B which is important for protein dimerization and interaction with lamin B85. Another potential 
explanation of the disease mechanism came from studies on posttranslational modifications of 
lamin A/C, which showed that DCM-linked mutations could affect sumoylation of lamin A at the 
residue K 201 and thus cause its abnormal nuclear localization86. Interestingly, a mutation in 
LAP2α (c. 2068C>T, p. R690C), which lowers the in vitro binding affinity of the protein to lamin 
A/C, has also been linked to dilated cardiomyopathy28, emphasizing the role of lamins and their 
interaction partners in development and/or maintenance of striated muscle tissue. 
 
1.3.1.1.5 Heart-hand syndrome of Slovenian type (HHS-S) 
 
HHS is a clinically and genetically diverse disorder characterized by the co-occurrence of 
cardiac disease and limb malformations87. Recently, a new type of HSS was reported in a 
Slovenian family which presented a late onset progressive sinoatrial and atrioventricular conduction 
disease, tachyarrhythmias with high yield of sudden death, DCM and brachydactyly88. Upon 
exclusion of gene-perturbing changes in several known disease-causing candidates, such as 
TBX5, TBX3, ROR2 and SCN5A, the study identified a new variant of LMNA intron 9 was 
identified89. This novel mutation (c. 1609-12 or IVS9-12, T>G) predicts an additional acceptor splice 
site, 11 nucleotides upstream of the wild type site, and introduces a frame shift in the LMNA 
mRNA, which leads to the premature termination and potential production of a truncated, 550 
residues long, protein with a unique 14 aa long C-terminus. Analysis of cultured patient skin 
fibroblasts showed aberrant localization of lamin A/C and dysmorphic nuclei, which can be found in 
most of the LMNA-linked striated muscle conditions89. 
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1.3.1.2 Partial lipodystrophies and related syndromes  
 
In contrast to LMNA-linked striated muscle disorders, adipose tissue laminopathies are 
mainly linked to a specific site in the lamin A/C gene – the R482 codon90. Familial partial 
lipodystrophy of Dunnigan type (FPLD) is a rare condition characterized by a selective loss of 
adipose tissue. Patients with FPLD have normal fat distribution until the onset of puberty, when 
almost all subcutaneous adipose tissue from lower and upper extremities, as well as gluteal and 
truncal region disappears, and starts accumulating in the face and neck. Metabolic complications 
increase with the extent of fat loss and include insulin resistance, diabetes mellitus, 
hypertriglyceridemia and liver steatosis. The molecular pathway of this disease is predicted to 
involve accumulation pre-lamin A and its aberrant interaction with the adipose tissue-specific factor 
SREBP1 (reviewed in [79]). 
A case of A-type insulin resistance syndrome including polycystic ovary syndrome with severe 
hyperandrogenism, acanthosis nigricans and marked insulin resistance was also linked to a 
mutation in LMNA (G602S). Skin fibroblasts of affected patients exhibited abnormalities of nuclear 
shape and several defects in the insulin transduction pathway91.  
 
1.3.1.3 Peripheral nerve disorders 
 
1.3.1.3.1 Autosomal recessive Charcot-Marie-Tooth type 2 (AR-CMT2, CMTB1) 
 
CMT disorder comprises a clinically and genetically heterogeneous group of hereditary 
motor and sensory neuropathies. According to electrophysiological criteria, CMT patients are 
divided in two major classes. Demyelinating forms of CMT, characterized by a motor median nerve 
conduction velocity <38 m/s constitute the type 1 and the axonal form, with a normal or slightly 
reduced nerve conduction velocity, the type 2 disorder. A unique homozygous LMNA mutation 
(R298C) was found to cause the CMT2B1 in a large Moroccan family. The main clinical 
symptomsin thios case included early onset symmetrical muscle weakness and wasting of distal 
lower limbs, foot deformities and walking difficulties associated with reduced or absent tendon 
reflexes. Interestingly, mice lacking lamin A/C present an axonal clinical and pathological 
phenotype highly similar to patient symptoms (reviewed in [79]). 
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1.3.1.3.2 Autosomal dominant axonal Charcot-Marie-Tooth disease (AD-CMT2) 
 
LMNA has also been implicated in the development of autosomal dominant CMT disorder 
associated with muscular dystrophy, cardiac disease and leukonychia in one, as well as both – 
cardiac disease and partial lipodystrophy in two other families92. 
 
1.3.1.4 Premature ageing syndromes 
 
1.3.1.4.1 Mandibuloacral dysplasia (MAD) 
 
MAD is a rare autosomal recessive disorder characterized by postnatal growth retardation, 
mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, joint 
contractures, lipodystrophy and mottled cutaneous pigmentation. Currently, two mutations in LMNA 
(R527H93 and A529V94) and one in its functionally-associated gene FACE-195,encoding a lamin A 
processing enzyme, have been found to cause this devastating human condition. 
 
1.3.1.4.2 Hutchinson – Gilford progeria syndrome (HGPS) 
 
HGPS, a rare fatal genetic disorder characterized by accelated aging in children, has been 
linked to 8 different LMNA mutations. The most common one represents a single base substitution 
(c. 1824C>T) in the LMNA exon 11, resulting in the activation of a cryptic splice site and an in-
frame deletion of 50 amino acids from the C-terminal tail of the prelamin A. The aberrant lamin A 
variant called progerin can not be cut during the process of protein maturation, as it lacks the 
endoproteolytic cleavage site, and therefore remains farnesylated at its Caax box. HGPS skin 
fibroblasts and lymphoblasts show nuclear abnormalities, including altered size and shape, NE 
interruptions accompanied by chromatin extrusions, as well as defects in heterochromatin 
organization, genome stability and DNA repair (reviewed in [79]). 
 
1.3.1.4.3 Atypical Werner syndrome 
 
The clinical symptoms of Werner syndrome (WS) include premature appearance of 
features associated with normal aging as well as higher cancer predisposition. In the case of the 
typical WS, disease causing mutations are found in the DNA helicase-like gene (RECQL2), 
whereas the atypical WS arises from perturbing changes in the lamin A/C gene. Just like in other 
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laminopathy disorders, patient fibroblasts demonstrate altered nuclear morphology and lamin 
mislocalization (reviewed in [8]).  
 
1.3.1.5  Restrictive dermopathy (RD) 
 
A rare tight skin syndrome with neonatal lethal course within the first week of life, also 
known as RD, was found to develop due to mutations leading to a complete or partial in-frame loss 
of LMNA exon 11, as well as a unique mutation in the FACE-196. 
 
1.3.1.6 Lethal foetal akinesia 
 
A homozygous LMNA nonsense mutation (Y259X) was found to underlie a lethal foetal 
phenotype characterized by dysmaturity, facial dsymorphism with retrognathia, severe contractures 
of fingers and toes, long bone fractures, as well as generalized muscular dystrophy with almost 
complete absence of fibers in intercostal muscles. Patient skin fibroblasts showed nuclear 
abnormalities such as blebbing and protrusion of DNA into the cytoplasm, local absence of lamin B 
and NPCs, as well as a reduced level of emerin staining at the NE92. 
 
1.3.1.7 LIRLLC syndrome 
 
Generalized lipoatrophy, insulin-resistant diabetes, leukomelanodermic papules, liver 
steatosis and hypertrophic cardiomyopathy, known as the LIRLLC syndrome, were found to co-
segregate with the R113L mutation in the LMNA affecting the rod domain of lamin A/C protein, and 
cause nuclear abnormalities in primary patient fibroblast cultures97. 
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1.4 Modeling human laminopathies – lessons learned from mice 
 
In an attempt to disclose the molecular mechanisms underlying human laminopathies, 
several mouse lines bearing Lmna disease-specific gene alterations have been generated, giving 
an invaluable insight into lamin-dependent nuclear processes. 
 
1.4.1 Lmna-/- mouse 
 
While there is still no report of human patients completely lacking lamin A/C protein and a 
homozygous nonsense mutation that introduced a premature stop codon in LMNA caused prenatal 
lethality98, Lmna-/- mice are able to survive until the age of 6-7 weeks51. These animals appear 
normal at birth but stop thriving after 2-3 weeks of age when clinical and histological signs of 
muscular dystrophy begin to appear. By the age of 4-6 weeks Lmna-/- mice developed DCM-DC 
which largely contributed to their early mortality51, 99. Nikolova et al. (2004)99 found Lmna-/- mouse 
heart size to be similar to the wild type but the left ventricle (LV) remained thin-walled, globular-
shaped and dilated, indicating that the severe functional defect, characterized by global reduction 
in LV contraction, was not accompanied by compensatory myocardial hypertrophy. In support of 
this finding, Northern blot analyses showed appropriate increases in LV expression of ANP and 
BNP, the factors usually upregulated during pathological heart conditions, whereas levels of α-
skeletal actin and β-myosin heavy chain, involved in myocardial remodeling, remained unaltered. 
The isolated lamin A/C deficient cardiomyocytes were relatively short and thin, had reduced 
sarcomere length and exhibited contractile dysfunction. Although there was no obvious apoptosis 
at 2 weeks of age, myocardial tissue sections from 4-6 weeks old Lmna-/- hearts showed focal 
myocyte degeneration with destabilization of the nuclear lamina and the concomitant nuclear 
deformability. Electron microscopy revealed discernible disorganization of desmin filaments in 
Lmna-/- cardiomyocytes, as well as dilation of the nuclear envelope luminal space with distortion of 
nuclear pores. The perinuclear space was increased, with regions in which the nucleus and the 
adjacent cytoskeleton appeared completely disconnected. The nuclear morphological defects in 
Lmna-/- cardiomyocytes at 4-6 week of age were accompanied by an impaired translocation of the 
cleaved, active form of lamin A/C binding partner SREBP1 into the nucleus, and the consecutive 
reduction of its downstream target PPARγ, both of which play an important role in regulation of 
cholesterol and fatty acid synthesis in adipose tissue. Although defective lamin A/C-SREBP1 
interaction has been postulated as a possible mechanism in the development of familial 
lipodystrophy, this probably does not represent the primary mechanism of lamin A/C-linked DCM99. 
The reductions in intranuclear SREBP1 and PPARγ in Lmna-/- mice are more likely caused by 
acquired defects in nuclear pore transport in LV myocytes. The extranuclear accumulation of 
SREBP1 in the heart might cause defects in myocardial energetics and exacerbate the LV 
contractile dysfunction99 . 
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The causative connections to skeletal muscle dystrophy of Lmna-/- mice are still unclear, as 
in vivo muscle regeneration after cardiotoxin treatment, as well as in vitro primary myoblast 
differentiation appears normal100. In contrast, immortalized Lmna-/- myoblasts showed impaired 
differentiation, presumably due to downregulation of the major myogenic determinant MyoD and its 
targets, such as the muscle-specific intermediate filament desmin101. As a consequence, the 
immortalized Lmna-/- myoblasts upregulated another myogenic factor named Myf5, which can 
partially compensate for the loss of MyoD102. 
pRb plays a role in early steps of muscle differentiation possibly by preventing MyoD 
inactivation through HDAC1-mediated deacethylation103, which also puts lamin A/C (the regulator 
of pRb stability and function31) into the context of muscle differentiation. Interestingly, protein levels 
of pRb are also affected in Lmna-/- myoblasts, pointing to a reduction of its stability, as described in 
Lmna-/- fibroblasts104.  
Interestingly, neurons of the sciatic nerve in Lmna-/- mice show extensive demyelination, 
suggesting that their muscular dystrophy phenotype could also be a consequence of neuronal 
degeneration and the subsequent loss of muscle innervation105. However, according to the recent 
study by Mejat et al. (2009), the primary cause of muscle innervation defects in AD-EDMD mouse 
models might be a destabilization of neuromuscular junctions due to mislocalization of lamin A/C 
and their NE-associated interacting proteins106. 
Another feature of Lmna-/- mice is the disrupted spermatogenesis characterized by 
apoptosis of pachytene stage spermatocytes, due to a failure in prophase I progression and 
defective sex chromosome pairing, presumably caused by the lack of the meiosis specific lamin C2 
variant107. 
 
1.4.2 LmnaH222P/H222P mouse 
 
A missense mutation (histidine-to-proline substitution at amino acid 222), originally 
identified in a family with AD-EDMD, was introduced into the mouse Lmna gene to study the effects 
of muscle disease-causing mutations on lamin A/C protein function108. Although indistinguishable 
from their WT siblings at birth, male LmnaH222P/H222P mice stopped thriving at the age of 3 months, 
exhibited reduced locomotion with abnormal stiff walking posture, as well as rapid shallow 
breathing. In addition to skeletal muscle dystrophy characterized by general fiber atrophy and type 
II fiber hypertrophy, they developed cardiac fibrosis, progressive LV and atrial dilation as well as 
hypokinesia with conduction defects, which lead to a premature death between 4 and 9 months of 
age. Similar to Lmna-/- mice, the LV dysfunction in LmnaH222P/H222P mice was not accompanied by 
cardiomyocyte hypertrophy, suggesting a role of lamin A/C in the process of cardiac stress-induced 
hyperthrophic growth. Cardiac and skeletal muscle cells of LmnaH222P/H222P mice showed alteration 
of heterochromatin distribution and an increased nuclear translocation of Smad proteins. These 
effects probably originated from a systemic rise in circulating TGF-β, generated by the failing heart 
and dystrophic muscles, rather than from a defect in nuclear shuttling of Smad proteins through 
nuclear pore complexes or an abnormal retention at the nuclear lamina, caused by mutated lamin 
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A/C proteins. Interestingly, female LmnaH222P/H222P mice developed the dystrophic phenotype later 
than males. At the age of 6 months, when the males already reached their terminal phase, 
LmnaH222P/H222P females only started showing the symptoms which became life threatening by the 
age of 13 months, implicating steroide hormones in the development of lamin A/C-linked striated 
muscle disorders. In contrast to human LMNA H222P mutation, which has an autosomal dominant 
effect, the mutation introduced into the mouse Lmna only results with a detrimental phenotype in 
the homozygous state108. 
 
1.4.3 LmnaN195K/N195K mouse 
 
LmnaN195K/N195K mice were generated to model the autosomal dominant form of human 
dilated cardiomyopathy with conduction system disease109. Mice homozygous for the Lmna N195K 
mutation showed characteristics consistent with the DCM-CD1 and died at the age of 3 months due 
to heart arrhythmia, with minimal or no obvious skeletal muscle dystrophy. It was suggested that 
this Lmna mutation may cause the disease by influencing the structural organization of 
cardiomyocytes and/or altering the expression of essential heart-specific transcription factors 
during development and aging, since LmnaN195K/N195K hearts exhibited misexpression and/or 
mislocalization of muscle-specific structural proteins (desmin, connexin 40 and 43), as well as 
transcription factors (Hf1b)109. 
 
1.4.4 Lmna M371K mouse 
 
Transgenic mice expressing a mutated EDMD-linked form of lamin A/C (M371K) under a 
heart-specific α-myosin heavy chain promoter showed extensive heart pathology (increased 
cytoplasmic eosinophilia of cardiomyocytes, focal edema, fragmented cardiomyofibrils and 
pyknotic-appearing nuclei), leading to premature death at 2-7 weeks of age110. Multifocal cardiac 
lesions, in the absence of fibrosis or inflammation in Lmna M371K hearts, pointed to an acute or 
sub-acute cardiac injury. Lmna M371K cardiomyocytes exhibited nuclear abnormalities 
demonstrating a potential dominant negative effect of mutant proteins on the endogenous wild type 
lamin A/C110. 
 
1.4.5 LmnaLCO/LCO mouse 
 
In contrast to Lmna-/- mice which present a plethora of pathological symptoms and die at 
early age, mice expressing only the lamin C variant of the Lmna gene appear normal through their 
entire lifetime52. Although LmnaLCO/LCO cells exhibit a slight increase in abnormal nuclear 
morphology, it seems that the enhanced production of lamin C can in a way compensate for the 
loss of lamin A and thereby prevent the emergence of the disease phenotype. Interestingly, earlier 
reports suggesting an essential role of lamin A in the retention of emerin at the NE, are challenged 
by the normal localization of emerin in LmnaLCO/LCO cells. 
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1.4.6 Progeroid syndromes in mice 
 
An in-frame deletion of the Lmna exon 9, due to the introduction of a splicing defect, 
resulted in the production of an aberrant lamin A/C protein, which caused a HGPS-like multiple 
tissue disorder in mice. The Lmna∆9/∆9 animals exhibited growth retardation, loss of subcutaneous 
fat, osteoporosis, as well as thin hyperkeratotic skin, and died by the age of 4 weeks111.  
Another mouse model of HGPS was generated by targeted deletion of the last 150 
nucleotides of Lmna exon 11 together with introns 10 and 11112. The resulting LmnaHG/HG mice 
expressed only an unprocessesed form of lamin A named progerin, with no lamin C, and 
developed severe osteoporosis followed by spontaneous bone fractures and early postnatal death. 
The symptoms of progeria had a later onset in heterozygous LmnaHG/+ mice, which survived till the 
age of 6-7 months and did not present significant muscle weakness. Similar to Lmna M371K 
cardiomyocytes, heterozygous LmnaHG/+ fibroblasts showed an increased frequency of misshaped 
nuclei, suggesting a dominant negative effect of progerin on endogenous lamin A/C112. 
A transgenic mouse line, created by the introduction of a 164-kb human bacterial artificial 
chromosome spanning four genes (RAB25, UBQLN4, MAPBPIP and LMNA with the HGPS-
specific 1824C>T transition) into the mouse genome, failed to recapitulate any of the early 
hallmarks of progeria113. However, Lmna BAC G608G mice did show a loss of smooth muscle 
cells in the media of the aorta, present in some HGPS patients113. 
Mice lacking ZMPSTE24, an enzyme involved in the maturation of A-type lamins and 
associated with restrictive dermopathy in human, were independently created by two different 
groups114, 115. The Zmpste24-/- animals appeared normal at birth and grew normally until weaning 
time, when the initial symptoms such as incisor abnormalities, alopecia, kyphosis and slow arthritic 
gait started to develop. By the age of 3-4 months the mice presented bone abnormalities leading to 
rib fractures near to costovertebral joint115. Muscle weakness and mild dystrophic skeletal muscle 
changes, observed in one independent mouse line114, were presumably secondary effects of 
neuropathy and not directly caused by ZMPSTE24 absence in skeletal muscle. In culture, 
Zmpste24-/- cells exhibited enhanced senescence, possibly associated with an upregulation of p53-
responsive genes (reviewed in [116]). 
In an attempt to neutralize the toxic effects of accumulated farnesyl-prelamin A/progerin, 
Zmpste24-/- and LmnaHG/+ mice were treated with inhibitors of farnesyltransferases (FTI)117, 118, 
which were supposed to prevent farnesylation and the subsequent integration of prelamin A into 
the NE. The FTI treatment enhanced growth of the treated animals and improved the morphology 
of their nuclei, but although ameliorated to some extent, most of the symptoms persisted further 
(reviewed in [116]). A similar effect was observed in transgenic LmnanHG/+ mice expressing 
nonfarnesylated progerin, suggesting that the inhibition of farnesylation might be therapeutically 
useful, but also limited, as the protein is able to cause the disease, irrespective of its farnesylation 
state119. LmnaHG/LCO mice generated in another study indicated that the presence of the mature 
lamin A/C in LmnaHG/+ animals could be additionally aggravating the toxic effect of progerin. 
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LmnaHG/LCO mice, expressing only progerin and lamin C, exhibited a milder phenotype than 
LmnaHG/+ mice and had lower protein levels of progerin, possibly due to the altered composition of 
the lamina and a higher, more efficient, turnover of the protein in lamin C-only environment120. 
Interestingly, a 50% reduction of lamin A/C in Zmpste24-/-Lmna+/- mice was sufficient to overrule the 
toxicity imposed by the presence of farnesylated prelamin A, and prevent the development of the 
disease121. Zmpste-/-LmnaLCO/+ and Zmpste-/-LmnaLCO/LCO mice showed that already a prevention of 
prelamin A accumulation is able to fully rescue the progeria phenotype of Zmpste24-/- mice52. To 
this end, treatment of Zmpste24-/- cells with prelamin A-specific antisense oligonucleotides 
efficiently reduced the synthesis of the toxic protein and normalized the nuclear morphology of 
mouse fibroblasts118. 
 
1.4.7 Emd-/- mice 
 
Mice lacking the integral NE protein emerin developed normally and were grossly 
indistinguishable from their wild type littermates100, 122. Although, in contrast to human patients with 
EMD mutations, Emd-/- and Emd-/Y mice did not exhibit any signs of muscular dystrophy or dilated 
cardiomyopathy122, their in vivo muscle regeneration, as well as in vitro differentiation was slightly 
delayed, probably due to a transient deregulation of the pRb/MyoD pathway100. Emd-/Y muscle 
showed an excess of MyoD and its associated transcriptional components at day three of 
regeneration, which however failed to exert their activity on a subset of downstream targets within a 
usual time frame. Inappropriately activated targets of the pRb/E2F transcriptional repressor 
complex also indicated a defect in pRb dephosphorylation process, which lead to an increase in 
absolute RB protein levels. Despite the observed changes, the pRb/MyoD pathway in emerin 
deficient mice was effective at inducing the expression of downstream factors and mediating 
muscle regeneration, albeit with a slight temporal shift100. 
 
1.4.8 Lmnb1-/- mice 
 
Since lamin B1 expression was shown to be essential for survival of HeLa cells in vitro, and 
the deletion of its rod domain caused nuclear structural abnormalities, Vergnes et al. decided to 
study the in vivo function of the protein by generating transgenic mice that carry an insertional 
mutation in Lmnb1123. The gene trap insertion resulted in the production of an mRNA fusion 
transcript consisting of the first five Lmnb1 exons, encoding the N-terminal head and a truncated α-
helical rod domain, followed by a βgeo reporter gene. The resulting protein lacked the NLS, the 
CaaX motif, as well as one of the two known phosphorylation sites. Whereas Lmnb1+/- mice were 
viable, homozygous lamin B1-deficient mice exhibited severe skeletal abnormalities and died only 
few minutes after birth due to respiratory failure. Lmnb1+/- mouse embryonic fibroblasts showed a 
plethora of cellular defects such as grossly misshapen nuclei, reduced replication rates, impaired 
differentiation, increased polyploidy and premature senescence123.  
 
Introduction 1-27
1.4.9 Lap2α-/- mice 
 
Cre-mediated germline deletion of α-specific exon 4 of the Lap2 gene resulted in the 
generation of Lap2α-/- mice32. Although grossly indistinguishable from their wild type littermates, 
LAP2α-deficient mice exhibited higher proliferation of progenitor cells in highly regenerative tissues 
like skin, intestine and the hematopoietic system, as well as more efficient tissue repair after 
treatment with stress-inducing agents. The tightly regulated tissue homeostasis and fate decisions 
of progenitor cells in these systems were shown to depend on the phosphorylation status of pRb. In 
accordance, tissue lysates from Lap2α-/- mice showed increased pRb phosphorylation, consistent 
with a higher number of proliferating cells. Additionally, primary Lap2α-/- mouse fibroblasts 
exhibited a higher content of insoluble lamina-associated lamin A, in contrast to wild type cells 
which also have a significant nucleoplasmic pool, as well as delayed cell cycle arrest presumably 
due to impairment of contact inhibition, supporting the idea that LAP2α-lamin A complexes might 
be involved in the regulation of pRb activity32.  
 
 
Taken together, studies of human patients and mouse laminopathy models show that lamin 
proteins are involved in many nuclear processes and that the diseases caused by their mutations 
cannot be explained by simple straightforward hypotheses. Effects of changed nuclear mechanical 
properties, chromatin organization as well as transcriptional and posttranslational regulation may 
indiscernibly contribute to the complexity of laminopathy phenotypes. The newest studies 
supported the model previously proposed by Gotzmann and Foisner13, according to which A-type 
lamins and LEM-domain proteins might play an important role in cell cycle regulation and 
differentiation of stem cells during maintenance of tissue homeostasis32, 124, 125. A defect in stem 
cell-mediated tissue repair could then explain the late onset of tissue specific symptoms in most 
laminopathies. Scaffidi and Misteli (2008)125 and Espada et al. (2008)124 demonstrated for the first 
time that progeria and age-related nuclear defects are directly linked to stem cell dysfunction, 
which might be caused by deregulation of Notch and Wnt signaling – the two major pathways 
governing stem cell fate. The downstream effectors of these cascades, normally sequestered at the 
nuclear periphery, could lose their inhibitory queues in the presence of mutated lamin proteins and 
therefore inappropriately exert their functions in target gene regulation. In addition, Naetar et al 
(2008)32 showed that intranuclear LAP2α-lamin A complexes are involved in the tight regulation of 
committed-progenitor cell proliferation by their association with the pRb protein, fortifying the link 
between laminopathies and defects in adult stem cell-mediated tissue homeostasis. 
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1.5 The striated muscle story 
 
Heart and skeletal muscle are the two tissues most frequently affected by mutations in 
lamin A/C (reviewed in [76]). Although numerous studies performed in the past few years made an 
invaluable contribution to the understanding of lamin A/C-linked pathologies, the major question of 
how a gene expressed in various cells of the body can specifically cause tissue-restricted 
disorders, still remains to be answered. In this respect, it is essential to study the function of lamin 
complexes within the context of tissue-specific molecular pathways. 
 
1.5.1 Skeletal myogenesis in vertebrates 
 
Skeletal muscles of the trunk, the limbs and partially of the head, derive from transitory 
embryonic structures called somites – the segments of paraxial mesoderm that form following an 
anterior-posterior progression on either side of the neural tube and the notochord (reviewed in 
[126]). During somite maturation, myogenic progenitor cells become confined to its dorso-lateral 
epithelial part named the dermomyotome (Figure 8). At the onset of myogenesis (E 8.0 in mouse), 
cells expressing the myogenic determination factors Myf5 and Mrf4 start to delaminate from the 
epaxial, and later mainly hypaxial edge (lip) of the dermomyotome, and move underneath it, where 
they rapidly differentiate into the skeletal muscle of the primary myotome (reviewed in [126]). 
Subsequently, in the second phase of myogenesis, the central portion of the dermomyotome gives 
rise to a population of progenitor cells, expressing paired box transcription factors Pax3 and Pax7. 
These Pax3+/Pax7+ cells remain present in all late embryonic muscle masses and, by activating the 
myogenic program, make a major contribution to muscle growth. At certain levels, Pax3+/Pax7+ 
cells cells detach and migrate away from the hypaxial dermomyotome to generate limb, diaphragm, 
hypoglossal and tongue muscles. Later, at E10.5, the central region of the dermomyotome loses its 
epithelial structure, and Pax3+/Pax7+ cells enter into the muscle mass of the myotome, providing 
progenitor cells for the subsequent growth of trunk muscles (reviewed in [126]).  
Figure 8. Skeletal myogenesis in vertebrates – dermomyotomal sources of myogenic progenitor 
cells. M. Buckingham, Current Opinion in Genetics and Development, 2006. 
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In addition to myogenic cells, the dermomyotome gives rise to several other mesodermal 
cell types including dermal, endothelial and smooth muscle cells of the dorsal aorta (reviewed in 
[126]). 
Myogenic progenitor cells of the head derive from prechordal and anterior paraxial 
mesoderm cells, or from cells that migrated from anterior somites into the branchial arches. The 
upstream regulators of these cells include MyoR, Capsulin and the T-box factor Tbx1, which is also 
expressed by cells involved in heart formation (reviewed in [126]). 
The process of myogenesis in the somite is orchestrated by surrounding tissues through 
the hedgehog (HH), Wnt, Notch, p38 MAPK, FGF, BMP, TGFβ, IGF, N-Cam and c-met signaling 
pathways. The HH factors secreted from the notochord and the ventral neural tube maintain the 
expression of myogenic genes in the dorsomedial lip of the dermomyotome – the primordial site of 
myogenesis (reviewed in [126, 127]). Maintenance of the epithelial structure of the dermomyotome 
depends on β-catenin-dependent Wnt signaling from dorsal ectoderm and the neural tube, which 
has also been implicated in the regulation of MyoD (Wnt7a) and Myf5 (Wnt1) activity during 
myogenesis through the protein kinase A-CREBP pathway128 (Figure 9). Upon formation of the 
myotome and later muscle masses, endocrine TGFβ signaling affects the growth of these 
structures by limiting the proliferation of Pax-positive progenitor cells129. 
Figure 9. Signaling pathways regulating myogenic induction in the mouse. The neural tube is depicted in 
turquoise, the notochord in green and the dorsal ectoderm in orange. The epaxial and hypaxial parts of the 
dermomyotome are shown in pink and red respectively. Adapted from R.J. Bryson-Richardson and P.D. 
Currie, Nature Reviews Genetics, 2008. 
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During late foetal development (at approximately day E17.5), the resident hypaxial-derived 
Pax-positive progenitor population generates Pax7+ myogenic cells, which occupy a satellite 
position around mature myofibers upon formation of the myotube-surrounding basal lamina 
(reviewed in [130]). These satellite cells account for ~30-35% of the sublaminal nuclei associated 
with myofibers in early postnatal mouse muscle and make the major contribution to bulk postnatal 
muscle growth. Adult mouse muscle possesses only 1-4% of mainly mitotically quiescent satellite 
cells (comprising 3-5.5% of all myofibre nuclei) which can be activated in response to external 
queues and either self-renew or produce myonuclei during homeostasis, hypertrophy and muscle 
regeneration (Figure 10) (reviewed in [131]). At present, the satellite cell pool is considered to 
contain a heterogeneous population of stem and committed progenitor cells, which exhibit different 
self-renewal and myogenic potentials, and display a range of cell surface markers such as CD34, 
CXCR4, β1-integrin, c-met, N-cadherin, as well as the transcriptional factor Pax7132, 133. The 
absence of a specific uniform satellite cell marker presents an additional obstacle in an effort to 
disclose the cellular pathways governing muscle homeostasis and regeneration. 
Interestingly, a recent analysis of myofiber-associated satellite cell division suggested that 
the plane of cell division might be the determinant factor of daughter cell fate132. Satellite cells 
undergoing planar divisions are thought to give rise to cells with symmetric expression of Myf5, 
whereas apical-basal plane divisions would result in a committed progenitor cell expressing Myf5-
positive and a Myf5-negative quiescent satellite cell responsible for maintenance of the stem cell 
pool (Figure 10). 
Figure 10. Shematic diagram of a skeletal myofiber with its associated satellite cells. Modified 
according to R.J. Bryson-Richardson and P.D. Currie, Nature Reviews Genetics, 2008. 
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Recently, the microenvironmet or the niche which modulates the function of adult stem 
cells, has been put into the spot light to address the issue of age-related changes in the stem cell 
pool (reviewed in [134]). The niche represents a dynamic environment that switches between states 
that support quiescence and those that contribute to the activation of stem cells in response to local 
and systemic influences. Muscle satellite cells reside between the myofiber and the basal lamina, 
which together with the microvasculature, the neural components, as well as occasionally present 
cells of the immune system, represent the adult muscle stem cell niche able to respond to systemic 
queues and modify their fate.  
The myofiber association negatively effects proliferation of satellite cells in the steady state, 
keeping them in a quiescent mode135. In contrast, muscle damage causes upregulation of Delta, a 
transmembrane ligand that binds the Notch receptor, in the injured myofibers and induces 
proliferative expansion of satellite cells. Interestingly, aged muscle fibers fail to induce Delta 
expression, resulting in reduced proliferation of satellite cells and impaired muscle regeneration136. 
The basal lamina, composed of collagen type 4, perlecan, laminin, entactin, fibrinectin and 
several glycoproteins/proteoglycans, can also positively and negatively affect proliferation of 
satellite cells. In this regard, laminin, fibronectin and several proteoglycan receptors of inactive 
growth factor forms have been shown to support their proliferation. In aging muscle, the function of 
basal lamina and muscle regeneration are compromised due to degradation of connective tissue 
components and accumulation of their toxic by-products (reviewed in [137]). The reduced 
regeneration potential of aged muscle might also be a consequence of age-related systemic 
increase in Wnt signaling, which suppresses stem cell function and increases fibrogenesis in 
multiple tissues (reviewed in [134]). 
 
1.5.2 Satellite cells in action 
 
In response to external activating signals, Pax7+ satellite cells initiate the expression of 
MyoD, the major myogenic transcription factor, and initiate the process of terminal muscle 
differentiation, which involves fusion of single myoblasts into multinucleated myotubes, as well as 
downregulation of Pax7130 (Figure 11). MyoD, together with Myf5, myogenin and Mfr4 proteins, 
belongs to a family of myogenic basic helix-loop-helix (bHLH) transcription factors which form 
heterodimers with ubiquitously expressed bHLH-E proteins and regulate the expression of muscle 
specific genes by binding to a special DNA motif called the E-box (reviewed in [138]). Although 
expressed in undifferentiated myoblasts, MyoD, Myf5 and E proteins remain in an inactive state 
until the extracellular queues are interpreted as pro-differentiation signals and their post-
translational modifications allow association with muscle-specific promoters and co-factors. Histone 
deacethylase III family member Sir2, found in a protein complex with the acethyltransferase pCAF 
(p300/CBP-associated factor) and MyoD in undifferentiated myoblasts, was proposed to inhibit the 
MyoD-specific gene activation by histone and/or pCAF/p300/MyoD deacethylation (reviewed in 
[138]). Another protein complex involved in the inhibition of muscle-specific regulatory regions 
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contains the Polycomb group protein Enhancer of zeste 2 (Ezh2), a histone lysine 
methyltransferase (HKMT), the transcriptional regulator YY1 and HDAC1, which all have to be 
removed from promoters before MyoD and SRF (Serum response factor) can initiate the 
differentiation process. Since Sir2 is also required for Polycomb-mediated silencing, the two 
pathways most probably intertwine in order to keep the cells in an undifferentiated state138. 
Figure 11. Schematic representation of adult myogenesis. Adapted from F. Le Grand and M.A. 
Rudnicki, Current Opinion in Cell Biology, 2007. 
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Once the inhibitory complexes are removed from promoters, activated MyoD recruits 
histone acethyletransferases (HATs), SWI/SNF chromatin-remodeling complexes, as well as 
polymerase II activating kinases, and promotes the expression of myogenic genes during muscle 
differentiation. In addition, MyoD activates pRb and p21 gene expression in an E-box independent 
mechanism followed by downregulation of cyclin D1, E and A. The hypophosphorylated, 
acethylated pRb inhibits cell cycle progression by preventing the interaction of E2F with its target 
genes and further upregulates and co-activates MyoD in a feed forward loop, which results in 
terminal cell cycle withdrawal and induction of muscle-specific transcription (reviewed in[139]). 
Whether MyoD and pRb are able to interact directly remains to be elucidated, but since both 
proteins have been found in complexes with lamin A/C, it is tempting to speculate that LAP2α-
lamin A/C complexes might form the missing link between these two proteins. pRb is also essential 
for promoting functional cooperation between MyoD and MEF2 (Myocyte enhancer factor 2) 
proteins belonging to a larger evolutionary ancient MADS (MCM1, agamous, deficiens, SRF) family 
of transcription factors, which then act together on downstream targets such as myogenin, myosin 
heavy chain (MyHC) and muscle creatine kinase (MCK) and orchestrate the differentiation 
process103.  
Mice lacking MyoD develop normally and do not display a severe muscle phenotype, 
indicating that other myogenic factors like Myf5 and Mrf4 can compensate, at least in a part, for its 
loss during embryonic development140. The adult skeletal muscle of MyoD-/- mice however displays 
deficiency in regeneration caused by accelerated growth and delayed differentiation of myoblasts, 
supporting the role of MyoD in regulation of the satellite cell transcriptional program140. Although a 
full deletion of pRb causes embryonic lethality in mice due to defects in various tissues including 
muscle141, a skeletal muscle-specific ablation of pRb demonstrated a role of the protein in 
progression through myogenic differentiation, as well as its redundancy during maintenance of 
terminal differentiation142, consistent with its function in cell cycle withdrawal and MyoD-dependent 
gene regulation. 
Interestingly, during myoblast differentiation the nucleoplasmic pool of lamin A/C becomes 
rearranged and antigenetically masked, without an apparent change in peripheral lamin 
organization143, 144. In addition, the expression of a mutant AD-EDMD-causing lamin A in C2C12 
myoblasts promotes apoptosis and inhibits myotube formation145, suggesting that a specific form of 
a functional lamin scaffold is required during muscle differentiation. What is more, a gene 
expression study of mouse muscle regeneration process showed an increase in LAP2 and LMNA 
transcription at day 3.5, when a strong induction of MyoD and its downstream targets was 
observed, suggesting a role of these proteins in muscle-specific gene expression, as well as NE 
remodeling at the time of myoblast cell cycle exit146. The gene expression profile of EDMD patients 
carrying EMD or LMNA mutation analyzed in the same study, found an upregulation of the LMNA 
and LAP2 gene products, as well as members of the CREBP/p300 acethylase pathway, suggesting 
disease specific perturbations of the lamin A-emerin-pRb-MyoD mechanism. An intriguing 
observation that the short C-terminal peptide produced during lamin A maturation might be involved 
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in myoblast fusion, as it resembles the yeast mating factor, adds another level to the lamin A/C 
functional complexity147.  
 
1.5.3 Transforming skeletal muscle 
 
MyoD, myogenin and MEF2 factors not only play essential roles in muscle formation, but 
are also important for transformation of muscle fibers in response to external physiological signals 
such as innervation and endocrine/nutritional cues (reviewed in [148]). Skeletal muscle tissue is 
composed of muscle fibers – large syncytial cells individually surrounded by basal lamina – which 
present a heterogeneous population in respect to size, metabolism and contractile function. On the 
basis of specific myosin heavy chain isoform expression, myofibers are classified into two major 
groups: type I and type II (IIa, IId/x, IIb) fibers. Type I fibers (and IIa) exhibit oxidative metabolism 
and are also termed “slow-twitch” due to their slow contraction mode, owing to the specific activity 
of the ATPase associated with type I myosin. They are rich in mitochondria, have more surrounding 
capillaries and exhibit low velocity of shortening, as well as high resistance to fatigue. Whereas 
slow fibers are required for tasks involving endurance and maintenance of posture, the primarily 
glycolytic, fast – type II fibers, which exert quick contractions and fatigue rapidly, are involved in 
movements which involve strength and speed (reviewed in [148]).  
Skeletal muscle is able to adapt to environmental demands and respond to physiological 
and pathological signals by transforming and remodeling the myofiber content. Muscle exercise 
causes an increase in oxidative metabolism and fast-to-slow myofiber transition, whereas muscle 
disuse and aging have an opposite effect. The properties of skeletal muscle fibers depend on the 
pattern of nerve stimulation, where low frequencies of neuron firing promote slow, and high 
frequencies fast muscle phenotype. The neuronal stimulation causes changes in the intracellular 
calcium content, which then serves as a second messenger in the signaling pathway leading to 
altered gene expression (reviewed in [148]). 
Muscles predominantly composed of fast myofibers, like Tibialis anterior (TA) and Extensor 
digitorum longus (EDL), exhibit high MyoD content and MyoD cis regulatory regions seem to 
restrict the expression to IIx and IIb fibers. In accordance, MyoD-/- mice show a subtle shift in fiber 
content of fast muscles toward a slower type, while slow muscles tend to switch to a faster type149. 
Slow fiber containing muscles, like Soleus, express more myogenin, which was shown to induce 
oxidative enzymes in adult fast muscles in response to calcineurin (calcium-dependent 
phosphatase) signaling (reviewed in [150, 151]). 
MEF2 contributes to establishment of slow fiber phenotype by driving oxidative, slow fiber-
specific gene expression activated by calcium-dependent signaling152 (Figure 12)148. 
Calcium/calmodulin-dependent protein kinase (CaMK), which senses the frequency of calcium 
oscillations and becomes activated during hypertrophic growth and endurance adaptations, 
phosphorylates class II HDACs thereby initiating their transport out of the nucleus. As a 
consequence, MEF2 is relieved of the inhibitory activity of HDAC II-recruited SUMO2 and SUMO3 
enzymes and can fulfill its transcriptional function (reviewed in [138]). Skeletal muscle-specific 
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deletion of Mef2c results in a substantial reduction of slow myofibers, whereas overexpression of 
its super-active form promotes the slow fiber phenotype and enhances endurance exercise 
(reviewed in [148]). 
 
 
An important partner of MEF2 in the process of fiber type switching is the nuclear factor of 
activated T cells (NFAT), whose translocation from the cytoplasm to the nucleus upon calcineurin-
dependent dephosphorylation activates the slow – type I – muscle fiber program. In addition, 
another target of calcineurin signaling, the transcriptional coactivator peroxisome-proliferator-
activated receptor gamma coactivator-1 (PGC-1), preferentially enriched in type I myofibers, which 
is considered to be a master regulator of mitochondrial gene expression activating mitochondrial 
biogenesis and oxidative metabolism, also activates transcription in cooperation with MEF2. PGC-1 
associates with the skeletal muscle-predominant form of peroxisome proliferator-activated receptor 
- PPAR∆, which serves as the major transcriptional regulator of fat metabolism in adipose tissue. 
By activating enzymes associated with long-chain fatty-acid β-oxidation, PPAR∆ in excess also 
causes an increase of type I fibers (reviewed in [148]).  
PGC-1α also functions as Foxo coactivator, implicating the Foxo pathway in the process of 
fiber type switching, although the reduced number of type I fibers in myogenin-Foxo1-/- transgenic 
animals seemes more as a consequence of increased MyoD expression and deregulated 
differentiation than impaired PGC-1α transcription153. The O subfymily of forkhead (Fox) proteins 
Figure 12. Signaling pathways in skeletal muscle remodelling. Adapted from Rhonda Bassel-Duby and 
Eric N. Olson, Annual Review of Biochemistry, Vol. 75, 2006. 
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promotes cell survival and metabolism by regulating hormonal, nutrient and stress responses 
through the phosphatidylinositol 3-kinase (PI3K) mechanism. In addition to their role in terminally 
differentiated cells, Foxo proteins are involved in myoblast, preadipocyte and endothelial cell 
differentiation. The Foxo pathway was also shown to physically and functionally interact with Notch 
signaling to control the myogenic program by promoting corepressor clearance from the Csl 
factor153. The Notch pathway plays an important role in embryonic development and adult stem cell 
regulation during neural, vascular, endocrine, as well as muscle differentiation. The ligand-induced 
receptor cleavage causes the translocation of the Notch intracellular domain (NICD) to the nucleus 
and the subsequent association with the DNA-binding protein Csl, which changes its transcriptional 
properties from a suppressive to an activating form. The Csl targets Hairy and Enhancer of split 
(Hes) and Hes-related (Hey) then inhibit the MyoD protein and suppress myoblast differentiation 
(reviewed in [154]). 
The slow muscle atropy found in striated muscle laminopathies155, 156 and a specific type II 
fiber hypertrophy in LmnaH222P mice108 suggest a role of lamin A/C proteins in fiber type 
determination and/or age related muscle remodeling. 
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1.6 The developing heart 
 
The first organ formed in a developing vertebrate embryo is the heart. Mouse 
cardiogenesis starts at embryonic day 6.25 with the induction of the precardiac mesoderm which 
will later give rise to the two distinct mesodermal heart fields in a temporally and spatially specific 
manner (reviewed in [156]). During mouse development, at E7.5, the cells in the anterior lateral 
mesodermal plate form a crescent shape corresponding to the primary or first heart field (FHF), 
which will form the primitive heart tube consisting of an interior layer of endocardial cells, separated 
by extracellular matrix from the exterior layer of myocardial cells, by day E8.0 (Figure 13) (reviewed 
in [157, 158]). 
Whereas the FHF differentiates at the cardiac crescent stage, differentiation of the second 
heart field (SHF) is relatively delayed and occurs as the second lineage migrates in, to join the cells 
from the first lineage which have created a scaffold for the subsequent SHF cell migration and 
chamber formation. During heart tube development, the SHF cells originating from the dorsal-
medial aspect of the cardiogenic plate migrate into the midline and position themselves dorsal to 
the heart tube in the pharyngeal mesoderm. Rightward looping of the heart tube is followed by 
Figure 13. Schematic diagram of mammalian heart development. Oblique views of whole embryos and 
frontal views of cardiac precursors during human cardiac development are shown in upper and lower panels 
respectively. FHF – first heart field, SHF – second heart field, CNC – cardiac neural crest, V – ventricle, LV –
left ventricle, LA – left atrium, RA – right atrium, AS – aortic sac, Ao – aorta, PA – pulmonary artery, RSCA –
right subclavian artery, LSCA - left subclavian artery, RCA – right carotid artery, LCA – left carotid artery, DA 
– ductus arteriosus. Adapted from Deepak Srivastava, Cell 126, 2006. 
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migration of SHF cells into the large portion of the outflow tract, the future right ventricle and atria. 
The left ventricle, in contrast, appears mainly derived from the FHF cells (reviewed in [157]).  
Migration and proliferation of both cell-lineages appear to be regulated by complex positive 
and negative queues of the BMP, SHH, FGF, Wnt and Notch signaling pathways (Figure 14), 
though the exact transcriptional cascades still remain to be elucidated. Following the rightward 
looping, cardiac neural crest (CNC) cells migrate from the neural folds into the outflow tract and 
pattern the bilaterally symmetric aortic arch arteries. Septation of the ventricles, the atria and 
atrioventricular valves finally results in the four-chambered mammalian heart (reviewed in [157]). 
Whilst many of the central transcriptional regulators of cardiac development in the FHF, 
such as Nkx2.5 and GATA4, also appear in the SHF and may target its development, the 
regulation of SHF still calls for the expression of specific genes (reviewed in [158]). In this regard, 
the basic helix-loop-helix transcription factor Hand2 was found to be enriched in the mouse right 
ventricle and required for SHF expansion159. Similarly, right ventricular hypoplasia was observed in 
mice lacking MEF2c160, which serves as a target of Isl1, GATA4, Foxh1 and Tbx20 in the SHF161. 
Interestingly, the LIM-homeodomain transcription factor Isl1, which is highly expressed in cells of 
the SHF and required for their population of the heart, also seems to be present in niches of 
undifferentiated cardiac progenitor cells in the postnatal heart162, 163. However, in contrast to 
skeletal muscle, which has an outstanding potential to regenerate after damage due to the 
presence of satellite cells, the currently highly controversial cardiac stem cells make a limited 
contribution to tissue repair, leaving the heart scarred. 
Figure 14. Pathways regulating region-specific cardiac morphogenesis. Positive signals are depicted by 
arrowheads and negative by bars, whereas dashed lines indicate physical interactions between factors. FHF –
first heart field, SHF – second heart field. Adapted from Deepak Srivastava, Cell, 2006. 
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During the process of mouse cardiogenesis, the immature cardiomyocytes are still able to 
proliferate while differentiating, but soon after birth they stop cycling and arrest mainly in G0/G1 
phase of the cell cycle as binucleated cells164. The major cell cycle regulator pRb seems to play a 
critical role in early heart development, directing stem cells toward a cardiac lineage through its 
association with a cardiomyogenic factor LEK1165. Rb expression in the heart exhibits a decreasing 
gradient from the blastocyst stage, through embryonic and neonatal heart. The other two members 
of the pocket protein family, p107 and p130, seem to take over some of the pRbs’ activities in the 
late foetal and early postnatal heart respectively, since they are the predominant forms expressed 
in those stages166. Upregulation of pRb also occurs in the adult mouse heart, although the nature of 
these changes still remains to be elucidated167. 
A-type lamins are also expressed in the postnatal heart, but the number of positive nuclei 
seems to decrease with age168. In contrast to skeletal muscle, molecular mechanisms implicating 
lamins in heart development and homeostasis are only starting to be unraveled. The defects 
observed in Lmna-/- cardiomyocytes99 suggest a role of lamin A/C proteins in cardiac-specific gene 
expression at baseline, as well as stress induced hypertrophic growth. 
Mechanisms regulating hypertrophic growth in cardiomyocytes are thought to include 
multiple signaling cascades activated by second messengers in response to mechanical and 
molecular queues such as PI3, PKC, MAPK and calcineurin. These pathways then convey stress 
signals into hypertrophy-specific transcription, which in part mirrors gene expression fingerprint of 
embryonic heart development. The factors prominently involved in cardiac-specific transcription 
and hypertrophic stress response include GATA4, Nkx2.5 and MEF2c. The plethora of their targets 
comprises the early (c-fos, c-myc, c-jun, BNP and Egr-1), the intermediate (ANP, β-myosin, 
skeletal α-actin, AM, phospholamban) and late response genes (cardiac α-actin, CT-1, NCX, 
MMPs, SERCA) (reviewed in [169]). Since the exact upstream, as well as downstream, effectors of 
these pathways are currently unknown, it is tempting to hypothesize that lamin A-LAP2α 
complexes might influence the activity of MEF2c or other factors through the interaction with 
another bHLH protein equivalent to skeletal muscle-specific MyoD, such as Hand2, or through 
general rearrangement of the active chromatin. 
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1.7 The aim of the study 
 
Since LAP2α and lamin A/C mutations have been implicated in cardiac and skeletal 
muscle-specific disorders, the aim of the study was to shed more light onto molecular mechanisms 
underlying striated muscle laminopathies. To this end, the functionality, the structural properties, as 
well as regeneration potential and stress response of striated muscles were analyzed in the 
previously generated mouse lacking LAP2α protein (Figure 15). To study the ability of the LAP2α-
deficient striated muscle to recover after stress, Lap2α-/- mice were subjected to procedures 
causing acute and chronic tissue damage, as well as crossed with the musclular dystrophy mouse 
model line Mdx, which experiences inherent constant muscle damage, to yield compound Lap2α-/-
/Mdx mice. In order to more closely determine the time frame of the specific muscle-associated 
LAP2α function, two additional conditional mouse lines, which lose the protein at different stages of 
muscle differentiation were generated and analyzed. In the case of Lap2α-/-/Pax7-Cre+ mice, 
LAP2α protein is absent from muscle satellite and other cells expressing the transcription factor 
Pax7, which enables the study of its function during muscle stem cell self-renewal and proliferation. 
The Lap2α-/-/Mck-Cre+ mice, on the other hand, lose LAP2α only later in the process of muscle 
differentiation allowing the analysis of its function during myoblast-myotube transition. 
MDX
LAP2α
KO
LAP2α floxed
Pax7-
Cre
MCK-
Cre
LAP2α
KO
Notexin, Isoproterenol, Left 
anterior descending  
coronaryartery ligation
Figure 15. Schematic overview of the LAP2α-striated muscle project designed to analyze the 
function of the protein in the striated muscle context. 
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~Extended version of materials and methods described in the submitted manuscripts~ 
2.1 Mouse phenotyping 
 
2.1.1 The SHIRPA protocol 
 
The SHIRPA protocol is a simple first-line phenotyping screen which provides a behavioral 
and functional profile of genetically altered mice by observational assessment170. The original 
protocol used by the Harwell Medical Research Council was slightly modified by EUMORPHIA, a 
project funded by the European Commission under FP5 which developed a database of Standard 
Operating Procedures (SOPs) used for mouse phenotype characterization (www.eumorphia.org). 
 
2.1.1.1 Behavior recorded in a viewing jar 
 
A clear cylindrical viewing jar was placed upright on top of a sandpapered plastic sheet 
standing on a tripod (~7.5 cm high). The mouse was removed from its home cage, gripping the tail 
between the thumb and the forefinger, and placed into the viewing jar. Without disturbing the 
animal the following behaviors were recorded: 
 
Feature 
 
Description 
 
Score 
 
Body position 
 
Observe the mouse and identify the 
level of activity. 
 
0 – inactive; 
1 – active; 
2 – excessive activity 
 
Tremor 
 
Make a note of whether or not the 
mouse appears to tremble. 
 
0 – absent; 
1 – present 
 
Palpebral closure 
 
Observe the closing of the eyes. 
 
0 – eyes open; 
1 – eyes closed 
 
Coat appearance 
 
Look at the mouse coat, how tidy and 
well groomed it is and note deviances 
like piloerection. 
 
0 – tidy and well groomed; 
1 – irregularities 
 
Whiskers 
 
Observe whether the mouse has intact 
or trimmed whiskers. 
 
0 – present; 
1 – absent 
 
Lacrimation 
 
 0 – present; 
1 – absent 
 
Defecation 
 
 0 – present; 
1 – absent 
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2.1.1.2 Behavior recorded in the arena 
 
The floor of a Perspex arena (60×37×18 cm) was marked with 15 squares (~11 × 11 cm). 
The mouse was transferred to the centre of the arena inside of the viewing jar, using the plastic 
sheet underneath the jar to constrain the mouse. The plastic sheet was then carefully removed at 
approximately 25 cm above the arena floor and the behavior of the animal inside of the arena was 
recorded: 
Feature 
 
Description of the test 
 
Score 
 
Transfer arousal 
 
Observe the immediate reaction of the 
mouse to the new environment and 
make a note whether it appears to 
freeze for a period longer than 5 s, 
freezes briefly before it begins to move, 
or moves immediately. 
 
0 – extended freeze (over 5 s); 
1 – brief freeze followed by  
      movement; 
2 – immediate movement 
 
Locomotor activity 
 
Start the stop watch and make a note of 
the total number of squares the mouse 
enters with all four feet in 30 s. 
 
  
Gait 
 
Study the gait of the mouse and 
determine how fluid its movement is as 
well as the extent to which the pelvis is 
elevated during forward motion. 
 
 
0 – fluid movement and  
     approximately 3 mm pelvic 
     elevation; 
1 – lack of fluidity in movement 
     (eg. retropulsion, more than 3  
     mm pelvic elevation) 
 
Tail elevation 
 
During forward motion, observe the 
position of the tail making a note of 
whether it is dragging, horizontally 
extended or is elevated. 
 
0 – dragging; 
1 – horizontal extension; 
2 – elevated/straub tail 
Touch response 
 
Approach the mouse from the front with 
a bent index finger before stroking on 
the back of the neck and observe the 
response. 
 
0 – no response; 
1 – response to touch; 
2 – flees prior to touch 
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2.1.1.3 Behavior recorded above the arena 
 
The mouse was removed from the arena by gripping the tail between the thumb and the 
forefinger and following features were observed: 
 
Feature 
 
Description of the test 
 
Score 
 
Positional passivity 
 
Measure the immediate response to 
sequential handling of the mouse. 
0 – struggles when held by the tail; 
1 – struggles when held by the 
     neck; 
2 – struggles when held laid 
      supine; 
3 – no struggle 
 
Skin color 
 
Make a note of the color gradations of 
the plantar surface and digits of 
forelimbs. 
0 – blanched; 
1 – pink; 
2 – bright, deep red flush 
 
Trunk curl 
 
Make a note of forward curling (i.e. 
head to abdomen) of the mouse when 
held by the tail. 
0 – absent; 
1 – present 
 
Limb grasping 
 
Make a note of the mouse grasping its 
limbs when held by the tail. 
0 – absent; 
1 – present 
Pinna reflex 
 
Place the mouse gently on to a grid and 
touch the proximal part of the inner 
canthus lightly with the tip of a fine 
cotton probe, observing ear retraction. 
0 – present;  
1 – absent 
 
Corneal reflex 
 
Whilst the mouse is on the grid, touch 
the cornea lightly with the tip of a fine 
cotton probe, observing the eye-blink 
response. 
0 – present; 
1 – absent 
 
Evidence of biting 
 
Make a note of whether or not the 
mouse bites during the screen. 
0 – none; 
1 – biting in response to handling 
 
Vocalization 
 
Make a note of whether or not the 
mouse is vocal during the screen.  
0 – none; 
1 – vocal 
 
Wire maneuver 
 
Animal is held above the wire by tail 
suspension and lowered to allow the 
forelimbs to grip the horizontal wire. 
The mouse is held in extension, rotated 
around the horizontal and released. 
0 – active grip with hindlegs; 
1 – difficulty to grasp with  
      hindlegs; 
2 – unable to grasp with hindlegs; 
3 – unable to lift hindlegs, falls 
      within seconds; 
4 – falls immediately 
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2.1.2 Swim test  
 
The laboratory sink was cleaned and filled with 20 cm depth of water at 24 – 26ºC . The 
mouse was removed from its home cage, carefully lowered into the water and observed for 30 s. 
The swimming ability was assessed in the following way: 
0 – Swims. [Mouse body is elongated and the tail propels in a flagella-like motion]. 
1 – Irregular swimming. [Includes vertical swimming, swimming in a circle, swimming on side 
(left/right preference noted), swimming in an unbalanced manner (tail is raised and beat about in an 
unstable manner)]. 
2 – Immobile floating. [Some vestibular mutant mice, that display initial passive immobile floating, 
soon unbalance and display full underwater tumbling or irregular swimming, which should be 
reported as such]. 
3 – Underwater tumbling. [Mouse is unable to maintain a balanced body position and continuously 
tumbles. This represents an extremely severe behavior and the mouse must be scooped up and 
rescued immediately on displaying underwater tumbling]. 
 
After swimming, the mouse was carefully removed from the water, dried with paper towels 
and placed in a fresh cage containing dry paper towels. The cage was placed under a heat source 
(a red lamp) for 15 min before the mouse was returned to its home cage. 
 
2.1.3 The voluntary wheel test 
 
Prior to the official experiment, each mouse was allowed to adjust to the hamster-wheel 
placed inside a big mouse cage (3 hours/3 consecutive days). On the 4th day, the mouse was 
returned to the wheel and its performance was measured within 3 hours (daily ride time [h], 
average speed in km/h, daily ride distance in km, and maximum speed in km/h). The experiment 
was always done at the same time during the day to avoid variations caused by different circadial 
activity phases of the animal. 
 
2.1.4 The forced wheel test 
 
In the first phase, the mouse was placed inside a motorized wheel (d = 14 cm) and its 
spontaneous activity – wheel turning - was recorded for 15 min. Subsequently, the wheel was set 
to a constant rotational speed of 0.1 – 1 round/s and the physical endurance of the mouse was 
assessed by measuring the time of active running. Each experiment was repeated 3 times. 
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2.1.5 The rotarod test 
 
Mice were placed on the rotarod and their ability to adjust to accelerating rotational speed 
(0 – 60 rounds/60 s) was measured in 3 separate trials. 
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2.2 In vitro systems 
 
2.2.1 Adult muscle fiber isolation 
 
Adult muscle fibers were isolated according to the modified protocol described by Shefer 
and Yablonka-Reuveni171. Mice were euthanized and rinsed with 70% ethanol. The skin was cut 
around the ankles and pulled towards the trunk exposing the underlying muscles. The tendons 
were cut and, by careful pulling to avoid fiber damage, particular muscles (Tibialis anterior (TA), 
Extensor digitorum longus (EDL), Soleus (SOL), Gastrocnemius (GC) and Quadriceps (QC)) 
muscles were isolated. After removal of the surrounding connective tissue, muscles were collected 
in PBS and subsequently transferred to sterile 0.2% collagenase I/DMEM solution (3 ml/50 mg of 
tissue). The samples were incubated for 1.5 – 2 hours in a shaking water bath at 37ºC until single 
muscle fibers were loosened. In the mean time, plastic 6-cm Petri dishes were coated with 1 ml of 
undiluted filtered horse serum (HS) and incubated for 5 min at 37ºC. The HS was removed and the 
dishes, filled with 7 ml of DMEM, were subsequently stored in the incubator. Muscle digestion was 
stopped after 2 h by transferring the samples to DMEM-containing coated Petri dishes. The digests 
were then moved to fresh Petri dishes and single fibers were liberated by gentle trituration through 
a series of wide bore pipettes rinsed with 10%FCS/DMEM. Individual fibers were lifted with minimal 
residual medium and distributed into 24-well plates coated with 10% Matrigel/DMEM. Fibers were 
allowed to settle down for 10 min in the incubator before 500 μl of warm culture medium (20% 
FCS/10% HS/1% CEE/DMEM) was added to each well. Single fibers were cultured for 2-3 days 
until single satellite cells started to migrate off of them and proliferate. The cells were then 
trypsinized, washed in Hams’ F-10 medium supplemented with 20% FCS, pre-plated for 2 hours on 
plastic dishes to get rid of the fibroblasts and finally plated on collagen-coated dishes (5 cm Petri 
dish incubated over night with 0.5 ml of 10% rat tail collagen/0.53% acetic acid and rinsed with 
PBS).  
Alternatively, single fibers were either placed on glass coverslips and immediately processed 
for immunofluorescence, or cultured on chamber slides and stained at particular time points. 
 
2.2.2 Muscle fiber immunofluorescence 
 
For immunofluorescence analysis, 5 – 7 freshly isolated myofibers were placed on Dako-
pen-sealed glass coverslips and fixed for 10 min in 4% para-formaldehyde. After 2×2 min washing 
with PBS, the samples were incubated in 50 mM NH4Cl/PBS for 5 min, washed in PBS and 
blocked in 20% normal goat serum/0.5% gelatine/0.5 Triton X-100/PBS for 30 min at room 
temperature. Primary antibodies were diluted in PBS (eg. rat anti-mouse CD34 1:133) and applied 
over night at 4ºC. After washing, samples were incubated for 1 hour with matching secondary 
antibodies, either directly coupled to a fluorochrome or indirectly through streptavidin – biotin 
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association. Nuclear DNA was counterstained for 10 min with Hoechst dye diluted 1:50 000 in 
dH2O and fibers were subsequently mounted in Mowiol 4-88 (Roth). 
 
2.2.3 Neonatal satellite cell isolation 
 
Neonatal satellite cells were isolated from 2-5 days old mice. Animals were sacrificed by 
decapitation, rinsed with 70% ethanol and de-skinned. Front and hind limbs were isolated and 
muscle tissue was trimmed of fat. The samples were then incubated with 0.2% collagenase 
I/DMEM solution (3 ml/mouse) for 1.5 hours in a shaking water bath at 37ºC. Muscle digests were 
transferred to a series of HS coated Petri dishes filled with DMEM and single fibers were liberated 
by gentle trituration. Samples were collected in 15 ml tubes filled up with DMEM and centrifuged for 
3 min at 300 rpm. The pellet was washed once in PBS and re-suspended in DMEM. Undigested 
bulk fibers were allowed to settle down by gravity for 2-3 min before the transfer of the supernatant 
to new 15 ml tubes. After centrifugation at 500 rpm for 5 min, samples were re-suspended in 
culture medium and plated on Matrigel-coated dishes. Muscle fibers were cultured for 48-72 hours 
before the satellite cells were harvested and plated on collagen-coated dishes. 
 
2.2.4 Primary mouse myoblast culture 
 
Satellite cells were cultured on collagen coated dishes in growth medium, consisting of 
Hams’ F-10 medium supplemented with 20% foetal calf serum/2.5 ng/ml basic FGF/50 U/ml 
Penicillin/ 50 μg/ml Streptomycin, in a humidified 5% CO2 atmosphere at 37ºC. Proliferating 
cultures were maintained at ~ 40% density with medium changes every 2 days. For splitting, the 
medium was soaked off, cells washed with PBS and trypsinized for 5 min at 37ºC. Subsequently, 
they were collected in PBS, centrifuged at 1100 rpm (cell culture Heraeus centrifuge) for 3 min and 
re-suspended in growth medium. Before being plated on collagen coated dishes, the cells were 
pre-plated for 2-3 hours on plastic Petri dishes to get rid of the contaminating fibroblasts. Myoblast 
differentiation was induced by replacing the growth medium with differentiation medium 
(5%HS/DMEM). During the course of differentiation the medium was changed daily. 
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2.2.5 Cell immunofluorescence 
 
Cultured cells were fixed in 4% paraformaldehyde/PBS for 10 min, washed in PBS and 
incubated for 5 min in 50 mM NH4Cl/PBS. After washing in PBS, cells were permeabilized in 
0.5%Triton/PBS for 5 min, washed again and incubated for 30 min in 0.5% gelatine/PBS blocking 
solution. Primary antibodies were applied for 1 h at RT diluted in PBS [anti-LAP2α 245-2 rabbit 
serum23 1:500, goat anti-lamin A/C N-18 (Santa Cruz) 1:100; rabbit anti-MyoD1 M-318 1:500; rabbit 
anti-NCL-Ki67p (Novocastra) 1:1000; mouse anti-embryonic myosin heavy chain F1.652 and 
mouse anti-myogenin F5D (Developmental Studies Hybridoma Bank Iowa) 1:10]. Samples were 
then washed in PBS and incubated with respective fluorochrome-coupled secondary antibodies for 
1 h at RT (Texas Red, Cy5 (Jackson Immuno Research) or Alexa Fluor 488 (Molecular Probes)). 
After washing in PBS, nuclei were counterstained with Hoechst 33342 dye (1:50 000 dilution in 
dH2O) for 10 min at RT and washed in dH2O. Samples were air-dried and mounted with Mowiol. 
 
2.2.6 Genotyping and semiquantitative PCR 
 
Genotyping of Lap2α-/-, Lap2αNeo-fl/Neo-fl and Mdx mice was done as previously described32, 
172. In addition, the following primers were used for genotyping of Cre recombinase and Flipase 
expressing mice: Cre_sense CCAATTTACTGACCGTACACC; Cre_antisense 
TAATCGCCATCTTCCAGCAGG; Flp_sense GTGGATCGATCCTACCCCTTGCG; Flp_antisense 
GGTCCAACTGCAGCCCAAGCTTCC. 
Primers used for semiquantitative analysis of PAX7 mRNA expression were Pax7_forw 
CCGTGTTTCTCATGGTTGTG and Pax7_rev GTGTTTGGCTTTCTTCTCGC173. PCR amplification 
was performed using Go Taq Green Master Mix (Promega) under following conditions: 95ºC 
2'/58ºC 1'/72ºC 1'30''/2 × (95ºC 40''/56ºC 1'/72ºC 1')/ 28 × (95ºC 40''/54ºC 45''/72ºC 45'')/72ºC 
10'/4ºC∞. 
 
2.2.7 Sirius red collagen staining 
 
Tissue cryo-sections were fixed in ice-cold methanol for 10 min, rinsed with PBS and 
incubated for 2 min in picro-sirius red solution (0.1% Sirius red F3B in saturated aqueous solution 
of picric acid). Samples were subsequently washed in two changes of acidified water (0.5% glacial 
acetic acid/H2O), dehydrated in ethanol (3 changes) and, after clearing in xylene, mounted with 
Enthelan® (Merck). 
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2.2.8 In vitro muscle force measurement  
 
The experiment was performed as previously described174. Shortly, mice were sacrificed by 
cervical dislocation and carefully de-skinned. Soleus and EDL muscles were exposed and their 
size was measured in the native position. Subsequently, cotton threads were placed on the 
opposing tendons near their bone-attachment sites and the entire muscles were isolated. The 
samples were kept in Krebs-Ringer solution (118.1 mM NaCl/3.4 mM KCl/2.5 mM CaCl2/0.8 mM 
MgSO4/1.2 mM KH2PO4/25.0 mM NaHCO3/11.1 mM Glucose/dH2O) during the experiment. Using 
the threads fixed to their tendons, muscles were suspended between 2 electrodes, respecting their 
native tension, and the force generated during externally-induced tetanic contraction was recorded. 
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2.3 In vivo systems 
 
2.3.1 Acute cardiac stress 
 
Acute cardiac stress was induced in mice by sustained infusion of β-adrenergic receptor 
agonist isoproterenol (Isoproterenol hydrochloride, Sigma Aldrich, I 6504) for 7 days. Mice were 
weighed and 15 mg/kg/day isoproterenol/0.5 mM ascorbic acid/PBS solution was prepared for 
each animal. Alzet® micro-osmotic pumps (model 1007D) were filled either with 100 μl of 
isoproterenol (ISO) or 0.5 mM ascorbic acid/PBS (sham) solutions according to manufacturers’ 
instructions and kept in PBS for 3 hours before implantation. Mice were anaesthetized with 5% → 
2% isofluorane/O2 mixture and placed on heated pads. The inter-scapular region of the back was 
shaved and disinfected with 70% ethanol followed by Wundesin® (10 mg/ml polyvidone-iodide 
aqueous solution). A small incision was made in the skin between the scapulae and, by using a 
haemostat, a pocket was formed by spreading the subcutaneous connective tissue apart. The filled 
osmotic pump was inserted into the pocket with the flow moderator pointing away from the incision 
and the skin was closed with 2-3 silk (6/0) sutures. During the whole deep sleep and waking period 
mice were kept on heated pads with their vital functions carefully monitored. Echocardiography was 
performed 2 h before and 7 days after the pump implantation. 
 
2.3.2 Ischemia-reperfusion injury model 
 
The surgical procedure was performed as previously described175. Briefly, left anterior 
descending artery (LAD) was occluded for 30 min using a ligature made of 8-0 silk and 1 mm 
section of a PE-10 tube. Following 1 week of reperfusion, animals were sacrificed and hearts were 
harvested for histological analysis. 
 
2.3.3 Acute skeletal muscle injury 
 
Notexin, the venom produced by the snake Notechis scutatus, is a myotoxic presynaptic 
phospholipase A2 which damages adult muscle fibers, but spares the satellite cells pool and is 
therefore used in muscle regeneration studies176. Acute mouse soleus muscle injury was induced 
in the following way: 
Mice were anesthetized with isoflurane/O2 mixture (5% starting and 2% maintenance 
concentration) and received 15 mg/kg piritramid analgesic injected subcutaneously. Outer sides of 
lower hind limbs were shaved and disinfected with Braunol® (polyvinylpyrrolidoneiodide aqueous 
solution). A small incision was made in the skin (~ 3 mm) and the underlying inter-muscular septum 
between anterior and posterior leg muscles. The soleus was exposed and 10 μl of 10 μg/ml 
notexin/saline solution was injected into the mid belly of the right muscle using a 30 G insulin 
syringe. Subsequently, the wound was closed with 7.0 nylon suture. The contra-lateral soleus 
Materials & Methods 2-55
muscle served as a healthy control. Post-operative analgesia included Piritramid dissolved in 
drinking water (15 mg/kg body weight/15 ml water/day). Mice were sacrificed and tissue samples 
were taken at day 0, 2, 4, 8 and 12 to follow the muscle regeneration process.  
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Abstract 
 
Lamina-Associated Polypeptide 2α (LAP2α) is a nuclear protein in mammalian cells that associates 
with chromatin and interacts with a fraction of A-type lamins in the nuclear interior. Mutations in 
lamins and LAP2α lead to cardiac disorders in humans. To study the molecular mechanisms of the 
disease, we analyzed heart structure and function in recently described Lap2α-/- mice. Unlike 
conditional deletion of LAP2α in late embryonic striated muscle, its complete knockout caused 
systolic dysfunction in young mice, accompanied by higher susceptibility to fibrosis in old animals, 
as well as deregulation of major cardiac transcription factors GATA4 and MEF2c. Activation of 
compensatory pathways, including downregulation of ß-adrenergic receptor signaling, resulted in 
reduced responsiveness of the myocardium to chronic β-adrenergic stimulation and stalled 
progression of LAP2α-deficient hearts from hypertrophy towards cardiac failure. Dystrophin 
deficiency in an Mdx background resulted in a transient rescue of the Lap2α-/- phenotype. Our data 
suggest a novel role of LAP2α in maintenance of cardiac function under normal and stress 
conditions.  
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Non-standard Abbreviations and Acronyms 
 
ANF Atrial Natriuretic Factor 
β-AR β-Adrenergic Receptor  
BNP Brain Natriuretic Peptide 
CTGF Connective Tissue Growth Factor 
DCM Dilated Cardiomyopathy 
EF% Ejection Fraction 
EDVI End-Diastolic Left Ventricular Volume Index 
ESVI End-Systolic Left Ventricular Volume Index 
FS% Fractional Shortening 
HW/BW Heart Weight/Body Weight 
ISO Isoproterenol 
IVS Interventricular Septum 
LA Left Atrium 
LAP2α Lamina-associated polypeptide 2α 
LEM LAP2-Emerin-MAN 
LVD Left Ventricular Diameter 
LVPW Left Ventricular Posterior Wall Thickness 
MAPK Mitogen Activated Protein Kinase 
MEF2c Myocyte Enhancer Factor 
PI3-kinase Phosphoinositide 3-kinase 
SE Standard Error 
SRF Serum Response Factor 
STARS Striated Muscle Activator of Rho Signalling 
TGFβ Transforming Growth Factor β 
WT Wild Type 
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Introduction 
 
Dilated cardiomyopathy (DCM) is a primary myocardial disease characterized by dilation and 
impaired contraction of one or both heart ventricles. One of the genes most frequently involved in 
the evolution of DCM is LMNA, which encodes nuclear intermediate filament proteins lamin A and 
C1. Mutations in lamin A/C cause the most severe forms of DCM posing a high risk of heart failure 
in symptomatic patients1. Besides heart muscle disease, mutations in LMNA cause a variety of 
pathological conditions also in skeletal muscle, skin, nerve, bone and adipose tissue, known as 
laminopathies2, emphasising the importance of the search for molecular disease mechanisms. 
Recently, research on laminopathies has focused on lamin A/C-interacting proteins, whose 
mutations have been linked to a similar spectrum of human disorders3. One of the best studied 
lamin A/C-binding partners is lamina associated polypeptide 2α (LAP2α), an unusual splice variant 
of the mammalian LAP2 gene4. All LAP2 proteins (α, β, γ, δ, ε, ζ) share a common chromatin-
binding structural motif called the LEM (LAP2-Emerin-MAN1) domain at their N-terminus. The C-
terminus of most LAP2 variants comprises a transmembrane region, which targets them to the 
inner nuclear membrane, where they serve mainly structural roles5. LAP2α lacks the common 
LAP2 transmembrane domain and possesses an additional chromatin-binding region at its C-
terminal end, which mediates targeting to the nuclear interior4. In the nucleoplasm LAP2α 
specifically interacts with a fraction of lamin A/C proteins via its unique C-terminal tail5, 6. Together, 
LAP2α and lamin A/C influence various nuclear processes, such as epigenetic chromatin 
regulation, gene expression and signal transduction7. In particular, LAP2α-lamin A/C complexes 
have been found to control the balance between proliferation and differentiation of early progenitor 
cells in regenerative tissues by affecting the E2F/retinoblastoma pathway8.  
Interestingly, a mutation in LAP2α (c. 2068C>T, p. R690C), which lowers its binding affinity for 
lamin A/C in vitro, has also been linked to familial dilated cardiomyopathy9. As changes in both, 
LAP2α and lamin A/C, cause pathological heart conditions, we hypothesized that an intact LAP2α-
lamin A/C complex may be necessary for proper cardiac function. Miss-localization or absence of 
one of the components would lead to disease.  
Most Lmna transgenic mice generated so far show complex phenotypes, including various stages 
of heart failure10, 11. To see whether LAP2α is also important for normal cardiac output, we 
analyzed heart structure and function in previously generated Lap2α-/- mice8. Here we describe a 
new mouse model of cardiomyopathy and provide novel insights into mechanisms governing heart 
development and tissue homeostasis. 
Results & Discussion Manuscript I 3-65
Materials and Methods 
 
Mice. Lap2α-/- mice were kept on a mixed Mus musculs C57BL/6×129 genetic background8. 
Compound mutant Lap2α-/-Mdx animals were obtained by crossing Lap2α-/- mice with the Mdx 
line12. Generation of conditional LAP2α knockout mice is described in Supplemental Figure 1. All 
histological and physiological analyses were done by observers blinded for the genotype as well as 
treatment of the animal. Mice aged 2 days were considered as newborn, 10 weeks as young and 
10-12 months as old. 
Mice were kept and handled in accordance with the procedures outlined in the Guide for the Care 
and Use of Laboratory Animals. Experiments were performed according to permissions from 
Austrian authorities. 
 
Echocardiograpy. Mice were anesthetized with 5% isoflurane/O2 and maintained on 2% mixture 
during the experiment. Trans-thoracic echocardiography was performed using Vivid Five/Vingmed-
GE Technology/USA equipped with a 10-MHz linear transducer13. 
 
Gravimetric, histological and western blot analyses were performed according to standard 
procedures described in more detail in the online supplement. Data processing, including 
quantification of fibrosis in Picro-sirius red-stained samples, was done using Adobe Photoshop 
CS2. 
 
Semi-quantitative and real time PCR. Total heart tissue RNA was isolated using TRIzol® reagent 
(Invitrogen) or RNeasy® Plus Micro Kit (Quiagen) and First Strand cDNA Synthesis Kit for RT-PCR 
(Roche) was used for cDNA synthesis according to manufacturers’ instructions. cDNA was 
amplified using Go Taq Green Master Mix (Promega) in semig.-PCR and MESA GREEN qPCR 
MasterMix Plus for SYBR® Assay I dTTP (Eurogentec), together with MasterCycler ep realplex 
(Eppendorf), in quantitative PCR (qPCR) analyses. Images of ethidium bromide-stained agarose 
gels were documented using UVP Gel Doc-It TS Imaging System and processed by Adobe 
Photoshop CS2. qPCR data were normalized to endogenous HPRT levels and analyzed according 
to Pfaffl method14. The list of primers can be found in online supplement. 
 
Isoproterenol-induced heart failure model. Mice anaesthesia and echocardiography before and 
after the experiment were performed as described above. Alzet mini-osmotic pumps (1007D), filled 
with 15mg/kg/day isoproterenol/PBS (Sigma Aldrich), were implanted according to manufacturers’ 
instructions. 6 old male Lap2α+/+ and 7 Lap2α-/- mice were infused with ISO and 2 littermate 
couples received only PBS (sham) for 7 days. At the end of the experiment animals were sacrificed 
for further analysis. 
 
Statistical analysis. Data were analyzed either by paired Students’t-test, one-way ANOVA or two-
way ANOVA (followed by Boniferroni post hoc test for multiple comparisons) where appropriate 
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using Microsoft Excel XP. P<0.05 was considered significant. Data are presented as mean values 
± standard error (SE) and n represents sample size. 
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Results 
 
LAP2α deficient mice used in this study were generated by Cre recombinase-mediated excision of 
the LAP2α-specific exon 4 of the Lap2 gene in the germline8. To confirm the absence of the gene 
product, we performed western blot, semi-quantitative PCR and immunofluorescence analysis of 
Lap2α-/- heart muscle tissue. LAP2α was neither detectable at mRNA, nor on protein level, while 
the expression, as well as localization of lamin A/C and other LAP2 isoforms were not significantly 
altered (Figure 1, Supplemental figure 2). 
 
Absence of LAP2α causes ventricular systolic dysfunction in mice 
The symptoms in LAP2α- and most lamin A/C-linked human cardiomyopathies appear mostly in 
adults5, 9. In mouse laminopathy models, however, heart defects develop in young animals and 
cause early mortality10, 11. As Lap2α-/- mice are grossly indistinguishable from their wild type (WT) 
littermates and have a normal life expectancy8, we analyzed heart function in young, as well as old 
animals. Echocardiography in 10 weeks old Lap2α-/- mice revealed ventricular systolic dysfunction, 
characterized by significantly decreased left ventricular fractional shortening (FS%) and ejection 
fractions (EF%). Moreover, enlarged left atria (LA) in male LAP2α-deficient mice emphasized the 
defective cardiac phenotype, indicating a possible left ventricular and left atrial volume overload 
(Figure 2, Supplemental table 1). The FS% and EF% values remained similarly impaired in old 
Lap2α-/- male mice (FS of 30.39% ± 1.67 at the age of 10-12 months compared to 27.97% ± 1.38 in 
young animals), suggesting that the heart functional defect was not progressive. Interestingly, 
cardiac parameters in Lap2α-/- females appeared largely comparable to wild type at both ages 
(Supplemental table 1).  
 
Old Lap2α-/- hearts are more susceptible to fibrosis  
To see whether the functional heart defect in Lap2α-/- mice was accompanied by structural 
changes, we performed gravimetric and histological analyses. Lap2α-/- hearts had normal 
morphology and similar heart weight/body weight (HW/BW) indexes compared to WT littermates in 
newborn, young and old animals (data not shown). Furthermore, no overt histological pathologies 
were detectable in young Lap2α-/- mice (Figure 3A). Old Lap2α-/- hearts, however, showed high 
phenotypic variability in the degree of fibrosis, assessed by the extent of interstitial collagen 
deposition in the left ventricle. Out of 11 tested mice, 18% developed extensive subendocardial 
fibrosis of the left ventricle (Figure 3B and data not shown). In addition to fibrosis, one mouse 
presented regions of extremely thin, transparent myocardium which collapsed in the absence of 
internal blood pressure (Figure 3C). In contrast, wild type animals did not exhibit any signs of 
fibrosis at any age.  
 
De-regulated expression of major cardiac transcription factors in LAP2α-deficient mice 
In an attempt to identify molecular mechanisms leading to systolic dysfunction in Lap2α-/- mice, we 
analyzed the expression of several markers connected to myocardial remodelling. Two major 
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cardiac transcription factors, GATA4 and MEF2c, as well as their downstream targets, brain 
natriuretic peptide (BNP) and proteins involved in serum response factor (SRF)-mediated 
transcription of immediate early and muscle specific genes, Myocardin A and Striated Muscle 
Activator of Rho Signalling (STARS)15-19, showed de-regulated expression patterns in Lap2α-/- mice 
(Figure 4A, B). Whereas MEF2c expression was repressed in newborn Lap2α-/- hearts and reached 
WT levels by the age of 10 weeks, GATA4, Myocardin A and STARS were down-regulated only in 
old hearts. In addition, consistent with the reported cooperative regulation of BNP expression by 
both GATA4 and MEF2c19, BNP mRNA levels were significantly lower in LAP2α-deficient hearts 
compared to wild type at all ages (Figure 4A). The expression of other MEF2c and GATA4 targets, 
such as α- and β-myosin heavy chain and atrial natriuretic factor (ANF)20 was not significantly 
changed in Lap2α-/- mice (data not shown). Our data show that loss of LAP2α affects the 
expression of GATA4 and MEF2C, as well as some of their downstream targets, which in turn may 
influence the expression of a plethora of genes involved in cardiovascular development and stress-
induced hypertrophic growth.  
Since old Lap2α-/- mice showed increased susceptibility to fibrosis, we analyzed the expression of 
know fibrotic markers in wild type and LAP2α-deficient hearts (Figure 4C). Interestingly, loss of 
LAP2α caused a downregulation of connective tissue growth factor (CTGF), an inducer of 
fibroblast proliferation and extracellular matrix synthesis21, but affected only mildly the expression 
of its activator transforming growth factor β2 (TGFβ2). Altogether our data demonstrate that loss of 
LAP2α in mice leads to deregulated expression of genes involved in cardiac remodelling and 
fibrosis.  
 
Lap2α-/- mice show a blunted response to chronic isoproterenol infusion 
GATA4 and MEF2c play important roles during cardiomyocyte hypertrophy22, 23. To see whether 
their deregulation in Lap2α-/- hearts affects the response to cardiac hypertrophic stimuli, we 
subjected Lap2α-/- mice to chronic infusion of the β-adrenergic agonist isoproterenol (ISO) for 7 
days. To detect ISO-induced changes in heart function and structure, we performed 
echocardiography before and after the treatment, as well as gravimetric and histological analyses 
at the end of the experiment. As shown by the HW/BW indexes, ISO administration caused a 
similar degree of cardiac hypertrophy in Lap2α+/+ and Lap2α-/- mice (Figure 5A), indicating that the 
hypertrophic growth response is not grossly affected by the loss of LAP2α. Similarly, the extent of 
subendocardial fibrosis caused by chronic ISO infusion24 was similar in Lap2α+/+ and Lap2α-/- mice 
(Supplemental figure 3).  
In addition to hypertrophy, ISO treatment caused dilatation of left heart ventricles, as shown by 
echocardiography (Figure 5B, Supplemental table 2). In wild type animals, systolic and diastolic left 
ventricular diameters (LVD) and the corresponding ventricular volumes exhibited a significantly 
increase, indicating the progression from cardiac hypertrophy towards heart failure. In contrast, left 
ventricles of Lap2α-/- mice were already slightly enlarged at baseline and showed only a milder 
additional dilatation upon ISO treatment, reaching end point sizes similar to WT. HW/BW indexes 
and echocardiograpy parameters of sham (PBS) treated animals were not altered by the procedure 
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(Supplemental table 2). These data point to a blunted cardiac stress response in LAP2α-deficient 
mice. 
FS values in treated animals were only slightly affected, showing that, in agreement with previous 
studies24, chronic ISO infusion did not significantly impair left ventricular systolic function either in 
Lap2α+/+ or Lap2α-/- mice (Figure 5B, Supplemental table 2). The preserved basal systolic function 
in ISO-induced cardiac hypertrophy has been associated with downregulation of β-adrenergic 
receptor (β-AR)-mediated inotropic responses24. An ISO-induced downregulation of β-AR has also 
been shown to cause a blunted reactivity to its subsequent re-administration24. Therefore, we 
questioned whether the reduced responsiveness of Lap2α-/- myocardium to ISO might also be a 
consequence of similar de-sensitization of the β-AR signalling pathway. To test this hypothesis, we 
analyzed the expression of β2-AR in LAP2α-deficient and wild type mice at baseline, as well as 
after ISO treatment. As expected, Lap2α-/- hearts showed lower baseline expression levels of β2-
AR in young and old mice (Figure 5C). Importantly, the difference in relative β2-AR mRNA levels in 
untreated LAP2α knockout versus wild type heart increased with age (Figure 5C), suggesting that 
the downregulation of β-AR signalling in Lap2α-/- mice is an aging-dependent phenomenon and 
may be a consequence of heart function impairment. ISO treatment caused an additional 
downregulation of β2-AR mRNA in Lap2α-/- hearts, albeit not as extensive as in the wild type 
situation (~71% in WT vs. ~39% in Lap2α-/-), resulting in comparable end-point expression levels in 
both genotypes (Figure 5C). 
Development of β-AR-mediated hypertrophy is associated with the activation of the foetal cardiac 
transcriptional program24, including the expression of embryonic transcription factors ANF and 
GATA425. In accordance, ANF and GATA4 mRNA levels were upregulated in ISO-treated hearts of 
both Lap2α+/+ and Lap2α-/- mice (Figure 5D). However, consistent with reduced ß-AR levels in old 
LAP2α-deficient mice, the increase in ISO-induced ANF expression was significantly lower in 
LAP2α-deficient myocardium than in wild type hearts. Relative GATA4 levels were also 
substantially lower in Lap2α-/- than in wild type hearts after ISO treatment, although the ISO-
mediated increase of GATA4 expression was similar in both genotypes. Overall, these results 
suggest that loss of LAP2α affects cardiac-specific transcription and progression of ISO-induced 
hypertrophy. 
 
Absence of dystrophin delays the onset of ventricular dysfunction in Lap2α-/-/Mdx mice 
Since baseline systolic dysfunction in Lap2α-/- mice was not progressive and did not affect their life 
span, we thought that the effect of LAP2α loss might be augmented in a cardiomyopathy 
background. Therefore, we crossed Lap2α-/- mice to Mdx mutants12, which develop skeletal muscle 
dystrophy and DCM with advanced age due to the absence of dystrophin26, 27. 
The homozygous Lap2α-/-/Mdx mutant animals were born according to Mendelian ratios and 
appeared grossly indistinguishable from their Mdx littermates. Unexpectedly, echocardiography in 
young Lap2α-/-/Mdx mice showed normal heart function, with FS values similar to WT and Mdx 
(Figure 6, Supplemental table 3). This suggests that the absence of dystrophin can pre-sensitize 
the heart and turn on compensatory pathways leading to a transient rescue of the Lap2α-/- 
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phenotype. Nevertheless, old compound mutant animals, as well as Mdx mice, developed similar 
heart function defects as Lap2α-/- mice (Figure 6, Supplemental table 1, 3).  
 
LAP2α is dispensable in late-embryonic and adult cardiomyocytes 
LAP2α is highly expressed in proliferating tissues28, 29. Since the vast majority of adult 
cardiomyocytes persists in a post-mitotic stage30, and only low levels of LAP2α are present in 
nuclei throughout adult myocardium9 (Figure 1), we thought that LAP2α may exhibit its major 
activity during early cardiomyocyte proliferation and myocardial growth, during which LAP2α 
expression is clearly detectable (Supplemental figure 4). To address this question, we generated 
conditional knockout mice by crossing Lap2αNeo-fl/Neo-fl (see Materials and Methods and 
Supplemental figure 1) animals to mice expressing Cre recombinase under the control of striated 
muscle-specific muscle creatine kinase (Mck) promoter31. In this system, the expression of Cre 
recombinase and the consequent deletion of LAP2α are turned on in heart and skeletal muscle 
during late stages of mouse embryonic development and striated muscle differentiation. Lap2αNeo-
fl/Neo-fl/Mck-Cre+ mice were born at Mendelian ratios and did not demonstrate any overt phenotype. 
LAP2α mRNA and protein levels were significantly reduced in Lap2αNeo-fl/Neo-fl/Mck-Cre+ hearts, 
indicating an efficient recombination in the myocardium (Figure 7A). In contrast, other tissues like 
spleen, which do not express MCK32, had normal levels of LAP2α (unpublished data). 
Echocardiography in Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice showed normal heart function (Figure 7B, 
Supplemental table 4) and histological and morphometric analyses did not reveal any pathological 
heart phenotype (Figure 7C and data not shown). The expression levels of MEF2c and GATA4 
mRNA were similar in Lap2αNeo-fl/Neo-fl/Mck-Cre+ and Lap2α+/+/Mck-Cre+ hearts (data not shown). 
Thus, LAP2α expression in late-embryonic and adult cardiomyocytes is dispensable for normal 
heart function, but may be important during earlier stages of heart development (before E13.5 
when Mck promoter becomes active) or in non-striated muscle cells in the heart.  
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Discussion 
 
In this study we describe a new mouse model of cardiomyopathy caused by the absence of 
LAP2α, a major binding partner of lamin A/C in the nucleoplasm6. Together with previous studies 
linking lamin A/C and the lamin-binding inner nuclear membrane proteins, emerin and nesprin to 
congenital heart disorders1, 3, 9, 33, our data suggest a major role of A-type lamin complexes in 
normal heart function. 
A mutation in the α-specific exon 4 of the human LAP2 gene has previously been linked to familial 
dilated cardiomyopathy9. Here we show that the absence of LAP2α in mice also leads to a heart 
disease. Interestingly, only male Lap2α-/- mice showed a heart defect, whereas female animals 
exhibited normal cardiac function, implicating gender specific factors in the development of the 
disease. Similar gender-related phenotype variations were described in other cardiomyopathy 
mouse models34, including mice carrying the H222P-Lmna mutation35. Although the exact 
background of this phenomenon is still unknown, gender based differences in cardiac dysfunction 
were linked to the activity of steroid hormones36. At present no data about the risk of heart failure in 
male versus female carriers of LAP2α mutations in humans are available. 
In an attempt to disclose the molecular pathway of the disease, we analyzed the expression of 
factors involved in development and remodelling of the myocardium. Lap2α-/- mice showed miss-
regulated expression of major heart transcription factors, MEF2C15 and GATA418, as well as some 
of their downstream targets, at different life stages. Both GATA4 and MEF2C play essential roles in 
embryonic heart development and hypertrophic growth15, 18, 22, 23. However, while systolic 
dysfunction was apparent already in young Lap2α-/- mice, Gata4 levels were decreased only in old 
Lap2α-/- mice, suggesting that the deregulation may be a consequence rather than the cause of the 
disease. Despite lower Gata4 expression levels, Lap2α-/- hearts were able to undergo hypertrophic 
growth. In support of our data, mice with reduced Gata4 levels (G4D mice) show a similar heart 
function defect at baseline, as well as the ability to grow under hypertrophic conditions22. In 
contrast to Lap2α-/- mice, which are at higher risk of heart fibrosis at baseline, G4D mice develop 
fibrosis only after pressure overload as a consequence of increased stress-induced cardiomyocyte 
death22. This discrepancy could be in part explained by differences in the origin, time course and 
extent of Gata4 down-regulation in the two strains (50% reduction of GATA4 in G4D mice versus 
20% in Lap2α-/- animals).  
GATA4 and MEF2c synergistically activate the expression of BNP19, a cardiac hormone involved in 
the regulation of blood pressure and fluid-electrolyte balance, which also plays a role in the 
inhibition of cardiac fibroblast proliferation and extracellular matrix production37. In line with GATA4 
and MEF2c deregulation, we also observed a decrease in BNP levels in Lap2α-/- hearts. 
Interestingly, BNP-deficient mice (Nppb-/-), which exhibit normal heart morphology and hypertrophic 
growth after ventricular pressure overload, also show higher incidence of fibrosis (~50%) in male 
vs. female mice at the age of 15 weeks38.  
The blunted response of LAP2α-deficient hearts to chronic isoproterenol infusion points to the 
existence of compensatory pathways activated in response to changes in cardiac function in 
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Lap2α-/- mice. The attenuated hypertrophic growth and lack of fibrosis observed in β-AR knockout 
mice after pressure overload39 indicate that the downregulation of β-AR signalling found in Lap2α-/- 
hearts might be a part of this process.  
The variability in the extent of fibrosis at baseline, as well as after chronic ISO infusion, might be 
explained by the observed de-regulated expression of pro- and anti-fibrotic factors in Lap2α-/- mice. 
Since LAP2α is highly expressed in proliferating tissues and only weakly in post-mitotic tissues9, 28, 
29, such as heart muscle30, we hypothesized that LAP2α might be required during cardiac 
development and/or postnatal myocardial remodelling, mediated by putative cardiac stem 
cells40.Therefore, we generated conditional knockout mice which lose LAP2α during later stages of 
embryonic development and adult striated muscle differentiation31. Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice 
showed normal heart function and normal levels of GATA4 and MEF2c, suggesting that the defect 
in complete knockout mice might arise in early embryonic development and at early stages of 
muscle differentiation, before Mck promoter becomes active, and/or it might be a consequence of 
LAP2α loss from heart stem- and non-striated muscle cells.  
We have previously shown that LAP2α retains a sub-fraction of the nuclear lamin A/C pool inside 
the nucleoplasm in proliferating skin fibroblasts and intestinal cells8. In contrast, nucleoplasmic 
lamin A/C is lost in non-dividing differentiated cells8, implicating the nucleoplasmic pool of lamin 
A/C in regulation of the transition from proliferating to the differentiated state. The nuclear 
localization of lamin A/C has also been shown to change in cardiomyocytes during aging and 
development from mainly nucleoplasmic to peripheral41. The elongated shape and different 
orientation of cardiomyocyte nuclei within heart tissue, however, precluded the detection of 
potential changes in lamin A/C localization in LAP2α-deficient tissue. In view of the lack of heart 
defects in muscle-specific conditional LAP2α knock out mice, there is a possibility that a potential 
mislocalization of lamin A/C in LAP2α-deficient cardiomyocyte precursor or non-striated muscle 
cells may be the primary cause of the Lap2α-/- cardiac defect. Alternatively lack of LAP2α may 
change the function, rather than localization of lamin A/C, such as binding to epigenetic modifiers 
and components of different signalling cascades7, 42, which in turn may lead to cardiomyopathy. 
This model is consistent with previous reports that have linked lamin A/C-related cardiomyopathies 
to changes in signalling pathways, such as TGFβ, PI3-kinase and MAPK43, which influence MEF2c 
and GATA4 expression during development and hypertrophic growth44, 45 and are also affected by 
β-AR signalling24.  
In summary, we show that the absence of LAP2α causes a baseline ventricular systolic dysfunction 
in male mice and activates compensatory pathways that prevent further decline of heart function 
under chronic stress conditions. The origins of these defects, which could lie in impaired 
proliferation and/or differentiation of early embryonic cardiomyocytes, resident cardiac stem cells or 
non-muscle cardiac tissue, remain to be discovered.  
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Figure legends 
 
Figure 1. LAP2α is absent from heart muscle tissue of Lap2α-/- mice. A) Immunofluorescence 
analysis of Lap2α+/+ and Lap2α-/- heart tissue. B) LAP2α mRNA and protein are absent from heart 
muscle tissue of Lap2α-/- mice, while the expression of lamin A/C and alternative LAP2 splice 
variants remains unaltered. (Western blot and semiq.-RT-PCR analyses. Samples were normalized 
for endogenous γ-tubulin and GAPDH content respectively). 
 
Figure 2. Loss of LAP2α impairs heart function in mice. Echocardiography data show left 
ventricular systolic dysfunction in young (10 weeks) and old male Lap2α-/- mice (10-12 months). 
(FS – fractional shortening; LA – left atrium diameter, *p<0.05 ANOVA, values are means ± SE). 
 
Figure 3. Old Lap2α-/- hearts are more susceptible to fibrosis. A) Young Lap2α-/- myocardium is 
histologically indistinguishable from the wild type, whereas B) 18% of the old Lap2α-/- hearts shows 
disperse fibrotic foci (upper panels haematoxylin & eosin, lower panels Picro-sirius red stained 
heart sections). C) Thinning of the old Lap2α-/- myocardium – arrows mark the transparent fibrotic 
regions of the heart. 
 
Figure 4. Deregulated expression of major cardiac transcription factors in LAP2α-deficient mice. A) 
MEF2c and GATA4, as well as their downstream targets BNP and Myocardin A (MYOCA), are 
downregulated on mRNA level at specific stages in Lap2α-/- mice. B) STARS mRNA levels are 
lower only in old LAP2α-deficient hearts. C) Old Lap2α-/- mice exhibit a decrease in CTGF 
expression and normal TGFβ2 mRNA content. qPCR and semiq.-PCR analyses of heart tissue. n = 
4 – 5 littermate pairs of each age. Samples were normalized for endogenous HPRT mRNA levels 
in qPCR according to Pfaffl method14, and GAPDH in semiq-PCR. Each knockout (KO) sample was 
compared to its respective wild type (WT) littermate sample. Data are presented as average 
WT/KO expression ratios ± SE. *p<0.05, ANOVA. 
 
Figure 5. Lap2α-/- mice show a blunted response to chronic isoproterenol infusion. A) Lap2α+/+ and 
Lap2α-/- exhibit a similar increase in heart weight/body weight (HW/BW) index after 7 days of ISO 
treatment. (*p<0.05 ANOVA). B) Echocardiography reveals the absence of significant left 
ventricular chamber dilatation in Lap2α-/- mice and a preserved basal systolic function in both 
genotypes. (LVDd/s – left ventricular diameter in diastole/systole; ESVl – end-systolic left 
ventricular volume; EDVl – end-diastolic left ventricular volume). Data were analysed using 
Students’ paired t-test (comparisons within one genotype before and after the treatment), one way-
ANOVA (comparisons between the two genotypes). (a) p<0.05, (b) p = 0.05. C) Relative baseline 
mRNA levels of β2-AR are lower in Lap2α-/- hearts compared to wild type, whereas ISO treatment 
causes its downregulation in both genotypes. D) ISO-induced increase in expression of foetal and 
pro-fibrotic genes is diminished in the absence of LAP2α. (qPCR analyses of heart tissue, n = 5 
ISO-treated + 4 – 5 untreated littermate pairs of each age; ANOVA, p<0.05 (c) WT vs. KO of the 
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respective age (mean ± SE), (d) WT baseline vs. WT ISO-treated and (e) KO baseline vs. KO ISO-
treated animals).  
 
Figure 6. Absence of dystrophin delays the onset of ventricular dysfunction in Lap2α-/-/Mdx mice. 
FS values in young Lap2α-/-/Mdx mice are higher compared to Lap2α-/- animals, whereas old mice 
of both genotypes show similar systolic dysfunction (ANOVA; p<0.05 for (a) WT vs. KO, (b) WT vs. 
Mdx and (c) WT vs. Lap2α-/-/Mdx mice). 
 
Figure 7. LAP2α is dispensable in late-embryonic and adult cardiomyocytes. A) Reduced LAP2α 
mRNA and protein levels in Lap2αNeo-fl/Neo-fl/Mck-Cre+ vs. Lap2α+/+/Mck-Cre+ heart tissue (samples 
were normalized to GAPDH in semiq PCR and to γ-tubulin in western blot analysis). B) Normal FS 
values in young Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice (p>0.05, ANOVA). C) Normal heart structure in 
conditional knockout mice. 
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Supplemental Legends 
 
Supplemental figure 1. Generation of Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice. 
A) Crossing Lap2αfl/flmice1 to Flp-deleter mice2 resulted in removal of the Neomycine resistance 
cassette from the transgenic Lap2 locus in all tissues. B) The newly generated Lap2αNeo-fl/Neo-fl 
strain was interbred to Mck-Cre transgenic line3 to create striated muscle-specific Lap2α-/- mice 
lacking the α-specific exon 4 of the Lap2 gene only in tissues expressing MCK (Lap2αNeo-fl/Neo-
fl/Mck-Cre+) C). 
 
Supplemental figure 2. Lamin A/C localization in Lap2α-/- heart cells appears normal. 
(Immunofluorescence analysis of old heart tissue). 
 
Supplemental figure 3. ISO-treatment causes subendocardial fibrosis in both Lap2α-/- and wild 
type mice. (Picro-sirius stained heart sections). 
 
Supplemental figure 4. LAP2α is highly expressed in developing cardiac tissue. 
Immunofluorescence analysis of heart tissue sections at embryonic day 12 and 14 (E12 and E14) 
and postnatal day 2 (P2). 
Manuscript I Results & Discussion 3-92
Supplemental table 1. Echocardiography reveals impaired heart function in male Lap2α-/- mice.  
Young mice (10 weeks)         
  Lap2α+/+  M Lap2α-/- M Lap2α+/+  F Lap2α-/-  F 
                  
n 8 8 4 4 
Heart rate/ bpm 410.63 ± 15.76 410.25 ± 21.72 380.00 ± 17.80 387.50 ± 12.50 
FS % 36.72 ± 1.23 27.97 ± 1.38* 37.22 ± 0.81 36.49 ± 1.44 
       
LVDd/cm 0.36 ± 0.01 0.35 ± 0.03 0.34 ± 0.02 0.33 ± 0.01 
LVDs/cm 0.23 ± 0.01 0.25 ± 0.02 0.22 ± 0.01 0.21 ± 0.01 
LVPWd/mm 0.85 ± 0.06 0.82 ± 0.10 0.74 ± 0.07 0.72 ± 0.03 
LVPWs/mm 1.43 ± 0.08 1.23 ± 0.07 1.26 ± 0.09 1.16 ± 0.05 
IVSd/mm 0.91 ± 0.04 0.81 ± 0.04 0.79 ± 0.06 0.73 ± 0.02 
IVSs/mm 1.26 ± 0.07 1.17 ± 0.09 1.11 ± 0.11 0.96 ± 0.06 
LA/mm 2.14 ± 0.15 2.82 ± 0.21* 2.70 ± 0.34 2.56 ± 0.07 
ESVI ml/m2 0.04 ± 0.00 0.05 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 
EDVI ml/m2 0.14 ± 0.01 0.14 ± 0.03 0.14 ± 0.02 0.12 ± 0.01 
EF % 73.18 ± 0.02 61.00 ± 0.02* 74.01 ± 0.96 73.08 ± 1.72 
       
        
Old mice (10-12 months)         
  Lap2α+/+  M Lap2α-/- M Lap2α+/+  F Lap2α-/-  F 
                  
n 11 13 4 5 
Heart rate/ bpm 418.91 ± 15.80 428.31 ± 10.31 430.00 ± 14.63 408.00 ± 35.28 
FS % 36.88 ± 0.86 30.39 ± 1.67* 33.00 ± 3.41 37.83 ± 3.94 
       
LVDd/cm 0.36 ± 0.02 0.38 ± 0.01 0.36 ± 0.01 0.39 ± 0.03 
LVDs/cm 0.23 ± 0.01 0.26 ± 0.01 0.23 ± 0.02 0.24 ± 0.03 
LVPWd/mm 0.91 ± 0.05 0.92 ± 0.06 0.71 ± 0.03 0.77 ± 0.04 
LVPWs/mm 1.48 ± 0.07 1.41 ± 0.07 1.33 ± 0.11 1.23 ± 0.17 
IVSd/mm 0.91 ± 0.03 0.92 ± 0.04 0.84 ± 0.02 0.75 ± 0.07* 
IVSs/mm 1.30 ± 0.07 1.28 ± 0.07 1.16 ± 0.06 1.01 ± 0.07 
LA/mm 2.37 ± 0.16 2.75 ± 0.23 2.40 ± 0.29 2.13 ± 0.22 
ESVI ml/m2 0.04 ± 0.01 0.05 ± 0.01 0.03 ± 0.00 0.04 ± 0.01 
EDVI ml/m2 0.13 ± 0.01 0.13 ± 0.02 0.13 ± 0.01 0.16 ± 0.00 
EF % 73.43 ± 0.01 64.65 ± 0.03* 73.66 ± 2.06 73.78 ± 4.45 
*p<0.05 ANOVA, values are represented as ± standard error (SE). M – male; F – female; n = number of mice; 
bpm – beats per minute; FS% – fractional shortening; LVDd/s – left ventricular diameter in diastole/systole; 
LVPWd/s left ventricular posterior wall thickness in diastole/systole; IVSd/s – interventricular septum thickness 
in diastole/systole, LA – left atrium diameter; ESVI – end-systolic left ventricular volume index; EDVI – end-
diastolic left ventricular volume index; EF% – ejection fraction. 
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Supplemental table 2. Lap2α-/- mice show a blunted response to chronic isoproterenol infusion. 
Echocardiography parameters recorded before and after ISO-infusion.  
Isoproterenol         
  Lap2α+/+ M Lap2α-/-M Lap2α+/+ M Lap2α-/-M 
Old mice (10 months) Before Isoproterenol 
n 6 7 6 7 
Heart rate/ bpm 489.50 ± 26.27 452.57 ± 10.16 507.17 ± 36.33 532.29 ± 14.55** 
FS % 33.44 ± 2.37 29.77 ± 1.61 29.63 ± 3.70 25.84 ± 2.94 
       
LVDd/cm 0.30 ± 0.01 0.35 ± 0.02 0.41 ± 0.01** 0.41 ± 0.02 
LVDs/cm 0.20 ± 0.01 0.24 ± 0.01 0.29 ± 0.02** 0.31 ± 0.02 
LVPWd/mm 1.14 ± 0.09 1.05 ± 0.06 1.00 ± 0.05 1.06 ± 0.10 
LVPWs/mm 1.60 ± 0.08 1.51 ± 0.03 1.42 ± 0.10 1.41 ± 0.09 
IVSd/mm 1.07 ± 0.04 0.96 ± 0.05 0.89 ± 0.07 1.02 ± 0.10 
IVSs/mm 1.50 ± 0.07 1.40 ± 0.04 1.31 ± 0.08 1.45 ± 0.11 
LA/mm 3.02 ± 0.31 3.05 ± 0.38 3.44 ± 0.31 3.81 ± 0.39 
ESVI ml/m2 0.02 ± 0.00 0.04 ± 0.01 0.06 ± 0.01** 0.07 ± 0.01 
EDVI ml/m2 0.07 ± 0.01 0.10 ± 0.01 0.15 ± 0.01** 0.16 ± 0.02 
EF % 68.82 ± 3.28 63.69 ± 2.43 62.21 ± 6.00 56.52 ± 5.00 
         
Sham (PBS)         
  Lap2α+/+ M Lap2α-/-M Lap2α+/+ M Lap2α-/-M 
  Before PBS 
n 2 2 2 2 
Heart rate/ bpm 465.00 ± 55.00 500.00 ± 40.00 445.00 ± 15.00 477.50 ± 37.50 
FS % 34.64 ± 4.49 34.07 ± 0.29 33.44 ± 3.01 32.70 ± 1.93 
       
LVDd/cm 0.31 ± 0.01 0.31 ± 0.02 0.30 ± 0.00 0.34 ± 0.00 
LVDs/cm 0.20 ± 0.02 0.21 ± 0.01 0.20 ± 0.01 0.23 ± 0.01 
LVPWd/mm 0.97 ± 0.00 1.07 ± 0.09 1.06 ± 0.09 1.14 ± 0.17 
LVPWs/mm 1.17 ± 0.20 1.37 ± 0.04 1.38 ± 0.05 1.43 ± 0.13 
IVSd/mm 1.01 ± 0.30 1.17 ± 0.01 1.05 ± 0.05 1.11 ± 0.07 
IVSs/mm 1.33 ± 0.23 1.72 ± 0.03 1.42 ± 0.07 1.72 ± 0.16 
LA/mm 2.40 ± 0.00 1.87 ± 0.40 2.35 ± 0.35 2.15 ± 0.20 
ESVI ml/m2 0.02 ± 0.01 0.02 ± 0.00 0.02 ± 0.00 0.03 ± 0.00 
EDVI ml/m2 0.06 ± 0.01 0.06 ± 0.01 0.06 ± 0.00 0.08 ± 0.00 
EF % 70.54 ± 5.89 70.17 ± 0.33 69.21 ± 4.05 68.15 ± 2.65 
Data were analysed using Students’ paired t-test (comparisons within one genotype before and after the 
treatment) and ANOVA (comparisons between the two genotypes and multiple comparisons), followed by 
Boniferroni adjustment where applicable. **p<0.05 Students’ paired t-test; mean values ± SE are shown. 
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Supplemental table 3. Echocardiography parameters – Lap2α-/-/Mdx mice. 
  Lap2α+/+/Mdx Lap2α-/-/Mdx Lap2α+/+/Mdx Lap2α-/-/Mdx 
  Young (10 weeks) Old (10-12 months) 
n 3 3 4 5 
Heart rate/ bpm 400.00 ± 0.00 413.33 ± 17.64 442.50 ± 63.03 404.00 ± 26.94 
FS % 39.51 ± 0.43* 39.58 ± 1.46* 31.22 ± 2.74** 28.24 ± 2.21** 
       
LVDd/cm 0.37 ± 0.03 0.38 ± 0.02 0.42 ± 0.01 0.41 ± 0.01 
LVDs/cm 0.22 ± 0.01 0.23 ± 0.02 0.29 ± 0.02 0.30 ± 0.01 
LVPWd/mm 0.58 ± 0.08 0.70 ± 0.11 0.73 ± 0.07 0.70 ± 0.04 
LVPWs/mm 1.15 ± 0.09 1.28 ± 0.11 1.17 ± 0.07 1.03 ± 0.10 
IVSd/mm 0.75 ± 0.04 0.71 ± 0.02 0.91 ± 0.10 0.87 ± 0.07 
IVSs/mm 1.10 ± 0.13 1.10 ± 0.09 1.11 ± 0.11 1.08 ± 0.06 
LA/mm 2.16 ± 0.16 2.50 ± 0.07 3.43 ± 0.14 3.27 ± 0.18 
ESVI ml/m2 0.03 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 
EDVI ml/m2 0.14 ± 0.03 0.15 ± 0.02 0.16 ± 0.01 0.15 ± 0.01 
EF % 76.63 ± 0.43 76.62 ± 1.70 65.45 ± 3.97 61.05 ± 3.64 
*p<0.05, ANOVA, Lap2α-/- vs Lap2α+/+/Mdx and Lap2α-/-/Mdx young mice. 
**p<0.05, ANOVA, Lap2α+/+ vs Lap2α+/+/Mdx and Lap2α-/-/Mdx old mice. 
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Supplemental table 4. Echocardiography parameters – Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice. 
  Lap2α+/+/Mck-Cre+ Lap2αNeo-fl/Neo-fl/Mck-Cre+ 
Young (10 weeks)         
n 5 5 
Heart rate/ bpm 360.00 ± 7.07 378.00 ± 18.81 
FS % 32.54 ± 1.01 33.88 ± 1.42 
    
LVDd/cm 0.39 ± 0.01 0.38 ± 0.01 
LVDs/cm 0.26 ± 0.01 0.25 ± 0.01 
LVPWd/mm 0.72 ± 0.05 0.72 ± 0.02 
LVPWs/mm 1.22 ± 0.08 1.28 ± 0.07 
IVSd/mm 0.79 ± 0.02 0.84 ± 0.05 
IVSs/mm 1.05 ± 0.09 1.06 ± 0.07 
LA/mm 2.38 ± 0.13 2.35 ± 0.19 
ESVI ml/m2 0.05 ± 0.00 0.04 ± 0.01 
EDVI ml/m2 0.14 ± 0.01 0.13 ± 0.01 
EF % 67.78 ± 1.38 69.55 ± 1.97 
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Supplemental table 5. Primer sequences used for quantitative and semi-quantitative PCR. 
Name/Target Sequence Tm ºC Source 
Adrb2_forward TCTGTGCCTTCGCAGGTCTT 59,4 
Adrb2_reverse GTCCGTTCTGCCGTTGCTA 58,8 
4 
ANF_forward CGGTGTCCAACACAGATCTG 59,4 
ANF_reverse TCTCTCGAGGTGGGTTGAC 58,8 
5 
mBNP_forward CTGCTGGAGCTGATAAGAGA 57,3 
mBNP_reverse TGCCCAAAGCAGCTTGAGAT 57,3 
6 
Cre2_forward CGAACGCACTGATTTCGA 56,7 
Cre2_reverse GGCAACACCATTTTTTCTGAC 55,9 
7 
Ctgf_forward TGTGTGACGAGCCCAAGGA 58,8 
Ctgf_reverse TTGGGTCTGGGCCAAATGT 56,7 
8 
GAPDH-hm1 CATCACCATCTTCCAGGAGCGA 62,1 
GAPDH-hm2 CCTGCTTCACCACCTTCTTGAT 60,3 
9 
GATA4b_forward CACTATGGGCACAGCAGCTCC 63,7 
GATA4b_reverse TTGGAGCTGGCCTGCGATGTC 63,7 
10 
Hprt_forward TGATTAGCGATGATGAACCAGG 58,4 
Hprt_reverse CTTTCATGACATCTCGAGCAAG 60,3 
11 
LAP2com_hm1 GTGGGAACAACCAGGAAGCTATATGA 63,2 
LAP2ar_hm1 AGAGTGCTAAGTCCAACTGCTGAT 61,0 
LAP2br_hm1 CTCCCACTTCAGCTCTTGTCAATG 62,7 
1 
mLamAC1091f CATCAAGCTGGCCCTGGACATGGA 67,9 
mLamAC1549r TGCGCCTTCCACACCAAGTCAGTA 66,3 
1 
MEF2C-RT2-1 GTATGTCTCCTGGTGTAACA 55,3 
MEF2C-RT2-2 GGATATCCTCCCATTCCTTG 57,3 
12 
MCK_forward GAGATCTTCAAGAAGGCTGGTCA 60,6 
MCK_reverse GAGATGTCGAACACGGCG 58,2 
13 
MyocardinA_forward TCACTGTGTGGAGTCCTCAGGTC 64,2 
MyocardinA_reverse TGGCATCGGCTGGCATTT 58,8 
14 
STARS_forward GGCTCCTGCCAGGATCAAAC 61,4 
STARS_reverse TAGCCCTCGTCTCCCTTGTG 61,4 
NM_175456.4
TGFβ_forward AGCGCTACATCGATAGCAAG 57,3 
TGFβ_reverse TCCTGTCTTTGTGGTGAAGC 57,3 
8 
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Abstract 
 
Lamina-associated polypeptide 2α (LAP2α) is a nucleoplasmic protein implicated in cell cycle 
regulation through its interaction with A-type lamins and the retinoblastoma protein (pRb). 
Mutations in lamin A/C and LAP2α cause late onset striated muscle diseases, but the molecular 
mechanisms are poorly understood. To study the role of LAP2α in skeletal muscle function and 
postnatal tissue homeostasis, we generated complete and muscle-specific LAP2α knockout mice. 
While overall muscle morphology, function and regeneration were not detectably affected, the 
myofibre-associated muscle stem cell pool was increased in LAP2α-deficient mice. At molecular 
level, the absence of LAP2α preserved the stem cell-like phenotype of primary myoblasts and 
delayed their in vitro differentiation. In addition, loss of LAP2α shifted the myofibre type ratios of 
adult slow muscles towards fast fibre types. Muscle-specific ablation of LAP2α affected early 
stages of myoblast differentiation, as well as fibre type determination, but did not change fibre-
associated stem cell numbers. Our data demonstrate multiple and distinct functions of LAP2α in 
muscle stem cell maintenance, early phases of myogenic differentiation and muscle remodelling.  
Results & Discussion Manuscript II 3-103
Keywords: Lamin / LAP2α / Muscle fibre type / Regeneration /Satellite cells 
 
List of Abbreviations  
BMP4  Bone Morphogenetic Protein 4 
CSM4B  CD45-Sca1-Mac1-CXCR4+β1-integrin+ 
EDL   Extensor Digitorum Longus 
EDMD   Emery Dreifuss Muscular Dystrophy  
GAPDH Glycerinaldehyde-3-phosphate-Dehydrogenase 
GO  Gene Ontology 
H & E   Haematoxylin and Eosin 
HPRT  Hypoxanthine-Guanine Phosphoribosyl Transferase 
IGF  Insulin-like Growth Factor 
LAP2  Lamina Associated Polypeptide 
LEM   LAP2-Emerin-MAN1 
MAPK  Mitogen-activated Protein Kinase 
MCK   Muscle Creatine Kinase 
MEF2c  Myocyte Enhacner Factor 
MFPL  Max F. Perutz Laboratories 
MyHC   Myosin Heavy Chain 
PDGF  Platelet-derived Growth Factor Receptor 
qPCR    Quantitative PCR 
Rb  Retinoblastoma protein 
SE   Standard Error 
SHH  Sonic Hedgehog 
TA   Tibialis Anterior 
3-104 Manuscript II Results & Discussion 
Introduction 
 
 Muscular dystrophies are clinically and genetically heterogeneous disorders 
characterized by progressive muscle wasting and weakness. The most prominent genes involved 
in their development encode structural components of the sarcolemma, the cytoskeleton and the 
extracellular matrix (1). In the past decade, a group of idiopatic muscular dystrophies has been 
linked to mutations in nuclear envelope proteins, including lamin A/C and some of its binding 
partners. Lamins form a supporting framework for the nucleus and regulate various cellular 
processes such as DNA replication, transcription and signal transduction (2).  
 The onset of pathological symptoms in most lamin A/C-associated striated muscle 
disorders, such as Emery-Dreifuss and Limb-girdle muscular dystrophy 1B, occurs in early 
adulthood (2), pointing to a defect in stem-cell mediated adult tissue homeostasis and damage 
repair (3). Adult stem cells in muscle are represented by a heterogeneous population of quiescent, 
autonomously myogenic, cells in a satellite position between the myofibre and the basal lamina (4). 
The maintenance and self-renewal of these, so called, satellite cells depends on the expression of 
a member of the paired box transcription factor family, Pax7, which antagonizes the activity of the 
major myogenic regulatory factor MyoD and keeps the cells in an undifferentiated state (5). 
 Lamina-associated polypeptide 2α (LAP2α) is a lamin A/C binding protein that has 
been implicated in the regulation of proliferation and differentiation of adult tissue progenitor cells 
(6). LAP2α is a mammal-specific non-membrane-associated isoform of the vertebrate LAP2 gene 
(7), which localizes to the nucleoplasm and interacts with chromatin through its LAP2-common N-
terminal LEM (LAP2-emerin-MAN1) domain and a unique C-terminal α-specific region (8, 9). The 
C-terminus of LAP2α also binds a distinct fraction of lamin A/C inside the nucleus and regulates 
cell cycle progression by affecting retinoblastoma (Rb)-mediated E2F-dependent transcription (6, 
10). Interestingly, a mutation in LAP2α affecting its lamin A/C interaction has also been linked to a 
pathological heart condition (11), symptomatically similar to lamin A/C-linked cardiomyopathies (2), 
pointing to a common disease mechanism of these two proteins.  
Taking into account the potential impairment of muscle homeostasis and tissue 
regeneration in striated muscle disorders linked to mutations in lamin A/C and LAP2α, we analyzed 
the functional properties of the satellite cell pool in the recently described Lap2α-/- mice. Here we 
demonstrate that lack of LAP2α preserves the stem cell phenotype of satellite cells and delays their 
differentiation and has an additional role in muscle fiber type remodelling. 
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Results 
 
Absence of LAP2α in mice causes an increase in the muscle satellite cell pool 
Deletion of the α-specific Lap2 exon 4 in mice (6) resulted in complete ablation of LAP2α protein in 
skeletal muscle, without affecting the expression of other LAP2 isoforms. In addition, loss of LAP2α 
did not markedly alter the expression or localization of its major binding partner lamin A/C in 
muscle tissue (Supplemental Figure 1a; 1b). Lap2α-/- mice showed no overt dystrophic muscle 
phenotype at histological level under normal conditions within 19 months after birth (Supplemental 
Figure 2) (6). Based on our previous findings, demonstrating a role of LAP2α in proliferation of 
adult tissue stem/progenitor cells (6), we hypothesized that the activity and maintenance of the 
satellite cell pool, which normally expresses LAP2α (Figure 1a), might be affected in LAP2α-
deficient muscle tissue. To identify the putative self-renewing stem cell population in adult muscle, 
we used a combination of cell surface markers (CD45, Sca1, Mac1 and CXCR4, β1-integrin), 
whose absence or presence, respectively, defines the majority of autonomously myogenic cells 
(>90% Pax7+) within the myofibre-associated satellite cell compartment (12). Fluorescence-
activated cell sorting (FACS) analysis of enzymatically digested skeletal muscle tissue revealed a 
~43% increase in the CD45-Sca1-Mac1-CXCR4+β1-integrin+ (CSM4B) satellite cell pool within the 
fibre-associated CD45-Sca1-Mac1- cell population in young (aged 10 weeks) Lap2α-/- mice 
compared to their wild type (WT) littermates (Figure 1b), pointing to a defect in the regulation of the 
stem cell pool. In WT mice, CSM4B cell numbers gradually decreased during aging, reaching 65% 
and 46% of the level in young muscle after 6 (defined as adult) and 19 (defined as old) months 
respectively. Interestingly, the increase in the CSM4B satellite cell population in young Lap2α-/- vs. 
WT mice was completely lost by the age of 6 months, suggesting that the initial increase in CSM4B 
cell numbers might be a consequence of their accelerated proliferation and/or delayed myogenic 
commitment during early postnatal muscle growth.  
 
Activated Lap2α-/- satellite cells retain a stem cell-like phenotype in vitro 
To identify genes and molecular pathways directly or indirectly affected by the loss of LAP2α in 
skeletal muscle, we performed genome-wide microarray (GeneChip) analyses and compared 
global gene expression profiles of primary Lap2α+/+ and Lap2α-/- neonatal myoblasts, representing 
activated satellite cell progeny. Surprisingly, the differential gene expression profile revealed that 
only a small number of genes, other than Lap2, was affected by the Lap2α knockout: a total of 124 
probe sets corresponding to 98 well-annotated genes, showed altered expression, with the majority 
(~66%) being downregulated. (Figure 2, Supplemental Table 1). Interestingly, among the few 
genes whose expression was enhanced in the absence of LAP2α, we found genes encoding 
proteins involved in stem cell renewal, early stages of muscle differentiation and tissue 
development/regeneration, such as Pax7 (13), Myf5 (14) syndecan 4 (Sdc4) (15), netrin 4 (Ntn4) 
(16) and the Notch signaling target Hey1 (17) (Table 1). In addition, components of several 
signaling cascades, such as BMP4, SHH, IGF, PDGF and MAPK, which influence muscle 
development and homeostasis (18, 19), were downregulated in Lap2α-/- cells (Table 1). 
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Furthermore, LAP2α-deficient cells exhibited downregulation of several extracellular matrix proteins 
(Table 1), consistent with the observed looser attachment of the knockout cells to the surface of the 
culture dish (data not shown). The decreased expression of genes encoding extracellular matrix 
components, accompanied by the upregulation of stem cell genes, indicates a preservation of a 
stem cell-like phenotype of activated Lap2α-/- satellite cells, which favour self-renewal as opposed 
to skeletal muscle commitment, potentially explaining the increase in CSM4B cell numbers 
observed in vivo. 
 
Lap2α-/- myoblasts exhibit delayed differentiation 
To test whether the upregulated expression of stem cell determinants in proliferating Lap2α-/- 
myoblasts causes a concomitant defect in their differentiation towards myotubes, we compared the 
in vitro differentiation potentials of LAP2α-deficient and WT primary myoblasts (Figure 3). As 
previously reported (20), protein and mRNA levels of LAP2α in wild type cells peaked at the onset 
of myoblast differentiation and declined at later stages (Figure 3a, b upper panels). Loss of LAP2α 
did not substantially affect the expression of lamin A/C at protein level in primary myoblasts, 
although a slight temporal upregulation of the mRNA transcript was observed during initial stages 
of their differentiation (Figure 3a; 3b). Consistent with the microarray data, Pax7 was upregulated in 
proliferating Lap2α-/- myoblasts compared to WT cells at both mRNA and protein level (Figure 3a 
and data not shown). Interestingly, loss of LAP2α caused a decrease in protein levels of the major 
myogenic differentiation factor MyoD (Figure 3a middle panels), while the mRNA levels of both 
MyoD and its related myogenic regulatory factor Myf5 were upregulated, indicating a compensatory 
mechanism in response to reduced MyoD protein levels (Figure 3b, middle panels). In line with the 
downregulation of MyoD protein, LAP2α-deficient cells also showed delayed expression of MyoD 
target genes and co-factors, such as desmin and myocyte enhancer factor 2c (MEF2c), which 
specify early phases of myoblast differentiation. Similarly, the expression of the late stage 
differentiation marker myosin heavy chain (MyHC) (5, 21) was reduced in LAP2α-deficient 
myoblasts (Figure 3a; 3b lower panels). Still, Lap2α-/- myoblasts were able to differentiate in vitro 
into MyHC-containing myotubes (Figure 3c), albeit in a slightly delayed manner. The transient rise 
in LAP2α and lamin A/C expression, within the first 3 days of in vitro differentiation in WT 
myoblasts, and the delayed expression of muscle-specific markers in LAP2α-deficient cells, point 
to a role of LAP2α in early stages of myoblast differentiation. These data are consistent with the 
proposed function of LAP2α and lamin A/C in controlling the balance between proliferation and 
differentiation of progenitor cells in adult tissues (6). 
 
Loss of LAP2α does not affect in vivo muscle regeneration in mice  
As proliferation of activated satellite cells and differentiation of their progeny represent the 
hallmarks of muscle regeneration, we wondered whether the observed delay in in vitro 
differentiation of LAP2α-deficient myoblasts would also affect tissue repair in vivo. Taking into 
account the observed age-related differences in CSM4B satellite cell numbers, we tested the ability 
of young, as well as old, Lap2α-/- muscle to regenerate after notexin-induced acute injury. Within 
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the first 4 days after injury, the muscle resident myogenic stem cells generated a population of 
proliferating myoblasts, which differentiated and fused into myofibres expressing the embryonic 
form of MyHC (EMyHC), in both, WT and Lap2α-/- mice (Figure 4a, right panels). During myofibre 
maturation, EMyHC was replaced by adult myosin isoforms and muscle integrity was restored by 
day 12 in both – WT and Lap2α-/- mice (Figure 4). To evaluate the efficiency of muscle regeneration 
in our system more precisely, we measured the size of the newly formed EMyHC+ myofibres within 
the damaged region at day 4 and calculated the corresponding fibrotic indexes (for details see 
Materials and Methods). Although muscle regeneration (lower fibrotic indexes) appeared better in 
young versus old Lap2α-/- animals, there were only subtle, statistically non-significant differences 
between WT and Lap2α-/- age-matched mice (Figure 4b). Thus, the increased satellite cell pool of 
young Lap2α-/- mice was not able to enhance muscle regeneration, probably due to a delay in 
myogenic differentiation, leading to a net effect of zero.  
In order to test whether muscle regeneration would be affected in Lap2α-/- mice under conditions of 
constant muscle damage, we crossed Lap2α-/- mice with the Duchenne muscular dystrophy mouse 
model line Mdx (22). Chronic muscle damage in Mdx mutants, caused by the absence of the 
sarcolemma-linked protein dystrophin, evokes repetitive satellite cell activation and tissue repair 
(22). Lap2α-/-/Mdx mutant mice appeared indistinguishable from their Mdx littermates and 
presented signs of muscle damage and hypertrophy starting at the age of 3 weeks (data not 
shown), as described for the Mdx mice (22), suggesting that LAP2α loss does not significantly 
affect muscle regeneration in vivo.  
 
Absence of LAP2α promotes fast fibre phenotype in predominantly slow muscles  
Muscle is a highly dynamic tissue able to modify its metabolic and contractile properties according 
to physiological needs. On the basis of specific MyHC isoform expression, size and metabolic 
profile, skeletal muscle fibres are classified into two major groups: the thinner, type I or slow-twitch 
fibres, which exhibit low velocity of shortening and are required for maintenance of posture and 
muscle endurance, and thicker, fast or type II (IIa, IIx/d, IIb) fibres which exert quick contractions 
and are engaged in movements requiring strength and speed (23). MyoD and MEF-2c transcription 
factors orchestrate the transformation of mature muscle fibres in response to physiological signals, 
such as enervation and endocrine/nutritional cues. Whereas, high levels of active MyoD are found 
in muscles predominantly composed of fast myofibres, the slow muscle phenotype seems to 
depend on MEF2c, among other factors (23). Since MyoD and MEF2c showed aberrant expression 
patterns during in vitro differentiation of LAP2α-deficient myoblasts, we predicted that the tightly 
regulated process of muscle remodelling might be affected in Lap2α-/- mice. To test this hypothesis 
we analyzed fibre type composition of predominantly fast (Tibialis anterior – TA) and slow (soleus) 
muscles in WT and Lap2α-/- mice by immunohistochemistry (Figure 5a). Interestingly, whereas 
myofibre type and size distributions of Lap2α-/- TA muscle were similar to WT (data not shown), the 
soleus muscle of adult Lap2α-/- mice exhibited a shift towards the fast fibre phenotype (from 53% 
type I + 47% type II → 44% type I + 56% type II fibres) (Figure 5a; 5b) without a significant change 
in the myofibre cross-sectional area (Figure 5c). However, the change in fibre type composition of 
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particular slow muscles did not affect muscle strength and general fitness of Lap2α-/- mice at 
measurable level. Their performance in various tests assessing muscle and lower motor neuronal 
function, such as locomotor activity, wire manoeuvre, forced and voluntary wheel, rotarod and swim 
test, included in the SHIRPA mouse phenotypic assessment protocol (24), were similar to that of 
their WT littermates (data not shown). 
 
Muscle-specific ablation of LAP2α reveals functions during early myoblast differentiation 
and muscle transformation distinguishable from those in stem cell maintenance  
In order to determine the stage of muscle differentiation during which LAP2α exerts its specific 
functions in vivo and to test the possible contribution of defects in other tissues to the observed 
muscle phenotype in full LAP2α knockout mice, we generated conditional, striated muscle-specific 
LAP2α-deficient animals. By using the previously described Mck-Cre+ line (25), which expresses 
Cre recombinase under the control of late muscle-specific promoter Mck (muscle creatine kinase), 
we generated mice that lose LAP2α expression during later stages of muscle differentiation 
(unpublished data). As expected, proliferating myoblasts and non-muscle tissues such as spleen, 
which do not express MCK and Cre recombinase, exhibited WT levels of LAP2α (Figure 6a), 
whereas differentiated muscle tissue of Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice expressed only low levels of 
LAP2α (Figure 6a). Similar to complete LAP2α knockout animals, Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice 
did not exhibit an overt skeletal muscle defect (Supplemental Figure 3). Consistent with the 
sustained LAP2α expression in Lap2αNeo-fl/Neo-fl/Mck-Cre+ satellite cell progeny, Lap2αNeo-fl/Neo-fl/Mck-
Cre+ mice had similar CSM4B cell numbers as their WT Cre recombinase-expressing littermates at 
all ages (Figure 6b), supporting the hypothesis that loss of LAP2α expression in satellite cells or in 
other non-muscle cells (e.g. stem cell niches) causes the muscle stem cell phenotype in complete 
LAP2α knockout animals.  
Interestingly, in vitro differentiation of Lap2αNeo-fl/Neo-fl/Mck-Cre+ primary myoblasts revealed a 
temporary lag at day 3 (Figure 6c, d), coinciding with the activation of the Mck promoter and 
induction of Cre recombinase. Compared to WT cultures, which predominantly contained myotubes 
at day 3, differentiating Lap2αNeo-fl/Neo-fl/Mck-Cre+ cultures had a higher number of single non-fused 
myoblasts and exhibited lower level of MyHC mRNA (Figure 6c, 6d). Since LAP2α expression was 
highest at day 3 of WT myoblast differentiation (Figure 6d, Figure 3b), we concluded that the in 
vitro differentiation defects in Lap2αNeo-fl/Neo-fl/Mck-Cre+ cells are a direct consequence of their 
inability to upregulate LAP2α. These data confirm the role of LAP2α during early myogenic 
differentiation. Interestingly, the delay in in vitro differentiation was more extensive in Lap2αNeo-fl/Neo-
fl/Mck-Cre+ than in Lap2α-/- myoblasts (compare Figures 3c, 6c). This discrepancy may be 
explained by the activation of compensatory mechanisms in response to loss of LAP2α during 
development of complete LAP2α knockout animals. 
Like in complete Lap2α-/- animals, the muscle-specific downregulation of LAP2α in Lap2αNeo-fl/Neo-
fl/Mck-Cre+ mice affected the process of skeletal muscle transformation. While the number of fibres 
reactive with anti-type I antibodies in soleus muscle was similar in wild type and conditional LAP2α 
knockout mice, significantly fewer type I negative fibres reacted with anti-type II (a and x/d) 
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antibody in Lap2αNeo-fl/Neo-fl/Mck-Cre+ muscles (Figure 6e). Since these type II negative fibres were 
also negative for IIb myosin heavy chain, we concluded that they represent an intermediate type, 
pointing towards a defect in fibre type determination in LAP2α-deficient muscle. 
Overall these results suggest that the role of LAP2α in myoblast differentiation and fibre type 
determination is distinct and independent of its role in stem cell maintenance. 
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Discussion 
  
Laminopathies are complex human disorders caused by mutations in lamins and their interacting 
proteins (2). Recently, we and others provided evidence for the, so called “stem cell disease 
model”, explaining the late onset of particular laminopathic disorders by defective cell cycle 
regulation and differentiation of stem cells during maintenance of tissue homeostasis (6, 26, 27).  
In this study, we demonstrate that the absence of LAP2α affects the maintenance of satellite cells – 
the putative stem cells in adult muscle. The Lap2α-/- stem cell phenotype described here, including 
increased number of CSM4B cells within the myofibre-associated satellite cell population of young 
LAP2α-deficient mice and their normalization during aging, as well as upregulated expression of 
stem cell determinants and delayed differentiation of primary Lap2α-/- myoblasts, points to a defect 
in proliferation and/or myogenic commitment of muscle stem cells in Lap2α-/- mice during early 
postnatal growth. The specific contributions of these two processes are hard to discriminate, as the 
effect of delayed differentiation of an increased pool of stem cells may have a zero net effect, 
potentially explaining the absence of an overt muscle phenotype in young Lap2α-/- mice. The 
grossly unaffected muscle regeneration after acute injury in young Lap2α-/- mice might be 
explained by the same phenomenon. Interestingly, although Lmna-/- mice develop muscular 
dystrophy and die by the age of 8 weeks, their skeletal muscle regeneration also seems to be 
unaffected (28).  
As for the molecular cause of the stem cell phenotype in Lap2α-/- mice, our study suggests a role of 
LAP2α in the regulation of MyoD-dependent muscle-specific transcription during the transition from 
proliferation to early differentiation states. Interestingly, a similar phenotype – higher number of 
satellite cells, whose progeny displays an accelerated growth rate and delayed terminal 
differentiation – has been reported in MyoD-deficient mice (29). A temporal impairment of MyoD 
activity, as observed in Lap2α-/- mice, may not cause serious regeneration defects under 
physiological conditions, as opposed to complete loss of MyoD (30), presumably due to the 
upregulation of other compensating myogenic transcription factors, such as Myf5 (31). Although 
neither MyoD nor Myf5 can fully substitute for the complete loss of the other protein during adult 
muscle regeneration (14, 32), the slight upregulation of Myf5 in proliferating Lap2α-/- myoblasts may 
be sufficient to overcome the defects caused by MyoD downregulation. 
Striated muscle laminopathies and muscle regeneration in mice bearing mutations in lamin A/C and 
in another lamin-binding protein, emerin, show a disruption of the Rb-MyoD transcriptional pathway 
(28, 33). Since MyoD was found in protein complexes containing lamin A/C (33), and primary 
Lmna-/- (33) and Lap2α-/- myoblasts show reduced MyoD protein levels, it is tempting to speculate 
that LAP2α-lamin A/C complexes might serve as scaffolding proteins or regulators of MyoD and its 
co-activator Rb during initial phases of muscle differentiation. The slightly increased expression of 
the respective binding partner during in vitro differentiation of Lmna-/- (28) or Lap2α-/- primary 
myoblasts points to a compensatory effect of the two interacting proteins during muscle 
differentiation.  
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In addition to its role in satellite cell regulation, our studies reveal an additional function of LAP2α in 
muscle physiology, namely in adult myofibre type-specification. Skeletal muscle is able to adapt to 
environmental demands and respond to physiological and pathological signals by changing the 
myofibre properties of challenged muscles (23). Whereas exercise causes an increase in oxidative 
metabolism and fast-to-slow myofibre transitions, muscle disuse and aging have an opposite effect 
(23). Here we report a subtle shift in the fibre type distribution of adult Lap2α-/- mice towards faster 
phenotypes. In view of similar effects described in MyoD- and MEF2c-deficient mice (34, 35), fibre 
type switching in Lap2α-/- mice might be a consequence of deregulated expression of major 
myogenic transcription factors involved in muscle transformation. As Lap2α-/- animals did not 
exhibit any behavioural defects or altered physical performance, muscle disuse as a major reason 
for the observed changes in fibre type composition is rather unlikely. Intriguingly, however, the 
Lap2α-/- myofibre phenotype could also be a sign of accelerated muscle aging, which is particularly 
appealing in view of the reported involvement of A-type lamins in age related changes (36). In 
support of our data, type II fibre hypertrophy found in LmnaH222P mice (37) and slow muscle atrophy 
in some human striated muscle laminopathies (38), point to a role of lamins and their interaction 
partners in adult muscle remodelling. 
The properties of skeletal myofibres also depend on the pattern of nerve stimulation, where 
low frequencies of neuron firing promote slow, and high frequencies fast muscle phenotype by 
affecting the calcium/calmodulin signaling pathway (23). However, the observed shift towards 
faster fibre types in the soleus muscle of conditional Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice, which show 
normal LAP2α expression in non-muscle tissues, rules out a defective neuronal stimulation as the 
primary cause of fibre type switching in complete LAP2α knockout animals.  
In conclusion, our study implicates LAP2α in the regulation of multiple distinct events in 
skeletal muscle – maintenance and differentiation of satellite cells and their progeny, and adult fibre 
type switching and postnatal remodelling of slow muscles.  
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Materials and methods 
 
Mouse lines  
In this study we used Lap2α-/- (6), Lap2α-/-/Mdx and Lap2αNeo-fl/Neo-fl/Mck-Cre+ (I. Gotic, manuscript 
in preparation) mouse lines. Animals were categorized according to their age as young (10 weeks) 
adult (6-8 months) and old (16-19 months). All experiments were performed according to 
permissions from Austrian authorities (BMBWK-66-009/0130-BrGT/2006). Mice were maintained 
and handled following the procedures outlined in the Guide for the Care and Use of Laboratory 
Animals. Data acquisition was done by observers blinded for the genotype of the animal.  
 
Immunofluorescence and histochemistry  
3.7% formaldehyde/1% methanol-fixed tissue cryo-sections were washed in PBS and incubated for 
30 min in blocking solution containing 20% normal goat serum/0.5% gelatine/0.5% TritonX-
100/PBS. Primary antibodies were diluted in PBS and applied overnight at 4ºC. Sections were then 
washed in PBS and incubated with respective fluorochrome-coupled secondary antibodies for 1 h 
at RT. After washing in PBS, nuclei were counterstained with Hoechst 33342/dH2O for 10 min at 
RT and washed in dH2O. Samples were air-dried and mounted with Mowiol 4-88 (Sigma-Aldrich, 
Milwaukee, WI, USA). 
Cultured cells were fixed in 4% paraformaldehyde/PBS for 10 min, washed in PBS and incubated 
for 5 min in 50 mM NH4Cl/PBS. After washing in PBS, cells were permeabilized in 0.5%Triton/PBS 
for 5 min, washed again and incubated for 30 min in 0.5% gelatine/PBS blocking solution. Primary 
antibodies were applied for 1 h at RT, diluted in PBS. Samples were subsequently treated as 
described above. The list of primary antibodies used in these studies can be found in Supplemental 
Table 2. Appropriate secondary antibodies were coupled to either Texas Red, Cy5 (Jackson 
ImmunoResearch, West Grove, PA, USA) or Alexa Fluor 488 (Molecular Probes, Eugene, OR, 
USA) fluorochromes. 
For immunohistochemistry, incubation with primary antibodies was followed by washing in PBS and 
30 min application of biotinylated secondary antibodies. Consequently, samples were washed in 
PBS, incubated with Elite ABC Reagent (Vectastain Elite ABC Kit, Vector Laboratories, Burligame, 
CA, USA) for 20 min at RT and washed with dH2O. Finally, DAB detection solution (DAB substrate 
kit for peroxidase from Vector Laboratories) was applied for 5 min and samples were mounted in 
Mowiol after washing in dH2O.  
Haematoxylin and eosin (H & E) staining was done according to standard protocol. Fluorescence 
images were acquired on a Axiovert 200M microscope, equipped with LSM 510 META confocal 
laser-scanning unit, using LSM imaging software (Zeiss, Jena, Germany). Data were processed by 
Zeiss LSM Image Browser and Adobe Photoshop CS2.  
Bright field images were acquired using Axio Imager.M1 equipped with AxioCam MRc5 camera 
and AxioVision Rel. 4.6 software (Zeiss). Data were processed in Adobe Photoshop CS2 and 
figures were created in Adobe Illustrator CS2. 
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Western blot  
Frozen tissue samples were homogenized in modified RIPA buffer (150 mM NaCl/50 mM Tris-HCl 
pH 7.4/1 mM EDTA/1 mM PMSF/1 × Protease Inhibitor Cocktail Complete® EDTA free (Roche, 
Basel, Switzerland) using Precellys 24 homogenizer (PeqLab Biotechnology, Erlangen, Germany) 
and incubated for 2 h at 4ºC with 1% TritonX-100/ 0.1% SDS. Lysates were centrifuged at 15 000 g 
for 1 min, diluted in protein sample buffer and cooked for 5 min at 96ºC. 
Cells were lysed directly in the culture dish using standard protein sample buffer and cooked for 5 
min 96ºC. SDS-PAGE and immunoblotting of cell lysates and homogenized frozen tissue samples 
was performed according to standard protocols, using antibodies listed in Supplemental table 2. 
 
Semi-quantitative and quantitative real time PCR 
Total RNA was isolated from muscle tissue and cultured cells using TRIzol® reagent (Invitrogen, 
Carlsbad, CA, USA) or RNeasy® Plus Micro Kit (Quiagen, Hilden, Germany). cDNA was 
synthesized by First Strand cDNA Synthesis Kit for RT-PCR (Roche) according to manufacturers’ 
instructions and specific sequences were subsequently amplified using either Go Taq Green 
Master Mix (Promega, Madison, WI, USA) for semi-quantitative PCR or MESA GREEN qPCR 
MasterMix Plus for SYBR Assay I TTP (Eurogentec, Liege, Belgium) for quantitative PCR, and 
primers listed in Supplemental Table 3. Data were documented using UVP Gel Doc-It TS Imaging 
System and Mastercycler® ep realplex (Eppendorf, Hamburg, Germany) respectively and 
processed by Adobe Photoshop CS2 or Microsoft Excel XP. Endogenous levels of either GAPDH 
(semi-qPCR) or Hprt (qPCR) were used for data normalization according to Pfaffl method (39). 
 
Flow cytometry 
Myofibre-associated cells were isolated from mouse front and hind limb muscles (EDL, TA, 
quadriceps, gastrocnemius, soleus, and triceps brachii) according to the two-step enzymatic 
digestion protocol (12) and stained on ice for 30 min in 2% FCS/ PBS containing anti-CD45, anti-
Sca1, anti-Mac1, anti-CXCR4 and anti-β-integrin antibody cocktail. A list of used antibodies and 
their suppliers can be found in the Supplemental Table 2. The number of CD45-Sca1-Mac1-
CXCR4+β1-intergin+ cells within the parent CD45-Sca1-Mac1- population of the particular 
sample was determined using FASCAria equipped with DIVA acquisition software (BD 
Biosciences, San Jose, CA, USA). 
 
Primary myoblast isolation 
For primary myoblast culture, de-skinned front and hind limbs of neonatal mice (2 days old) were 
isolated and incubated for 1.5 hours in 0.2% collagenase I (Gibco)/DMEM solution at 37ºC. Single 
muscle fibres were released by gentle trituration, collected in fresh DMEM and spun at 15 g for 3 
min. The pellets were subsequently washed twice in PBS (2 × 3 min at 15 g) and re-suspended in 
DMEM to allow fibre aggregates to settle down by gravity for 1 min. Single fibres remaining in the 
supernatant were pelleted (5 min at 50 g), collected in plating medium (20%FCS / 10% horse 
serum / 1% chicken embryo extract / DMEM / 50 U/ml Penicillin / 50 μg/ml Streptomycin) and 
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plated on MatrigelTM (BD Bioscience) coated dishes. 48 hours later outgrowing cells were collected 
in proliferation medium (20% FCS / 2.5 ng/ml basic FGF / Hams’ F-10 / Pen-Strep), pre-plated on 
plastic Petri dishes for 2 hours to get rid of the contaminating fibroblasts and transferred to collagen 
coated dishes. Cells were maintained in a humidified atmosphere containing 5% CO2 at 37ºC. To 
induce muscle differentiation, proliferation medium was substituted by DMEM containing 5% horse 
serum containing penicillin and streptomycin. 
 
GeneChip expression analysis 
Primary myoblasts were isolated from three independent Lap2α+/+ and Lap2α-/- littermate couples 
and expanded in culture for one week. Total RNA from proliferating cells was isolated with TRIzol 
reagent (Invitrogen) according to manufacturers’ instructions and quality-tested on Agilent 2100 
Bioanalyzer using RNA 6000 Nano chips (Agilent Technologies, Santa Clara, CA, USA). All kits 
and equipment in the subsequent steps were purchased from Affymetrix (Santa Clara, CA, USA). 
Double-stranded cDNA and the complementary cRNA were synthesized with GeneChip 
Expression 3' Amplification One-Cycle Target Labelling Kit following protocols provided in the kit. 
GeneChip Hybridization, Wash, and Stain Kit as well as Fluidics 450 Station were used for 
hybridization of high quality cRNA samples to Mouse Genome 430 2.0 Arrays for 16 h at 45 ºC with 
constant rotation at 60 rpm. Scanning of the chips and quality control parameter assessment were 
done using GeneChip 3000 Scanner and Affymetrix GCOS software respectively. Microarray data 
were deposited in the public ArrayExpress repository (http://www.ebi.ac.uk/microarray-as/ae/; 
accession number E-MEXP-2200). 
 
GeneChip data analysis and statistical procedures 
Data were analyzed using Bioconductor 2.01 (http://www.bioconductor.org) and R 2.7.0 software 
(40). Raw cell files were used for quantile normalization and generation of probe set signal 
intensities applying gcrma algorithm (41). Gcrma metrics was used for gene expression 
quantification. After exclusion of probe sets with low expression values (signal log2< 5 in >50 % of 
all arrays), statistical analysis was done on 18713 probe sets using the “CyberT" t-test based on 
Bayesian standard deviation estimation as previously described (42). For the final list of genes 
differentially expressed between Lap2α+/+ and Lap2α-/- myoblasts, a nominal significance level of P 
< 0.05 (Bayes t-test) was used. Probe set annotations, biological information of genes and gene 
ontology data were retrieved from the NetAffx Analysis Center (43). All probe set information 
provided in this paper is as of March 23 2009. 
 
Muscle injury 
Induction and maintenance of anaesthesia during the procedure was achieved by administration of 
5% and 2% isoflurane/O2 mixture, respectively. For analgesia, 15 mg/kg body weight of piritramid 
was injected subcutaneously before surgery and added to the drinking water during the 
regeneration phase (1μg/g of body weight/ml/day). The right soleus was surgically exposed and 10 
μl of 0.74 mM notexin solution (Notechis scutatus scutatus; Latoxan, Valence, France) was injected 
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into the mid belly of the muscle. The contra-lateral muscle served as uninjured control during the 
regeneration process. Mice were sacrificed at day 0, 2, 4, 8 and 12 days after injury and the 
efficiency of regeneration was assessed by histology and immunofluorescence. The size of total 
damaged area and the corresponding embryonic MyHC+ positive fibres were measured on five 
transverse muscle sections of each mouse obtained from fixed positions in the soleus mid belly 
using AxioVision Rel. 4.5 software. Fibrotic index was calculated according to the equation FI = (1- 
(total EMyHC+ fibre area/total damaged area)) × 100%. 
 
Statistical analysis 
Data were analyzed either by ANOVA (followed by Boniferroni post hoc test for multiple 
comparisons), or paired Students’t-test where appropriate using Microsoft Excel XP. P<0.05 was 
considered significant. Data are presented as mean ± standard error (SE) and n represents the 
sample size. 
 
Supplementary information is available at Cell Death and Differentiation website  
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Titles and legends to figures 
 
Figure 1 Absence of LAP2α in mice causes deregulation of the muscle stem cell pool. (a) 
Immunostainig of isolated satellite cells reveals LAP2α expression in Pax7-positive cells (bar = 20 
μm). (b) Flow cytometric analysis of skeletal muscle tissue shows an increase in the number of 
myofibre-associated CD45-Sca1-Mac1- and CXCR4+β1-integrin+ (CSM4B) cells within the parent 
CD45-Mac1-Sca1- satellite cell population in young Lap2α-/- mice (aged 10 weeks) compared to 
their wild type (WT) littermates (n = 5 WT + 6 knockout mice). The number of CSM4B satellite cells 
in Lap2α-/- skeletal muscle levels down to WT values by the age of 6 months (adult mice) and 
continues to decrease with age at a rate similar to the WT (n = 5 littermate pairs of each age, 
p<0.05 ANOVA for (a) WT young vs. KO young, (b) WT young vs. WT old, (c) KO young vs. KO 
adult and old; bars represent standard error (SE)). 
 
Figure 2 Loss of LAP2α in primary myoblasts predominantly causes downregulation of genes. 
Volcano plot of genes differentially expressed in proliferating Lap2α-/- and WT primary myoblasts 
shows that only a small number of genes other than Lap2 itself is affected by the loss of LAP2α. 
 
Figure 3 Lap2α-/- myoblasts exhibit delayed differentiation. Protein (a) and mRNA (b) analyses of 
sequentially expressed differentiation markers in LAP2α-deficient cells show delayed myoblast 
differentiation. The increase in Pax7 and decrease in MyoD protein levels (upper panels) are 
followed by the diminished expression of MyoD target genes and myogenic interaction partners 
such as MEF2c, desmin and myosin heavy chain (MyHC), as well as upregulation of the alternative 
basic myogenic factor Myf5 (lower panels). In contrast, the expression level of lamin A/C, the major 
binding partner of LAP2α, is not altered (upper panels). (c) Although Lap2α-/- myoblasts were able 
to differentiate into myotubes (left panels; bright field images, bar = 100 μm), immunostaining of 
differentiating myoblasts shows a slight delay in the expression of myosin heavy chain (right 
panels; confocal images, bar = 20 μm). Data were normalized to endogenous levels of actin in 
Western blot, and the housekeeping gene Hprt (Hypoxanthine-Guanine Phosphoribosyl 
Transferase) according to the Pfaffl method (39) in quantitative PCR analyses. WT mRNA levels at 
different time points were compared to the Day0 stage and each knockout sample was normalized 
to its corresponding WT time point (error bars represent SE of the WT/KO ratio, *p<0.05 ANOVA). 
Means of 3-4 independent experiments are shown. 
 
Figure 4 Lap2α-/- mice exhibit normal skeletal muscle regeneration. (a) H & E staining 
(Haematoxylin and eosin; left panels) and immunofluorescence analysis of notexin-injured LAP2α-
deficient skeletal muscle, using embryonic MyHC (EMyHC – red) antibody (right panels), showing 
normal in vivo muscle regeneration in Lap2α-/- mice (bar = 20 μm). (b) The efficiency of muscle 
regeneration quantified at day 4 post injury by measuring the size of embryonic MyHC-containing 
myofibres within the damaged region and calculating the corresponding fibrotic indexes (n = 4 
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littermate pairs of each age; p<0.05 ANOVA for (a) young vs. old knockout mice, bars represent 
SE). 
 
Figure 5 Absence of LAP2α in mice promotes fast myofibre phenotype in predominantly slow 
muscles. Soleus muscle of Lap2α-/- mice, (a) immunostained with anti-slow MyHC antibody (type I 
– depicted in brown, bar = 50 μm), reveals a myofibre shift towards faster phenotypes (b), without a 
change in fibre size distribution (c) (n = 8 littermate pairs, *p<0.05, ANOVA, bars represent SE). 
 
Figure 6 LAP2α is required during initial phases of myoblast differentiation as well as adult muscle 
remodelling. (a) Semi-quantitative PCR analysis of cell and tissue lysates showing a 
downregulation of LAP2α in the presence of MCK and Cre recombinase, which, in contrast to adult 
skeletal muscle, are not expressed in proliferating myoblasts and non-muscle tissues such as 
spleen. (Samples were normalized to endogenous levels of GAPDH). (b) CD45-Sca1-Mac1-
CXCR4+β1-integrin+ (CSM4B) muscle fibre-associated satellite cell numbers in Lap2αNeo-fl/Neo-fl/Mck-
Cre+ mice are similar to WT at all ages. (FACS analysis of whole muscle digests, n = 5 littermate 
pairs of each age; p<0.05 ANOVA for (a) young vs. old Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice, bars 
represent SE). (c) Bright field images of Lap2αNeo-fl/Neo-fl/Mck-Cre+ myoblasts showing a lag at day 3 
of the in vitro muscle differentiation (bar = 100 μm). (d) As a consequence of Mck promoter 
activation and Cre recombinase expression, LAP2α mRNA levels do not increase during 
differentiation in Lap2αNeo-fl/Neo-fl/Mck-Cre+ myoblasts, causing a delay in the expression of MyHC. 
Due to high variability in Cre recombinase expression and the consecutive substantial variation in 
LAP2α levels, which hindered the statistical analysis of qPCR data, representative images from 3 
separate experiments are shown. Data were analyzed as described in Figure 3. (e) Quantification 
of muscle tissue sections immunostained with anti-type I and anti-type II (a + x/d) MyHC-specific 
antibodies showing a myofibre shift towards an intermediate (type I and type II (a, x/d) negative) 
phenotype in Lap2αNeo-fl/Neo-fl/Mck-Cre+ soleus muscle. (n = 3 littermate pairs, *p<0.05, paired 
Students’ t-test, bars represent SE). 
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Table 1 Changes in gene expression associated with LAP2α loss in primary mouse myoblasts – 
selected GO-enriched microarray candidates. 
Category Gene 
Symbol 
Probe Set ID Name/GO-annotation Fold change p value 
(BayesT) 
Validation 
Nuclear structure      
 Tmpo (α isoform) 
1428976_at lamina-associated 
polypeptide 2a 
-203.53 0.00004 1RT/qRT/Ab 
  1421237_at  -12.53 0.0004 
1RT/qRT/Ab 
 Tmpo (β, γ, δ, ε) 
1426349_s_at lamina-associated 
polypeptide  
1.80 0.003 - 
  1452036_a_at  1.60 0.004 - 
 Lmna 1425472_a_at lamin A -1.50 0.01 - 
 Syne1 1421545_a_at synaptic nuclear envelope 1 -2.00 0.01 - 
Muscle stem cell determinants     
 Myf5 1420757_at myogenic factor 5 1.70 0.04 
1RT/qRT 
 Pax7 1444596_at paired box gene 7 1.60 0.05 
1RT/qRT 
 Sdc4 1448793_a_at syndecan 4 3.10 0.0006 - 
Cell signaling pathways      
 Pdgfra 1421917_at PDGF signaling                         -1.60 0.006 - 
 
 1438946_at marker for paraxial mesoderm 
derived ES cells with muscle 
regeneration potential  
-1.50 0.03 - 
 
Gja1 1415801_at gap junction protein, alpha 
1;connexin protein family 
-1.50 0.009  
 
Grem1 1425357_a_at gremlin 1; sonic hedgehog 
signaling;BMP4 signaling         
-1.80 0.01 - 
 Prrx1 1425526_a_at paired related homeobox 1       -1.60 0.02 - 
   FGF, sonic hedgehog signaling                        
   
 
Hey1 1415999_at hairy/enhancer-of-split related 
with YRPW motif 1; Notch 
signaling 
1.80 0.03 1RT 
 Igf2r 
1424112_at insulin-like growth factor 2 
receptor 
-1.50 0.03 - 
 Map3k2 
1438719_at mitogen-activated protein 
kinase kinase kinase 2 
-1.50 0.04 - 
Extracellular matrix      
 Capg 
1450355_a_at capping protein (actin 
filament), gelsolin-like 
-1.40 0.02 - 
 
Coch 1423285_at coagulation factor C homolog 
(Limulus polyphemus) 
-9.00 0.04 - 
 Col12a1 1434411_at collagen, type XII, alpha 1 -1.70 0.02 - 
  1427391_a_at  -1.80 0.03 - 
 Col5a1 1416740_at collagen, type V, alpha 1 -1.30 0.04 - 
 Ntn4 1450512_at netrin 4 -8.40 0.01 - 
 Pcolce 
1448433_a_at procollagen C-endopeptidase 
enhancer protein 
-1.60 0.01 - 
  1437165_a_at  -1.20 0.04 - 
 Smoc2 
1415935_at SPARC related modular 
calcium binding 2 
-3.80 0.05 - 
 Timp2 1454677_at tissue inhibitor of metalloproteinase 2 
-1.30 0.02 - 
1RT (semi-quantitative reverse transcriptase PCR), qRT (quantitative reverse transcriptase PCR), 
Ab (western blot and/or immunofluorescence). 
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Titles and Legends to Supplemental Figures 
 
Supplemental Figure 1 Skeletal muscle tissue of Lap2α-/- mice does not express the α-specific 
Lap2 isoform. (a) LAP2α is present in nuclei of postmitotic Lap2α+/+  skeletal myofibres (arrow) and 
muscle interstitial cells (arrow head) and absent from muscle tissue of Lap2α-/- mice, as shown by 
immunostaining of transverse muscle sections (bar = 20 μm). (b) Western blot (upper panels) and 
semi-quantitative RT-PCR (lower panels) analyses of skeletal muscle tissue from Lap2α+/+ and 
Lap2α-/- mice. Samples were normalized for endogenous levels of actin and GAPDH 
(Glycerinaldehyde-3-phosphate-Dehydrogenase), respectively. (* unspecific band appearing in 
striated muscle tissue lysates) 
 
Supplemental Figure 2 Absence of dystrophic changes in Lap2α-/- skeletal muscle. H & E stained 
transverse muscle sections of young (TA, upper panel) and old mice (lower panels), show no overt 
dystrophic muscle phenotype (bar = 50 μm). 
 
Supplemental Figure 3 Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice do not exhibit an overt skeletal muscle 
phenotype. H & E stained skeletal muscle sections (bar = 50 μm). 
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Supplemental Table 1 Changes in gene expression induced by LAP2α loss in primary mouse 
myoblasts. 
Symbol Probe Set ID Name Fold 
change 
p value (Bayes T) 
--- 1446130_at --- -23,17241 3,09969E-05 
Tmpo 1428976_at thymopoietin -203,5333 4,28991E-05 
Tmpo 1421237_at thymopoietin -12,53333 0,000430283 
Sdc4 1448793_a_at syndecan 4 3,0819672 0,000572144 
--- 1439794_at --- -6,9375 0,000901098 
Tmpo 1426349_s_at thymopoietin 1,8228782 0,003130126 
Tmpo 1452036_a_at thymopoietin 1,6117424 0,003680447 
Pdgfra 1421917_at platelet derived growth 
factor receptor, alpha 
polypeptide 
-1,566667 0,006293655 
--- 1427086_at --- -2,580524 0,006892995 
--- 1456973_at --- 2,9019608 0,006956688 
Afap1l1 1454727_at actin filament associated 
protein 1-like 1 
1,853229 0,00713412 
Frmd4b 1438169_a_at FERM domain containing 
4B 
1,8588469 0,007759323 
Gja1 1415801_at gap junction protein alpha 1 -1,497354 0,008821696 
Oaf 1424086_at OAF homolog (Drosophila) -1,585968 0,009516138 
Lmna 1425472_a_at lamin A -1,504692 0,010691108 
Grem1 1425357_a_at gremlin 1 -1,838122 0,011203551 
Pcolce 1448433_a_at procollagen C-
endopeptidase enhancer 
protein 
-1,639439 0,012095208 
Ntn4 1450512_at netrin 4 -8,434783 0,012615054 
Syne1 1421545_a_at synaptic nuclear envelope 1 -1,992063 0,01294275 
Pcdhb22 1418941_at protocadherin beta 22 1,6638655 0,014020096 
Bnip3 1422470_at BCL2/adenovirus E1B 
interacting protein 3 
-1,366605 0,015836859 
2900001G08Rik 1430642_at RIKEN cDNA 2900001G08 
gene 
3,3953488 0,01630495 
--- 1457483_at --- 3 0,016374156 
Timp2 1454677_at tissue inhibitor of 
metalloproteinase 2 
-1,27914 0,017249749 
Etv3 1418635_at ets variant gene 3 -1,846667 0,018160353 
Capg 1450355_a_at capping protein (actin 
filament), gelsolin-like 
-1,355938 0,018483491 
Zfp40 1435984_at Zinc finger protein 40 2,1372549 0,019103413 
Tpi1 1415918_a_at triosephosphate isomerase 
1 
-1,274766 0,019205485 
Pcdh19 1444422_at protocadherin 19 -1,59 0,019473094 
Slit3 1452296_at slit homolog 3 (Drosophila) -3,504425 0,020602275 
Hcfc1r1 1428406_s_at host cell factor C1 regulator 
1 (XPO1-dependent) 
-1,493255 0,020736075 
Cd248 1417439_at CD248 antigen, endosialin -1,472763 0,021241652 
Prrx1 1425526_a_at paired related homeobox 1 -1,602878 0,021633046 
--- 1441391_at --- 1,5963303 0,021979351 
S100a4 1424542_at S100 calcium binding 
protein A4 
-1,228758 0,022304232 
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Symbol Probe Set ID Name Fold 
change 
p value (Bayes T) 
1200009F10Rik 1429219_at RIKEN cDNA 1200009F10 
gene 
1,494311 0,022626502 
Cspg4 1450944_at chondroitin sulfate 
proteoglycan 4 
-2,21223 0,022911152 
Lrp1 1448655_at low density lipoprotein 
receptor-related protein 1 
-1,443643 0,023053676 
Jmjd3 1456610_at jumonji domain containing 3 -1,476582 0,023305136 
Frmd4b 1452123_s_at FERM domain containing 
4B 
2,0530035 0,023471035 
Serinc3 1434548_at serine incorporator 3 -1,52346 0,023654625 
Col12a1 1434411_at collagen, type XII, alpha 1 -1,729354 0,023728149 
Pdgfra 1438946_at platelet derived growth 
factor receptor, alpha 
polypeptide 
-1,47644 0,025216721 
P4ha2 1417149_at procollagen-proline, 2-
oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), 
alpha II polypeptide 
-1,453503 0,025242593 
Col12a1 1427391_a_at collagen, type XII, alpha 1 -1,772575 0,025592569 
Ly6a 1417185_at lymphocyte antigen 6 
complex, locus A 
-1,476317 0,025609628 
Pcdh19 1455145_at protocadherin 19 -1,402029 0,025699572 
Pnrc2 1416187_s_at proline-rich nuclear receptor 
coactivator 2 
1,3205503 0,026027527 
Tmem19 1443049_at Transmembrane protein 19 3,2537313 0,026073708 
Vasn 1427894_at vasorin -1,646499 0,02616581 
--- 1442019_at --- 3,6050955 0,026234459 
Grb14 1417673_at growth factor receptor 
bound protein 14 
-1,784638 0,026623827 
Igf2r 1424112_at insulin-like growth factor 2 
receptor 
-1,488342 0,026914393 
Mtdh 1455129_at Metadherin -1,377947 0,028602452 
Txnip 1415996_at thioredoxin interacting 
protein 
1,4662872 0,029118375 
Plod1 1416289_at procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
1 
-1,549333 0,029432255 
--- 1437199_at --- -1,407169 0,030006526 
Sfrs2ip 1452885_at splicing factor, 
arginine/serine-rich 2, 
interacting protein 
-1,486278 0,030832934 
Alkbh8 1429521_at alkB, alkylation repair 
homolog 8 (E. coli) 
1,347355 0,030918852 
Tspo 1416695_at translocator protein -1,460777 0,031121271 
Arid5b /// LOC100044968 1420973_at AT rich interactive domain 
5B (MRF1-like) /// similar to 
modulator recognition factor 
2 
-1,752381 0,03151538 
Aebp1 1450637_a_at AE binding protein 1 -1,387579 0,031556012 
Fstl1 1448259_at follistatin-like 1 -1,423422 0,031817203 
S100a10 1416762_at S100 calcium binding 
protein A10 (calpactin) 
-1,211698 0,032123314 
Slc5a3 1440227_at solute carrier family 5 
(inositol transporters), 
member 3 
-2,156198 0,03330394 
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Symbol Probe Set ID Name Fold 
change 
p value (Bayes T) 
Atp10d 1436544_at ATPase, class V, type 10D 2,5753425 0,034497037 
Hey1 1415999_at hairy/enhancer-of-split 
related with YRPW motif 1 
1,8009479 0,034497872 
Klhl24 1429351_at kelch-like 24 (Drosophila) 1,306374 0,034671495 
2900019G14Rik 1457800_at RIKEN cDNA 2900019G14 
gene 
-2,524272 0,034836324 
D0H4S114 1436736_x_at DNA segment, human 
D4S114 
2,0648929 0,035438816 
EG545124 /// 
ENSMUSG00000051559 /// 
Tdg 
1448462_at predicted gene, EG545124 
/// predicted gene, 
ENSMUSG00000051559 /// 
thymine DNA glycosylase 
1,4324324 0,035734189 
Loxl3 1418269_at lysyl oxidase-like 3 -1,659309 0,03588936 
Pi4k2a 1433462_a_at phosphatidylinositol 4-
kinase type 2 alpha 
-1,473389 0,036452501 
Pcolce 1437165_a_at procollagen C-
endopeptidase enhancer 
protein 
-1,246584 0,036583601 
Krit1 1448701_a_at KRIT1, ankyrin repeat 
containing 
1,3596713 0,037041671 
2900024C23Rik 1429503_at RIKEN cDNA 2900024C23 
gene 
-1,429896 0,037047549 
Irak1 1448668_a_at interleukin-1 receptor-
associated kinase 1 
-1,493166 0,037288555 
--- 1443057_at --- 1,8113208 0,037340928 
Map3k2 1438719_at mitogen-activated protein 
kinase kinase kinase 2 
-1,451499 0,037709723 
Col5a1 1416740_at collagen, type V, alpha 1 -1,296137 0,037850513 
Cramp1l 1456042_s_at Crm, cramped-like 
(Drosophila) 
1,4296081 0,037983815 
Nrk 1450079_at Nik related kinase -1,603004 0,038746284 
Tia1 1416812_at cytotoxic granule-
associated RNA binding 
protein 1 
1,6711864 0,039197992 
Ldha 1419737_a_at lactate dehydrogenase A -1,181132 0,039207225 
Myf5 1420757_at myogenic factor 5 1,6626263 0,03962744 
Hyou1 1423290_at hypoxia up-regulated 1 -1,771626 0,039723743 
Cd99l2 1456746_a_at CD99 antigen-like 2 -1,371672 0,040017481 
Kif1b 1423995_at kinesin family member 1B -1,540179 0,040453898 
Coch 1423285_at coagulation factor C 
homolog (Limulus 
polyphemus) 
-8,955224 0,041289639 
LOC100047339 1431004_at similar to lysyl oxidase-like 
2 
2,2330189 0,041731884 
Glrx3 1456244_x_at glutaredoxin 3 1,2024408 0,042128606 
Elmo2 1436011_at engulfment and cell motility 
2, ced-12 homolog (C. 
elegans) 
-1,5625 0,042219333 
Gda 1435748_at guanine deaminase 1,8252427 0,042557721 
Ly6e 1453304_s_at lymphocyte antigen 6 
complex, locus E 
-1,296086 0,042567597 
Aebp1 1422514_at AE binding protein 1 -1,51675 0,042636078 
Lpar1 1448606_at lysophosphatidic acid 
receptor 1 
-1,295117 0,042835961 
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Symbol Probe Set ID Name Fold 
change 
p value (Bayes T) 
Pfkl 1439148_a_at phosphofructokinase, liver, 
B-type 
-1,354676 0,043091608 
--- 1436003_at --- 1,9101796 0,043245586 
Sema3c 1429348_at sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3C 
-1,588801 0,043433807 
Mgst3 1448300_at microsomal glutathione S-
transferase 3 
-2,567987 0,044223481 
Ivns1abp 1450084_s_at influenza virus NS1A 
binding protein 
1,2882159 0,044241755 
Mtss1 1424826_s_at metastasis suppressor 1 1,7671756 0,044290716 
Prkcdbp 1423771_at protein kinase C, delta 
binding protein 
-1,937415 0,044299028 
Eya1 1457424_at eyes absent 1 homolog 
(Drosophila) 
1,4739677 0,045147903 
Pfkp 1416069_at phosphofructokinase, 
platelet 
-1,470732 0,045244371 
Smoc2 1415935_at SPARC related modular 
calcium binding 2 
-3,754991 0,045590637 
Plec1 1434610_at plectin 1 -1,34142 0,045747803 
Npepps 1417385_at aminopeptidase puromycin 
sensitive 
-1,392113 0,046026998 
Efemp2 1417018_at epidermal growth factor-
containing fibulin-like 
extracellular matrix protein 2
-1,276237 0,046256814 
Pax7 1444596_at paired box gene 7 1,6151515 0,046331877 
--- 1444126_at --- 1,5492958 0,04662409 
Srpx2 1427919_at sushi-repeat-containing 
protein, X-linked 2 
1,80937 0,046676924 
Kif5b 1418429_at kinesin family member 5B 1,2824014 0,046715423 
Qk 1417073_a_at quaking 1,3626325 0,04701093 
Tmem45a 1422587_at transmembrane protein 45a -1,647303 0,0471142 
Rbpj 1454896_at recombination signal 
binding protein for 
immunoglobulin kappa J 
region 
-1,270696 0,048120778 
Ptprf 1420841_at protein tyrosine 
phosphatase, receptor type, 
F 
-1,651934 0,048309123 
Gulp1 1453771_at GULP, engulfment adaptor 
PTB domain containing 1 
-1,412827 0,04869051 
Pcdh19 1437360_at protocadherin 19 -1,548319 0,04900889 
Eml1 /// LOC634102 1428321_at echinoderm microtubule 
associated protein like 1 /// 
similar to echinoderm 
microtubule associated 
protein like 1 
-1,588972 0,049105018 
Gadd45a 1449519_at growth arrest and DNA-
damage-inducible 45 alpha 
1,2864275 0,049190869 
Sned1 1435603_at sushi, nidogen and EGF-like 
domains 1 
-2,103226 0,049537552 
Stk4 1436015_s_at serine/threonine kinase 4 1,2966867 0,049738307 
Pdk1 1423748_at pyruvate dehydrogenase 
kinase, isoenzyme 1 
-1,451245 0,049963932 
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Supplemental Table 2 Primary antibodies used in the study. 
Name Clone Source Assay Dilution 
IF 1:500 
Anti-LAP2α serum  245-2 (1) WB 1:1000 
Anti-lamin A/C (N-18) sc-6215 Santa Cruz WB 1:200 
Anti-actin A-2066 Sigma WB 1:200 
Anti-dystrophin MANDRA1 Sigma IF 1:500 
Anti-myosin heavy chain (MyHC) MF20-s 
Developmental Studies 
Hybridoma Bank WB/IF 1:10 
Anti-MyoD1 (M-318) sc-760 Santa Cruz Biotech. WB 1:500 
anti-PAX7 PAX7-s 
Developmental Studies 
Hybridoma Bank WB 1:10 
Anti-desmin RD301 Abcam WB 1:100 
Anti-myogenin F5D-s 
Developmental Studies 
Hybridoma Bank WB 1:10 
Anti-fast MyHC (type IIa+IIx/d) A4.74-s 
Developmental Studies 
Hybridoma Bank IF 1:10 
Anti-slow MyHC (type I) A4.840-c 
Developmental Studies 
Hybridoma Bank IF 1:100 
Anti-embryonic MyHC F1.652  
Developmental Studies 
Hybridoma Bank IF 1:10 
FITC Anti-mouse CXCR4 (CD 184)  2B11 BD Pharmingen FACS 1:50 
PE Anti-mouse integrin β1 (CD 29)  
conjugate eBioHMb1-1 eBioscience FACS 1:40 
APC Anti-mouse CD 45 (Ly-5 LCA)   30-F11 eBioscience FACS 1:333 
APC Anti-mouse Mac-1a (CD11b, 
Integrin αM)   M1/70 eBioscience FACS 1:333 
PerCP-Cy5.5 Anti-mouse Sca-1 (Ly-
6A/E)  D7 eBioscience FACS 1:150 
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Supplemental Table 3 Primer sequences used for quantitative and semi-quantitative PCR. 
Name/Target Sequence Tm ºC Source 
QLAP2aII-forward  AGCAGGGAACTGAATCGAGA 57,3 
QLAP2aII-reverse  GCACCAGAGGGAGTAGATGC 61,4 NM_011605  
LAP2com_hm1 GTGGGAACAACCAGGAAGCTATATGA 63,2 
LAP2br_hm1 CTCCCACTTCAGCTCTTGTCAATG 62,7 (2) 
GAPDH-hm1 CATCACCATCTTCCAGGAGCGA 62,1 
GAPDH-hm2 CCTGCTTCACCACCTTCTTGAT 60,3 NM_008084  
mLamAC1091f CATCAAGCTGGCCCTGGACATGGA 67,9 
mLamAC1549r TGCGCCTTCCACACCAAGTCAGTA 66,3 (2) 
MyoD-forw-A GCAGGCTCTGCTGCGCGACC 67,6 
MyoD-rev-A TGCAGTCGATCTCTCAAAGCACC 62,4 (3) 
Mfy5-forw ACCAAGCTTTCGAGACGCTCAAGAG 64,6 
Mfy5-rev AGATGCTGTCAAAGCTGCTGTTCT 61,0 [3] 
MEF2C-RT2-1 GTATGTCTCCTGGTGTAACA 55,3 
MEF2C-RT2-2 GGATATCCTCCCATTCCTTG 57,3 (4) 
MyHC2b_forward ACAAGCTGCGGGTGAAGAGC 61,4 
MyHC2b_reverse CAGGACAGTGACAAAGAACG 57,3 (5) 
MCK_forward GAGATCTTCAAGAAGGCTGGTCA 60,6 
MCK_reverse GAGATGTCGAACACGGCG 58,2 (6) 
Cre2_forward CGAACGCACTGATTTCGA 56,7 
Cre2_reverse GGCAACACCATTTTTTCTGAC 55,9 (7) 
Hprt_forw TGATTAGCGATGATGAACCAGG 58,4 
Hprt_rev CTTTCATGACATCTCGAGCAAG 60,3 (2)  
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3.3.1 Phenotypic analysis of Lap2α-/- mice 
 
Lap2α-/- mice were generated by Cre-mediated excision of the α-specific exon 4 of the 
Lap2 gene in the germline32. The new LAP2α-deficient mouse line was crossed back for 11 
generations into the C57/B6 mouse background and analyzed on physiological, histological as well 
as molecular level. 
3.3.1.1 Physical & behavioural profile of Lap2α-/- mice 
 
Crosses between mice heterozygous for the α-specific deletion in the Lap2 locus resulted 
in live born progeny with Mendellian genotypic distribution. All genotypic variants had comparable 
body weight values at birth and thrived at a similar rate until weaning age (21 days) (Figure 16). 
Lap2α-/- mice continued to grow normally and, at the age of 2.5 – 3 months (young), as well as 16 – 
19 months (old), weighted as much as their wild type littermates (Figure 17). Average life spans of 
all animals were >2 years. 
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Figure 16. Heterozygous (Lap2α+/-) and homozygous (Lap2α-/-) LAP2α knockout mice exhibit normal 
postnatal growth. The average weight of Lap2α+/- as well as Lap2α-/- mice was normalized to the average 
weight of their wild type (Lap2α+/+) littermates at the particular time point and presented as mean weight ratio. 
[n = 13 litters (28 wild type, 22 KO and 56 heterozygous mice). Mean values ± 95% confidence intervals (CI) 
are shown]. 
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The physical appearance and behavioral profile of Lap2α-/- and Lap2α+/- mice did not 
substantially differ from the wild type, as assessed by the SHIRPA170 mouse phenotyping protocol. 
LAP2α-deficient mice had well groomed fur and whiskers, as well as normal skin color. Their body 
position, reflexes, transfer arousal, gait and tail elevation were indistinguishable from those of their 
wild type (WT) littermates. As shown in Figure 18, the locomotor activity of Lap2α-/- and Lap2α+/- 
mice was also similar to the WT. 
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Figure 18. Absence of LAP2α does not affect locomotor activity in mice. Animals were placed inside a 
grid floor arena and the total number of squares (122 cm2) simultaneously touched by all four feet in 30 
seconds was recorded. (n = 14 Lap2α+/+, 13 Lap2α-/- and 6 Lap2α+/- male and 7 Lap2α+/+, 7 Lap2α-/- and 3 
Lap2α+/- female old mice; p> 0.05, ANOVA followed by Boniferroni adjustment; values are means ± 95%). 
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Figure 17. Lap2α-/- mice have normal body weight. (Young mice – n = 16 male and 12 female littermate 
pairs aged 2.5 – 3 months; old mice – n = 31 male and 4 female littermate pairs aged 16 – 19 months. p> 0.05, 
ANOVA; values are means ± 95% CI). 
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3.3.1.2  Heart muscle tissue analysis 
 
3.3.1.2.1 Histological and gravimetric analyses of LAP2α-deficient hearts 
 
Since a mutation in LAP2α was linked to dilated cardiomyopathy in human28, it was 
interesting to see whether loss of LAP2α would have a similar effect on structural and functional 
properties of the heart muscle in mice. Indeed, echocardiographic analyses in Lap2α-/- mice 
revealed a gender-specific impairment of heart function, characterized by depression of left 
ventricular fractional shortening (FS%) and enlargement of left atria in male animals. Female 
Lap2α-/- mice, however, exhibited normal heart function (I. Gotic, submitted manuscript I). Although 
a slight increase in the left ventricular diameter was recorded in male Lap2α-/- mice during 
echocardiography (I. Gotic, submitted manuscript I), there were no statistically significant 
differences in the heart weight between LAP2α-deficient and wild type animals, irrespective of age 
or gender (Figure 19). 
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Figure 19. Lap2α-/- mice show normal heart weight. Heart weight (mg) was normalized to the body 
weight (g) of the animal and presented as HW/BW index. (Newborn mice – n = 9 Lap2α+/+ and 10 Lap2α-/- 
mice; young – n = 17 male and 10 female littermate pairs; old – n = 24 male and 4 female littermate pairs; 
p>0.05 ANOVA, values are means ± 95% CI). 
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At histological level, LAP2α-deficient hearts did not show any overt pathological changes in 
young mice. Old Lap2α-/- mice, however, exhibited high phenotypic variability in the extent of 
cardiac fibrosis. Whereas the majority (72%) of males had normal levels (WT) of myocardial 
collagen deposits (Figure 20), 18% of them showed extensive fibrosis of the heart tissue (I Gotic, 
submitted manuscript I). 
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Figure 20. Cardiac fibrotic indexes in the majority of LAP2α-deficient mice are comparable to wild type. 
Cases with severe fibrosis (18%) are not included in the calculation to avoid high variations between WT and 
KO values. n = 9 Lap2α+/+ and 8 Lap2α-/- mice aged >12 months, p>0.05, ANOVA, values are means ± 95% 
CI).  
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3.3.1.2.2 Molecular analysis of Lap2α-/- heart muscle tissue 
 
To elucidate molecular mechanisms leading to systolic dysfunction in LAP2α-deficient 
mice, I analyzed the expression of key cardiac transcription factors and their heart muscle-specific 
targets, which play major roles in embryonic development, postnatal tissue homeostasis and 
remodeling of the myocardium. Semi-quantitative and quantitative reverse transcription (RT)-PCR 
analyses of Lap2α-/- heart muscle tissue showed an age-dependent decrease in the expression of 
MEF2c and GATA4, the two transcription factors essential for cardiac development and postnatal 
myocardial remodeling158, 160, 177-179. Consequently, some of their downstream targets, such as brain 
natriuretic peptide (BNP)180, 181, Myocardin A182 and striated muscle activator of Rho-signaling 
(STARS)183 were down-regulated in LAP2α-deficient hearts, compared to wild type (I. Gotic, 
submitted manuscript I). On the other hand, targets like desmin184, α- and β-myosin heavy chain185, 
as well as atrial natriuretic factor (ANF)186, which show de-regulated expression in various other 
cardiomyopathy backgrounds187-190, were not affected by the loss of LAP2α (Figure 21). 
Figure 21. The expression of distinct MEF2c and GATA4 downstream targets is not affected by the 
loss of LAP2α in heart muscle tissue. Semi-quantitative A) and quantitative B) RT-PCR analysis of total 
heart lysates. (MyHC = myosin heavy chain; GAPDH = Glycerinaldehyde-3-phosphate-Dehydrogenase. 
Representative images of 5 separate experiments are shown in panel A). Panel B) shows mean values ± 
95% CI of n = 2 – 4 littermate pairs of each age; p>0.05, ANOVA). 
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3.3.1.2.3 LAP2α-deficient hearts under stress 
 
As the functional defect in Lap2α-/- mice was not progressing with age under normal 
conditions, I questioned whether the pathological phenotype would be augmented under chronic 
cardiac stress. Thus, I crossed Lap2α-/- mice with Mdx mutants191, which develop DCM later in 
life192. The evolution of DCM in Mdx mice has been linked to increased mechanical fragility of the 
myocardium caused by the absence of a sarcolemmal structural protein dystrophin193. Interestingly, 
loss of dystrophin caused a transient rescue of the Lap2α-/- heart phenotype, as young Lap2α-/-
/Mdx mice exhibited normal cardiac structure and function, similar to their Mdx littermates. 
However, by the age of 10-12 months, both Lap2α-/-/Mdx mice developed left ventricular systolic 
dysfunction and their FS% values leveled with those of the old Lap2α-/- and Mdx mice (I. Gotic, 
submitted manuscript I).  
Sarcolemmal instability evokes cardiomyocyte necrosis and accumulation of fibrous tissue 
in old Mdx mice193. Similarly, old Lap2α-/-/Mdx mice exhibited widespread fibrosis of heart muscle 
tissue (Figure 22). 
Figure 22. Old Lap2α-/-/Mdx and Mdx mice exhibit heart fibrosis. (H&E-stained transverse heart 
sections; white arrows mark the fibrotic areas; representative images of 5 separate experiments are shown; 
bar = 100 μm). 
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3.3.1.2.4 Conditional deletion of LAP2α in cardiomyocytes 
 
To see whether Lap2α-/- heart phenotype was a direct consequence of LAP2α loss in 
mature cardiomyocytes, or indirectly caused by defects in cardiac progenitors and/or other non-
striated muscle tissues, I generated striated muscle-specific conditional knockout mice. By crossing 
transgenic mice carrying the Lap2 exon 4 flanked by loxP sites32, with mice expressing Cre 
recombinase under the control of muscle creatine kinase (MCK) promoter194, I obtained animals 
that lose LAP2α during later stages of heart development and cardiomyocyte differentiation (I. 
Gotic, submitted manuscript I). 
Since Lap2αNeo-fl/Neo-fl/Mck-Cre+ exhibited normal heart structure and function, as well as 
wild type cardiac transcription profiles (Figure 23., I. Gotic, submitted manuscript I), I concluded 
that LAP2α might exert its function either earlier in the embryonic development, or in non-striated 
muscle cells of the heart. One way to test this hypothesis, would be to cross Lap2α-/- animals with 
transgenics expressing Cre recombinase under the control of an early cardiomyocyte-specific 
promoter, such as Nkx2.5195. 
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Figure 23. Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice have normal HW/BW indexes (A) and express wild type 
levels of GATA4 (B). (qPCR analysis, n = 3 littermate pairs, each floxed sample was compared to its 
respective WT littermate sample, values are mean floxed/WT expression ratios ± 95% CI, p>0.05, ANOVA). 
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3.3.1.3 Skeletal muscle analysis 
 
As mutations in lamin A/C and their interaction partners also cause skeletal muscle 
defects76, I wondered if the structure and function of skeletal muscle tissue would be affected by 
the loss of LAP2α in mice. Lap2α-/- mice did not exhibit an overt pathological skeletal muscle 
phenotype at any age under normal conditions (I. Gotic, submitted manuscript II). Since most 
striated muscle laminopathies manifest only with advanced age, recent studies proposed a model 
according to which, the impaired function of adult stem cells would play a key role in the 
development of the disease13, 32, 124, 125. Therefore, I analyzed the functional properties of LAP2α-
deficient muscle satellite cells in in vivo and in vitro systems.  
 
3.3.1.3.1 Lap2α-/- stem cell properties 
 
Consistent with the increase in their erytropoietic progenitor cell population32, young Lap2α-
/- mice showed a higher content of adult skeletal muscle satellite cells (I. Gotic, submitted 
manuscript II). However, LAP2α-deficient satellite cell progeny exhibited a delay in myogenic 
differentiation in vitro, characterized by stalled expression of muscle-specific genes and slightly 
belated myoblast fusion (Figure 24 – 26, I. Gotic, submitted manuscript II). 
LAP2α-deficient mouse primary fibroblasts and intestinal cells showed a loss of the 
nucleoplasmic lamin A/C pool32. In contrast, in vitro cultured Lap2α-/- myoblasts, which represent 
activated satellite cell progeny196, had seemingly similar distributions of peripheral and intranuclear 
lamin A/C as wild type cells (Figure 26). However, as rearrangement of the nuclear lamina and the 
re-localization of the nucleoplasmic lamin A/C fraction to the periphery represent the hallmarks of 
muscle differentiation144, the effects of LAP2α loss on lamin A/C pool could be masked by changes 
caused by improper differentiation.  
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Figure 24. LAP2α-deficient myoblasts show slightly delayed fusion and expression of early muscle-
specific differentiation factor myogenin. (Immunostained primary mouse myoblasts, bar = 20 μm). 
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Figure 25. The delay in differentiation does not affect the expression of proliferation marker Ki67 in 
LAP2α-deficient cells. (Immunofluorescence stained primary mouse myoblasts, EMyHC – embryonic 
heavy chain, bar = 20 μm). 
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Figure 26. Loss of LAP2α does not substantially affect lamin A/C localization in differentiating 
myoblasts. Re-localization of the intranuclear lamin A/C pool coincides with the downregulation of the early 
myogenic factor MyoD. (Immunofluorescence stained primary mouse myoblasts, bar = 20 μm). 
 „Data not shown“ Results & Discussion 3-154
3.3.1.3.2 Muscle transformation 
 
Myogenic factors MyoD, myogenin and MEF2c, which showed delayed expression patterns 
during in vitro differentiation of Lap2α-/- myoblasts, also play important roles in the process of 
muscle fiber transformation, driving the expression of fast (MyoD) or slow (myogenin, MEF2c) fiber 
type-specific genes (reviewed in [148]). As loss of LAP2α did not largely impinge on the steady-state 
mRNA levels of these factors, either in predominantly slow (Soleus) or fast (Extensor digitorum 
longus – EDL) muscle tissue (Figure 27), I wondered whether even a subtle change in their 
expression dynamics would have an impact on the tightly regulated process of fiber type 
specification. Therefore, I analyzed fiber size and type distribution patterns in predominantly slow 
and fast muscles of Lap2α-/- mice, represented by soleus and Tibialis anterior (TA) muscle 
respectively. Whereas the absence of LAP2α in mouse soleus muscle caused a slight shift towards 
faster fiber types, without affecting fiber size (I. Gotic, submitted manuscript II), myofibers type and 
size distributions in Lap2α-/- TA muscles were similar to wild type (Figure 28).  
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Figure 28. Steady-state mRNA levels of major myogenic transcription factors in Lap2α-/- muscle 
tissue are normal. (EDL – Extensor digitorum longus; qPCR analysis, n = 3 – 5 littermate pairs, p>0.05, 
ANOVA, values are means ± 95% CI)  
Figure 27. Absence of LAP2α does not affect myofiber type and size distribution in mouse TA muscle. 
Fiber type (A) and size (B) distribution was analyzed on transverse sections of TA muscle stained with 
antibodies specific for fast type IIa and IIx/d myosin heavy chain. (n >1000 fibers/mouse in 3 – 4 littermate 
pairs; p>0.05, ANOVA; mean values ± 95% CI are shown). 
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 Different muscle fiber types have distinct metabolic and contractile properties. Whereas 
fast myofibers exert quick contractions and fatigue rapidly, slow muscle fibers exhibit low velocity of 
shortening and high resistance to fatigue (reviewed in [148]). In order to see if the shift in myofiber 
type ratio in soleus muscle was affecting the physical performance and fitness of Lap2α-/- mice, I 
subjected the animals to a battery of muscle strength tests, such as voluntary wheel, forced wheel, 
rotarod, swim and wire test. In all tasks Lap2α-/- mice scored similar to their wild type littermates 
(Figure 29 and data not shown). This suggests that a slight change in the contractile profile of one 
muscle type does not significantly alter the physical performance of the whole organism. 
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Figure 29. General fitness and muscle strength of Lap2α-/- mice is similar to wild type. Performance of 
Lap2α+/+ and Lap2α-/- mice in voluntary wheel A) and wire test B). [n = 8 littermate pairs in A) and 29 pairs in 
B); p>0.05, ANOVA; mean values ± 95% CI are shown]. 
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3.3.1.3.3 Muscle regeneration 
 
Seeing that skeletal muscle of Lap2α-/- mice was not significantly affected by the absence 
of LAP2α at baseline, I analyzed its potential to regenerate after acute and chronic stress. 
Muscle regeneration is mediated by satellite cells, a population of putative adult muscle 
stem cells, which are able to generate myogenic progeny that will differentiate into adult myofibers, 
as well as self-renew131. To see whether the increase in stem cell numbers in young Lap2α-/- mice, 
as well as their delayed differentiation in vitro, would have an effect on muscle regeneration in 
young and old animals in vivo, I subjected the mice to acute and chronic muscle injury.  
 
3.3.1.3.3.1 Acute muscle injury 
 
To induce acute muscle damage, I injected notexin, a potent myotoxin from Notecis 
scutatus snake venom176, into the right soleus muscle and followed the regeneration process 
during the subsequent 12 days. Histological analysis of damaged muscles showed that skeletal 
muscle of young and old Lap2α-/- mice was able to regenerate at a rate similar to the wild type (I. 
Gotic, submitted manuscript II). The activated satellite cells gave rise to desmin/EMyHC positive 
proliferating myoblasts which fused and formed new muscle fibers within the first 4 days after 
notexin injection (Figure 30; I. Gotic, submitted manuscript II). At day 12 of regeneration, the 
damaged muscle tissue was fully restored. 
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Figure 30. Lap2α-/- mice show efficient muscle regeneration. At day 2 after notexin injection a low 
percentage of cells within the regenerating region stains positive for proliferation marker Ki67 (left panels, 
green) and satellite cell marker CD34 (left panels, arrows; diamonds mark undamaged fibers). The majority of 
single nuclei belongs to desmin positive myoblasts (middle panels, arrowheads) which fuse into new myofibers 
by day 4 (right panels, arrowheads). Degenerating old fibers surrounded by laminin (middle panels, red) also 
show a strong immunological reaction with anti-desmin antibody (asterisk). (Immunostained cryo-sections, bar 
= 50 μm). 
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3.3.1.3.3.2 Chronic muscle injury 
 
Chronic muscle degeneration and regeneration represent the hallmarks of the Duchene 
muscular dystrophy mouse model Mdx191, 197. The absence of dystrophin – a structural component 
of the myofiber sarcolemma – due to a nonsense point mutation, causes increased fragility of 
muscle fibers and damage upon mechanical stress. However, the degenerated muscle tissue is 
continuously repaired owing to the existence of resident adult muscle stem cells. Therefore, to 
study the long term effects of LAP2α loss on muscle regeneration, I crossed Lap2α-/- mice into the 
dystrophic background of the Mdx mouse. 
Although Lap2α+/-/Mdx mice exhibited decreased fertility and higher postnatal mortality of 
all progeny, Lap2α-/-/Mdx mice were born according to Mendellian ratios and appeared 
indistinguishable from their wild type and Mdx littermates at birth. The double mutants grew at a 
similar rate as Mdx mice until the age of 3 weeks (Figure 31), when both genotypes started to show 
signs of muscular dystrophy. As a consequence of repetitive muscle de- and re-generation, Lap2α-
/-/Mdx mice as well as Mdx mice, exhibited muscle hypertrophy and reduced fitness as assessed by 
SHIRPA protocol170 (Figure 32 and data not shown). Nonetheless, absence of LAP2α did not have 
a major effect on muscle regeneration in Mdx background, as double mutant mice presented a 
similar behavioral, physiological and histological phenotype as their Mdx littermates (Figure 33 and 
data not shown). 
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Figure 31. Newborn Lap2α-/-/Mdx and Mdx mice grow normally. The average weight of Lap2α-/-/Mdx as 
well as Lap2α+/+/Mdx mice was normalized to the average weight of their wild type (Lap2α+/+) littermates at the 
particular time point and presented as weight ratio. (n = 5 litters (6 wild type, 6 double mutant and 9 Mdx mice, 
mean values ± 95% CI are shown.) 
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Figure 32. Old Lap2α-/-/Mdx and Mdx mice have increased body weight due to muscle hypertrophy. (n = 
17 Lap2α-/-/Mdx + 7 Mdx + 31 Lap2α+/+ + 32 Lap2α-/- mice, p<0.05 for (a) Lap2α-/-/Mdx vs. Lap2α+/+ and (b) 
Mdx vs. Lap2α+/+; ANOVA followed by Boniferroni adjustment, mean values ± 95% CI are shown). 
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Figure 33. Skeletal muscle of Mdx and Lap2α-/-/Mdx mice shows signs of muscular dystrophy. A) 
Hypertrophic myofibers of irregular shape, fibrosis, fiber branching and size alterations, foci of inflammation, 
degeneration and regeneration, all characterize dystrophic mouse muscle. (Haematoxylin & eosin stained 
tissue cryo-sections. Bar = 50 μm). B) Myonuclei of hypertrophic Mdx and Lap2α-/-/Mdx fibers are stacked 
into multiple chains distributed throughout the fiber interior, compared to singly positioned nuclei that lie 
under the sarcolema of WT fibers. (Immunostaining of adult myofibers: CD34 red, DNA blue; bar = 50 μm). 
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Absence of LAP2α did not substantially affect the size of the Mdx satellite cell pool, as 
Lap2α-/-/Mdx mice showed similar CD45-Sca1-Mac1-CXCR4+β1-integrin+ (CSM4B)-satellite cell 
numbers as their Mdx littermates (Figure 34). However, as a consequence of fiber damage, 
constant satellite cell activation, proliferation and differentiation of their progeny might have masked 
the initial effect of LAP2α loss on the satellite cell population. In general, the CSM4B satellite cell 
pool was enlarged in Mdx mice, compared to wild type animals (Figure 34). Interestingly, a recent 
study reported a decrease in the CSM4B cell content in Mdx mice already at the age of 8 weeks198. 
What is more, total CSM4B cell numbers in young Mdx mice in the previous study were lower than 
the numbers found in my studies in old animals, which does not conform to the accepted model of 
aging-related loss of stem cells 136, 199. The discrepancy between the data presented here and the 
results of the aforementioned study may be explained by several means. Apart from potentially 
different genetic background of Mdx mice and experimental conditions used for CSM4B 
quantification in these two studies, the differences in satellite cell numbers might also reflect 
different regeneration/degeneration states of the animals. Thus, if old Mdx mice were sacrificed at 
the beginning of a massive regeneration phase, their satellite cell numbers might have been higher 
than those in young mice experiencing muscle fiber growth at the end of the regeneration process. 
Unfortunatelly, the same study did not show CSM4B cell numbers in old Mdx mice to confirm their 
decrease during natural aging.  
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Figure 34. Loss of LAP2α does not substantially affect the size of the Mdx CSM4B satellite cell pool. 
(CSM4B – CD45-Sca1-Mac1-CXCR4+β1-integrin+; n = 3 Lap2α-/-/Mdx + 3 Mdx + 5 Lap2α+/+ + 4 Lap2α-/- mice; 
p<0.05 (a) Lap2α-/-/Mdx vs. Lap2α+/+; p = 0.049 for (b) Mdx vs. Lap2α+/+; ANOVA followed by Boniferroni 
adjustment, mean values ± 95% CI are shown). 
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3.3.2 Mice with a conditional deletion of LAP2α 
 
In order to specify the phase of muscle differentiation during which LAP2α exerts its 
function more closely, I made use of the existing muscle-specific Cre recombinase-expressing lines 
and generated conditional LAP2α knockout mice.  
As already mentioned, by crossing Lap2αNeo-fl/Neo-fl and Mck-Cre lines32, 194, I obtained 
transgenic mice that lose LAP2α during later phases of striated muscle differentiation, when Mck 
promoter becomes active200. Similar to complete Lap2α-/- mice, Lap2αNeo-fl/Neo-fl/Mck-Cre+ animals 
grew normally and did not show an overt skeletal muscle phenotype (Figure 35; I. Gotic, submitted 
manuscript II). However, I observed delayed in vitro differentiation of primary myoblasts isolated 
from Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice, confirming the role of LAP2α at the onset of myogenic 
differentiation. In addition, the change in myofiber type ratios observed in soleus muscles, as well 
as the normal fiber type distribution in TA muscle, of Lap2α-/- mice was also phenocopied in 
Lap2αNeo-fl/Neo-fl/Mck-Cre+ animals (I. Gotic, submitted manuscript II & data not shown).  
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Figure 35. Newborn (A) and old (B) Lap2αNeo-fl/Neo-fl/Mck-Cre+ mice have normal body weight. A) The 
average weight of Lap2αNeo-fl/Neo-fl/McK-Cre+ mice was normalized to the average weight of their wild type Mck-
Cre+ littermates at the particular time point and presented as weight ratio. [ A) n = 8 Mck-Cre+ litters (11 wild 
type and 12 Lap2αNeo-fl/Neo-fl mice). B) n = 3 littermate Lap2αNeo-fl/Neo-fl/Mck-Cre+ and Lap2α+/+/Mck-Cre+ pairs; 
p> 0.05, ANOVA; values are means ± 95% CI]. 
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3.4 Unpublished data 
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3.4.1 Lap2α-/- hearts under chronic stress 
 
Since heart function in Lap2α-/- mice was not deteriorating further with age under normal 
conditions, I decided to test the ability of the LAP2α-deficient myocardium to cope with acute 
stress. To this end, as part of a collaboration project, I subjected the mice to ischemia-reperfusion 
injury, modeling myocardial infarction175. In this experimental set up, coronary ischemia was 
induced in mice by ligating the left anterior descending coronary artery (LAD) for 30 minutes. After 
one week of reperfusion, the extent of damage imposed upon the tissue was assessed by 
histological analysis. As shown in Figure 36, both – wild type and Lap2α-/- mice showed a great 
variability in the size of the damaged myocardium, precluding any conclusion about the effect of 
LAP2α loss on this process at present. Due to the nature of the experimental set up and the high 
variability in the system, further experiments on a larger cohort of animals would be necessary to 
yield a reliable result. However, the response of the LAP2α-deficient myocardium to ischemia-
induced hypoxic conditions is especially interesting, as transgenic mice lacking one of its binding 
partners – the heat shock protein Hsp7034 – show cardiac contractile dysfunction after ex vivo 
ischemia/reperfusion-induced heart stress, together with baseline left ventricular hypertrophy201. On 
the other hand, overexpression of this stress induced protein confers protection against simulated 
ischemia and metabolic stress202. 
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Figure 36. Lap2α+/+ and Lap2α-/- mice show high variability in the extent of myocardial damage after 
ischemia/reperfusion-induced injury. The size of myocardial infarction area was measured on 5 × 5 μm 
transverse sections taken at fixed positions starting from 1 mm below the ligature. (n = 4 Lap2α+/+ and 6 
Lap2α-/-mice, p>0.05, ANOVA, values are means ± 95% CI). 
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3.4.2 Contractile properties of LAP2α-deficient skeletal muscle – the in vitro study 
 
As the change in myofiber type composition of Lap2α-/- soleus muscles was too subtle to 
substantially affect the general physical performance of LAP2α-deficient mice, I decided to test the 
functional output of single isolated muscles. In a collaborative study, the force produced by isolated 
soleus (exhibiting slow to fast myofiber shift in Lap2α-/- mice) and Extensor digitorum longus (EDL – 
composed of predominantly fast myofibers) muscles was measured in an in vitro system174. 
Although the average maximum force generated by both – soleus and EDL – LAP2α-deficient 
muscles was lower than in the wild type case, and muscle fatigue induced by tetanic stimulation 
was faster in Lap2α-/- soleus muscle (Figure 37), the high variability in the experimental set up 
prevented a final conclusion about the effects of LAP2α loss on the muscle force production. Since 
the present study could not even confirm the previously reported deleterious effects of dystrophin 
deficiency on muscle force generated by the respective Mdx muscles used as a positive control198, 
the primary cause of recorded variability is more likely the sub-optimal experimental procedure than 
the biological variation. Therefore, the effects of LAP2α loss on muscle force production in an Mdx 
mouse background could also not be evaluated at this instance. To overcome the problem of high 
experimental variability, further development of the technique and a larger group of animals would 
be required. 
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Figure 37. Muscle force generated during in vitro tetanic stimulation of mouse Extensor digitorum 
longus (EDL) (A) and soleus (B) muscle. (n = 4 littermate mice of each genotype; mean values ± 95% CI are 
shown). 
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3.4.3 Phenotypic analysis of Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice 
 
The increase in the satellite cell pool of complete Lap2α-/- mice might be a consequence of 
intrinsic stem cell-specific defects and/or systemic changes caused by the absence of LAP2α in 
other non-muscle cells and tissues. To be able to discern between these two phenomena, I 
generated transgenic mice in which the Cre recombinase-mediated deletion of the α-specific LAP2 
exon 4 occurs at early phases of muscle development and stem cell specification – in cells 
expressing the paired box transcription factor PAX7203. Similar to complete Lap2α-/- mice, Lap2αNeo-
fl/Neo-fl/Pax7-Cre+ animals were born according to Mendellian ratios and thrived normally after birth 
(Figure 38). In addition, like Lap2α-/- and conditional late muscle-specific Lap2αNeo-fl/Neo-fl/Mck-Cre+ 
animals, Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice did not exhibit any overt pathological changes of striated 
muscle tissue at histological level (Figure 39). 
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Figure 38. Newborn (A) and old (B) Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice have normal body weight. A) The 
average weight of Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice was normalized to the average weight of their wild type 
Pax7-Cre+ littermates at the particular time point and presented as weight ratio. (n = 5 Pax7-Cre+ litters (10 
wild type and 8 Lap2αNeo-fl/Neo-fl mice). B) n = 5 littermate Lap2αNeo-fl/Neo-fl/Pax7-Cre+ and Lap2α+/+/Pax7-Cre+ 
pairs; p> 0.05, ANOVA; values are means ± 95% CI. 
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Figure 39. Absence of dystrophic features in Lap2αNeo-fl/Neo-/fl/Pax7-Cre+ striated muscle. (H&E stained 
TA (upper panels) and heart (lower panels) cryo-sections. Bar =50 μm). 
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Fluorescence-activated cell sorting (FACS) analysis of myofiber-associated satellite cells 
showed a slight increase in the CSM4B cell content in Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice compared to 
wild type Pax7-Cre+ animals at all ages (Figure 40 & 41). However, Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice 
did not fully reconstitute the stem cell phenotype of complete Lap2α-/- animals, as due to high 
variation, the difference between Lap2αNeo-fl/Neo-fl/Pax7-Cre+ and Lap2α+/+/Pax7-Cre+ CSM4B cell 
numbers was not statistically significant. Interestingly, all Pax7-Cre+ mice showed a lower content 
of CSM4B satellite cells in their skeletal muscle tissue, compared to Lap2α+/+ animals with 
predominantly C57/B6 background and Mck-Cre+ mice of mixed Mus musculus genetic background 
(I. Gotic, submitted manuscript II), indicating a potential defect in the maintenance of the muscle 
stem cell pool. What is more, CSM4B cell numbers in both Lap2α+/+ and Lap2αNeo-fl/Neo-fl Pax7-Cre+ 
mice did not exhibit the age-related decline observed in other mouse lines reported in this and 
other previously published studies136, 199. 
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Figure 40. Lap2α+/+/Pax7-Cre+ and Lap2αNeo-fl/Neo-fl Pax7-Cre+ mice show a deregulation of the CSM4B 
myofiber-associated satellite cell pool. (young – n = 5 WT + 7 floxed mice, adult – n = 2 WT + 2 floxed 
mice; old – n = 4 WT + 6 floxed mice; p>0.05, ANOVA, values are means ± 95% CI). 
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Figure 41. Fluorescence-activated cell sorting analysis of myofiber-associated satellite cells reveals a 
slight increase in the CSM4B cell population in Lap2αNeo-fl/Neo-fl Pax7-Cre+ mice. Cells were analyzed for 
their size, complexity and the expression of specific surface markers. Frame P1 represents the parent 
population selected for cell surface analysis. Every subsequent image in descending order represents further 
analysis of the parent gated population. (Representative images of 5 independent experiments are shown.
FSC – Forward Scatter (related to cell size); SSC – Side Scatter (a measure of cell granularity); APC, FITC, 
PE, PerCP-Cy5.5 – fluorochromes coupled to cell surface-specific antibodies). 
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The huge variability in the FACS data from Pax7-Cre+ mice might be a consequence of 
incomplete deletion of the LAP2 exon 4 in PAX7+ satellite cells and, therefore, in skeletal muscle 
tissue, resulting in high variability in LAP2α protein levels in Lap2αNeo-fl/Neo-fl/Pax7-Cre+ animals. As 
shown in Figure 42, in some Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice, skeletal muscle LAP2α mRNA levels 
were significantly lower than in the wild type tissue, whereas in other animals they were similar to 
wild type, suggesting that the Cre recombinase did not exert its activity in all mice. As the bulk 
postnatal muscle growth depends on the activity of PAX7+ stem cells (reviewed in [126]), most 
myofiber nuclei should be negative for LAP2α. Even myonuclei that originated from other PAX7-
negative cells should lose LAP2α, as Cre recombinase is small enough to diffuse inside the 
myofiber syncytium. Although the activity of the Pax7 promoter, and therefore the expression of 
Cre recombinase, is downregulated during initial phases of muscle differentiation, a low level of 
PAX7 expression still persists during myoblast fusion (reviewed in [130]), which should enable the 
Cre-mediated excision of LAP2 exon 4 in all myofiber nuclei. The remaining low levels of LAP2α 
mRNA in those Lap2αNeo-fl/Neo-fl/Pax7-Cre+ muscles which went through Cre-mediated LAP2α 
ablation might have originated from other non-muscle PAX7-negative cells present in the tissue.  
The Pax7-Cre+ mouse line was generated by site-specific insertion of the Cre cassette into 
the 3’ UTR of the endogenous Pax7 gene (Pax7tm1(cre)Mrc)203. Although the initial study claimed that 
this insertion did not affect the expression of the endogenous protein, the effects of this genetic 
manipulation on the specification and maintenance of PAX7+ satellite cells were not studied in 
detail. Since PAX7 is essential for satellite cell survival and >90% of CSM4B cells expresses this 
protein198, the deregulation of the Pax7-Cre+ CSM4B satellite cell pool observed in Pax7-Cre+ mice, 
might also be a consequence of the genetic manipulation in the Pax7 locus. The effect of LAP2α 
loss in Pax7-Cre+ CSM4B cells might thus be masked by impaired biological function of 
endogenous PAX7.  
Figure 42. Muscle tissue of Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice shows incomplete downregulation of 
LAP2α expression. (+/+ → Lap2α+/+/Pax7-Cre+; fl/fl → Lap2αNeo-fl/Neo-fl/Pax7-Cre+. Representative images 
of semiq-PCR analysis in 3 independent littermate couples. Data were normalized to endogenous levels of 
GAPDH). 
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Consistent with the in vivo results which showed an overall decrease in CSM4B cell 
population in Pax7-Cre+ muscles, primary myoblasts isolated from Lap2αNeo-fl/Neo-fl/Pax7-Cre+, as 
well as Lap2α+/+/Pax7-Cre+ transgenic mice, died after the induction of differentiation (removal of 
basic fibroblast growth factor and 20% foetal calf serum → 5% horse serum substitution). As 
shown in Figure 43, Pax7-Cre+ myoblasts initiated the differentiation process, but the majority of 
newly formed myotubes, as well as single cells, died by day 5 of differentiation. At this point, 
however it is not possible to distinguish whether these cells died due to cell-intrinsic defects or 
require special in vitro culturing conditions. Presumably, if the cell-intrinsic defects were as 
extensive in vivo, the mice would probably show signs of retarded postnatal growth, as observed in 
Pax7-/- mice, which lose their stem cell pool after birth due to apoptosis204, 205. Still, a reduced 
number of satellite cells, as observed in Pax7-Cre+ mice, may be sufficient to rescue the phenotype 
of Pax7-/- animals. 
Figure 43. Pax7-Cre+ primary myoblasts die after the induction of differentiation. Both Lap2α+/+/Pax7-
Cre+ (+/+) and Lap2αNeo-fl/Neo-fl/Pax7-Cre+ (fl/fl) myoblasts are able to differentiate into myotubes, but the 
majority of cells dies by day 5 of differentiation. (Representative bright field images of 5 independent 
experiments, bar = 50 μm). 
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The death of Pax7-Cre+ cells prevented the analysis of their muscle-specific gene 
expression patterns. However, as shown in Figure 44, the expression of LAP2α in Lap2α+/+/Pax7-
Cre+ myoblasts followed the standard differentiation curve described above for the other LAP2α 
lines. Lap2αNeo-fl/Neo-fl/Pax7-Cre+ cells used in this study showed an efficient ablation of LAP2α 
already in proliferating satellite cells progeny.  
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Figure 44. Lap2αNeo-fl/Neo-fl/Pax7-Cre+ cells show efficient deletion of LAP2α. (qPCR analyses of primary 
myoblast cultures; n = 3 separate experiments; *p<0.05 for Lap2α+/+/Pax7-Cre+ vs. Lap2αNeo-fl/Neo-fl/Pax7-
Cre+ samples, ANOVA; each wild type sample was compared to its respective Day 0 value and each floxed 
sample to its respective wild type littermate sample at the particular time point). 
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Histological analysis of soleus and TA muscles in Pax7-Cre+ mice revealed a general shift 
in soleus myofiber type ratios towards faster types (57% of slow fibers in C57/B6 background → 
30% in Pax7-Cre+ animals), specific for the Pax7-Cre+ transgenic line and irrespective of LAP2α 
presence (Figure 45). This phenomenon might originate from a specific genetic constitution of the 
mouse line used for the generation of Pax7-Cre+ mice, as it was shown that various laboratory 
mice exhibit substantial differences in muscle fiber type composition206. Conversely, the shift in 
myofiber type ratios might also reflect a general deficiency in muscle tissue homeostasis caused by 
defects in PAX7-expressing cells. Interestingly, similar changes in the fiber type distribution 
characterize muscle aging and disuse.  
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Figure 45. Lap2α+/+/Pax7-Cre+ and Lap2αNeo-fl/Neo-fl/Pax7-Cre+ soleus muscles show a shift in myofiber 
ratios towards faster types. A) Immunohistochemical analysis of TA (upper panels) muscle stained with 
antibodies specific for fast (Type IIa+x/d) myosin heavy chain. Bar = 50 μm. B) Quantification of specific 
myofiber types. (n = 3 Pax7-Cre+ littermate pairs and 5 Lap2α+/+ mice; p<0.05 for (a) Lap2α+/+ vs. 
Lap2α+/+/Pax7-Cre+ mice and (b) Lap2α+/+ vs. Lap2αNeo-fl/Neo-fl/Pax7-Cre+ mice; ANOVA followed by Boniferroni 
adjustment; values are means ± 95% CI). 
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In conclusion, the conditional muscle-specific Pax7-Cre+ LAP2α knockout mice did not 
allow the analysis of LAP2α function during early phases of muscle stem cell specification and 
establishment of satellite cell population, due to intrinsic defects of the Pax7-Cre+ line. To 
overcome this problem, an alternative Pax7-Cre+ transgenic line could be used in future studies207. 
Still, since PAX7 is also expressed in developing central neural system and the neural crest, and 
plays an important role in maintenance of adult neural cells208, the contribution of defects in other 
tissues to the skeletal muscle phenotype could not be excluded this way.  
Therefore, until an exclusive muscle-specific stem cell marker has been identified, 
alternative approaches could be used to elucidate LAP2α functions in stem cell maintenance. In 
particular, studies of mice in which the endogenous stem cell pool has been replaced by satellite 
cells with a specific LAP2α knockdown might give more conclusive answers. However, the loss of 
myogenic potential during in vitro culture of satellite cells and their complex re-administration into 
the native niche after isolation (reviewed in [133]), present serious pitfalls of such an approach. 
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loss of nucleoplasmic lAP2α–lamin A complexes 
causes erythroid and epidermal progenitor 
hyperproliferation
Nana Naetar1,6, Barbara Korbei1,6, Serguei Kozlov2, Marc A. Kerenyi1,3, Daniela Dorner1, Rosana Kral1, Ivana 
Gotic1, Peter Fuchs1, Tatiana V. Cohen2, Reginald Bittner4, Colin L. Stewart2,5 and Roland Foisner1,7
Lamina-associated polypeptide (LAP) 2α is a chromatin-
associated protein that binds A-type lamins1,2. Mutations in 
both LAP2α and A-type lamins are linked to human diseases 
called laminopathies3, but the molecular mechanisms are 
poorly understood. The A-type lamin–LAP2α complex interacts 
with and regulates retinoblastoma protein (pRb)4,5, but the 
significance of this interaction in vivo is unknown. Here we 
address the function of the A-type lamin–LAP2α complex 
with the use of LAP2α-deficient mice. We show that LAP2α 
loss causes relocalization of nucleoplasmic A-type lamins to 
the nuclear envelope and impairs pRb function. This causes 
inefficient cell-cycle arrest in dense fibroblast cultures and 
hyperproliferation of epidermal and erythroid progenitor cells 
in vivo, leading to tissue hyperplasia. Our results support 
a disease-relevant model6 in which LAP2α defines A-type 
lamin localization in the nucleoplasm, which in turn affects 
pRb-mediated regulation of progenitor cell proliferation and 
differentiation in highly regenerative tissues. 
LAP2α is one of six LAP2 isoforms7; it belongs to the LEM (LAP–Emerin–
MAN1) protein family characterized by a structural motif (LEM domain) 
that mediates binding to the chromatin protein Barrier to Autointegration 
Factor2. Most LAP2 isoforms and other LEM-domain proteins are integral 
proteins of the inner nuclear membrane and bind to the peripheral nuclear 
lamin network2, which organizes chromatin and regulates gene expression1. 
In contrast, LAP2α localizes to the nucleoplasm, where it interacts with 
A-type lamins8 and the cell-cycle regulator and tumour-suppressor pro-
tein retinoblastoma (pRb), and affects E2F–pRb-dependent gene expres-
sion4. Unlike B-type lamins, A-type lamins are expressed at later stages of 
development and their mutation causes a variety of diseases, including 
striated muscle diseases, lipodystrophy and Hutchinson–Gilford progeria3. 
A mutation in LAP2α that impairs binding to A-type lamins also causes 
dilated cardiomyopathy9. We hypothesized that A-type lamin–LAP2α 
complexes may control proliferation and differentiation of adult stem or 
progenitor cells through the pRb pathway and that a deregulation of this 
function in patients may impair stem cell activity and tissue homeostasis6. 
To test the role of LAP2α in pRb-regulated progenitor cell proliferation in 
vivo, we generated a Lap2α knockout mouse and analysed regenerative tis-
sues, whose homeostasis is known to depend on pRb. The LAP2α-specific 
exon 4 in the Lap2 gene (also known as thymopoietin, Tmpo) was flanked 
by loxP sites, and mice were crossed with Cre-recombinase-expressing 
mice10 (Supplementary Information, Fig. S2). Lap2α messenger RNA and 
LAP2α protein were absent in postnatal primary fibroblasts and tissue 
extracts of LAP2α-deficient mice, whereas the expression of other LAP2 
isoforms was not significantly affected (Supplementary Information, 
Fig. S2d–g). Immunofluorescence microscopy with LAP2 isoform-specific 
and pan-LAP2 antibodies revealed unchanged localization of the LAP2β 
isoform at the nuclear periphery and loss of LAP2α in the nuclear interior 
in Lap2α−/− fibroblasts (Supplementary Information, Fig. S2f).
Although the expression of A-type lamins was unchanged in LAP2α-
deficient primary fibroblasts at the mRNA and protein level (Fig. 1c and 
Supplementary Information, Fig. S2g), localization of A-type lamins was 
affected. In wild-type fibroblasts, which were synchronized in G1 phase 
to avoid cell-cycle-dependent effects, A-type lamins were found at the 
nuclear periphery and throughout the nucleoplasm. In Lap2α−/− fibroblasts, 
staining of nucleoplasmic A-type lamins was greatly decreased (Fig. 1a). 
Intensity profiles of A-type lamin staining along a central axis through 
nuclei revealed a decrease in nucleoplasmic lamin in LAP2α-deficient 
cells (Fig. 1b). In addition, histograms depicting the number of cells with 
a given ratio of nucleoplasmic over rim staining intensities showed a shift 
in A-type lamin localization from the nucleoplasm in wild-type cells to 
the nuclear periphery in LAP2α-deficient cells (Fig. 1b). Furthermore, 
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in wild-type fibroblasts extraction of nuclei at high salt concentrations 
solubilized a small fraction of lamins A and C (probably the nucleoplas-
mic pool), whereas lamins A and C from Lap2α−/− cells were completely 
insoluble (Fig. 1c). These data suggest that nucleoplasmic A-type lam-
ins translocated to the peripheral lamina in Lap2α−/− cells. To examine 
the direct role of LAP2α in nucleoplasmic A-type lamin localization, we 
expressed full-length LAP2α or truncated LAP2α lacking its lamin binding 
domain (LAP2α∆C) in Lap2α−/− fibroblasts. Unlike the truncated protein, 
full-length LAP2α rescued the nucleoplasmic localization of lamins A and 
C (Fig. 1d). Thus, localization of A-type lamins in the nuclear interior is 
mediated by LAP2α and requires the lamin-binding domain of LAP2α.
We showed previously that nucleoplasmic LAP2α and A-type lam-
ins affect the transition of cells between cycling and arrested states by 
repressing E2F–pRb-dependent promoter activity4,5. To test whether a 
loss of LAP2α and the accompanied decrease in nucleoplasmic A-type 
lamins disturbed pRb-mediated cell-cycle control, we followed con-
tact-mediated cell-cycle arrest in primary mouse fibroblasts. Lap2α−/− 
fibroblasts reached a density about 1.5-fold that of control cells before 
cell-cycle arrest (Fig. 2a). This effect was probably caused by impaired 
contact inhibition, indicated by the more than twofold increase in the cell 
proliferation marker protein proliferating-cell nuclear antigen (PCNA) 
in dense Lap2α−/− versus control cultures (Fig. 2b), and was not caused by 
differences in cell size (Supplementary Information, Fig. S3b) or apoptotic 
rates (Fig. 2c). Several observations linked the cell-cycle phenotype to 
a deregulation of the pRb pathway. First, whereas total levels of pocket 
proteins pRb and p107 were unchanged, hyperphosphorylated pRb was 
upregulated up to twofold in dense Lap2α−/− versus control primary 
fibroblasts (Fig. 2b) and in immortalized Lap2α−/− lines (Supplementary 
Information, Fig. S3a). Second, mRNA levels of the E2F target genes 
cyclin E1, PCNA and E2F1 were increased up to 50% in growth-arrested 
Lap2α−/− versus wild-type cells (Fig. 2d). Third, and in contrast, protein 
levels of the cyclin-dependent kinase inhibitors p16 and p27, which regu-
late pRb phosphorylation and cell-cycle arrest, were unchanged (Fig. 2b). 
Thus, loss of LAP2α in fibroblasts is accompanied by a p16- and p27-
independent deregulation of pRb, leading to delayed contact-mediated 
cell-cycle arrest.
To test whether pRb deregulation is a direct cause of LAP2α loss, 
we expressed full-length LAP2α or a LAP2α mutant lacking the pRb-
binding and lamin-binding domain (LAP2α∆C; see Fig. 1d), or green 
fluorescent protein (GFP) as a control in Lap2α−/− or wild-type cells, 
and analysed cell-cycle progression by the incorporation of bromode-
oxyuridine (BrdU) (Fig. 2e). BrdU incorporation rates were increased 
in untransfected and GFP-transfected Lap2α−/− compared with wild-
type cells. Re-expression of full-length LAP2α in knockout cells rescued 
the phenotype and decreased BrdU incorporation to wild-type levels 
(Fig. 2e). In contrast, expression of LAP2α∆C had no significant effect. 
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Figure 1 Lap2α−/− fibroblasts have reduced nucleoplasmic lamin A/C 
levels. (a) Immunofluorescence of aphidicolin-arrested wild-type (+/+) or 
Lap2α knockout (−/−) fibroblasts stained with antiserum against LAP2α 
and antibody against lamins A and C. Confocal images are shown. Scale 
bar, 10 µm. (b) Upper panel: fluorescence intensity of lamin A/C staining 
was determined along the axis shown as a dashed line in a, and plotted as 
a graph. Lower panel: ratios of nucleoplasmic to peripheral mean A-type 
lamin fluorescence intensity were calculated for 40 Lap2α knockout (−/−) 
and wild-type (+/+) fibroblasts and plotted in a histogram. (c) Total cell 
lysates (pre) or cytoplasmic (C) and nuclear (N) fractions, or soluble (S) and 
insoluble pellet (P) fractions after extraction of nuclei with low-salt (LS) 
or high-salt (HS) buffer were analysed by immunoblotting with antibodies 
against lamins A and C (La A and La C, respectively). (d) Lap2α−/− 
fibroblasts were transiently transfected with GFP-tagged full-length LAP2α 
or a LAP2α mutant lacking the pRb-binding and lamin-binding domain 
(LAP2α∆C) and processed for immunofluorescence microscopy 24 h after 
transfection with an antibody against lamins A and C. Confocal images are 
shown. Scale bar, 10 µm.
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Unlike with LAP2α∆C and GFP, expression of full-length LAP2α also 
impaired cell-cycle progression in wild-type cells. Thus, the cell-cycle 
phenotype observed in Lap2α−/− cells is directly linked to the absence of 
LAP2α and to the loss of binding of LAP2α to pRb and A-type lamins. 
Accordingly, the expression of full-length LAP2α in triple knockout cells 
lacking pocket proteins p107, p130 and pRb (ref. 11) had no effect on 
cell-cycle progression (Fig. 2f).
Next we tested the phenotypes of LAP2α loss at the organismal level. 
As LAP2α-deficient mice were viable and indistinguishable from their 
wild-type littermates, we investigated regenerative tissues immunohisto-
chemically, most of which were previously shown to require pRb function 
for proper homeostasis. Muscle and liver from 2-month-old animals did 
not reveal an overt phenotype (Supplementary Information, Fig. S4a). 
In addition, heart, which is affected in patients with a LAP2α mutation, 
was unaffected histologically. In contrast, we detected a phenotype in 
paw epidermis of Lap2α−/− mice. The thickness of the epidermis (basal 
to granular cell layers) was increased by about 20% in Lap2α−/− versus 
wild-type tissue (Fig. 3a). This phenotype was most pronounced in the 
thickest regions of the plantar paw epidermis but was undetectable in 
the thin epidermis of the paw dorsum and the back skin. Because the 
plantar epidermis is exposed to mechanical stress, causing epidermal 
thickening and a high proliferative index, we reasoned that the observed 
phenotype might be linked to mechanical-stress-induced high turnover 
of the epidermis. Immunostaining revealed a prominent expression of 
LAP2α in nuclei of the basal cell layer and neighbouring suprabasal cells 
(Fig. 3b). Intriguingly, the number of Ki67-positive, proliferating cells, 
was increased up to twofold (in plantar epidermis) in Lap2α−/− versus 
control tissue (Fig. 3b). The hyperproliferation phenotype was linked to 
a deregulation of the pRb pathway, because pRb phosphorylation was 
increased in Lap2α knockout versus wild-type tissue (Supplementary 
Information, Fig. S5a). Phosphorylation of pRb was similarly increased 
in back skin, suggesting that pRb phosphorylation is not indirectly caused 
by the hyperproliferation of cells but is a direct consequence of LAP2α 
loss. We also tested transit amplifier cells in hair follicles and detected the 
highest expression of LAP2α in the Ki67-positive, proliferative matrix 
cells at the hair base, but neither their number nor localization was visibly 
affected in Lap2α−/− mice (data not shown). However, an upregulation of 
proliferating transit amplifier cells was observed in large and small intes-
tine, yielding extended crypt lengths in large intestine (Supplementary 
Information, Fig. S4b). Thus, the effect of LAP2α loss on progenitor cells 
is most pronounced in highly regenerative regions of interfollicular epi-
dermis, but it also occurs in other regenerative tissues.
Because proliferation and differentiation of the epidermal transit 
amplifier cells are closely linked, we tested the expression of epithe-
lial differentiation markers by immunostaining. The layers expressing 
keratin 5, a basal cell marker, were significantly expanded in Lap2α−/− 
a
0
4
8
12
16
Day 4 Day 7
d
0 1 2 3 4 5 6 7
0
–/–
+/+
Day
c
e
– GFP
b
15 p16
100
100
100
37
100
+/+ +/+–/– –/–
Day 4 Day 7
Total Rb
Rb S807/811
Rb S780
PCNA
p107
50
25 p27
Tubulin
CyE1
+/+ –/–
Day 7
Actin
PCNA
E2F1
Day 7
0
0.4
0.8
1.2
1.6
2
CyE1 PCNA E2F1
f
0
0.4
0.8
1.2
1.6
0
0.4
0.8
1.2
200
200
300
200
0.006**
0.03* 0.03
*
To
ta
l c
el
l n
o.
 (x
 1
04
)
40
30
20
10
TU
N
E
L-
p
os
iti
ve
 c
el
ls
 (p
er
ce
nt
ag
e)
+/+
–/–
+/+
–/–
+/+
TKO+/+
–/–
N
or
m
al
iz
ed
 in
te
ns
ity
 
(fo
ld
 d
iff
er
en
ce
)
B
rd
U
-p
os
iti
ve
 c
el
ls
(fo
ld
 d
iff
er
en
ce
)
B
rd
U
-p
os
iti
ve
 c
el
ls
(fo
ld
 d
iff
er
en
ce
)
LAP2α∆CLAP2α GFP LAP2α
Figure 2 Loss of LAP2α in fibroblasts impairs cell-cycle arrest. (a) Primary 
postnatal Lap2α+/+ and Lap2α−/− fibroblasts were seeded at equal densities. 
Cell numbers were determined daily and plotted against cultivation time. 
Values are means ± s.d. for four biological replicates. (b, d) Cells were 
lysed at the indicated time points and analysed by immunoblotting with 
antibodies against the indicated antigens (b) or mRNA was isolated and 
analysed by RT–PCR for expression of cyclin E1 (CyE1), PCNA, E2F1 
and actin mRNA as control (d). An agarose gel of PCR fragments and 
quantification of band intensities normalized to actin mRNA levels are 
shown. Knockout values are depicted as fold difference from wild-type. 
(c) Apoptosis was quantified at the indicated time points with a TUNEL 
assay. (e, f) Primary Lap2α−/− (−/−) and wild-type (+/+) fibroblasts (e) or 
immortalized wild-type and p130−/− p107−/− Rb−/− triple knockout fibroblasts 
(TKO) (f) were transiently transfected with GFP-tagged full-length LAP2α, 
LAP2α∆C or GFP alone as indicated, and processed for BrdU incorporation 
assays 24 h after transfection. BrdU-positive transfected cells were counted 
and plotted in a bar graph. Values are shown as fold difference from GFP-
transfected wild-type cells. Untransfected cultures (−) were included in the 
analysis as a control. Means ± s.e.m. for three independent experiments 
are shown in c, e and f. P values are indicated as follows: two asterisks, 
highly significant; asterisk, significant. Numbers in b indicate the molecular 
masses of marker proteins in kDa. Numbers in d denote corresponding 
marker bands and their length in base pairs. Uncropped images of blots in b 
are shown in Supplementary Information, Fig. S7.
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tissue, as well as layers expressing keratin 10, a marker of suprabasal 
differentiated cells (Fig. 3c). Keratin-10-positive layers were negative for 
proliferation marker Ki67, and the expression and localization of the epi-
dermal proteins plectin, desmoplakin and involucrin were unaffected in 
Lap2α−/− mice (Supplementary Information, Fig. S5b, c). Thus, Lap2α−/− 
transit amplifier cells hyperproliferate but differentiate normally and do 
not differentiate prematurely before exit from the cell cycle.
To test whether hyperproliferation of progenitor cells in LAP2α-
deficient epidermis is accompanied by a delocalization of A-type lamins, 
we stained epidermal tissue sections for lamins A and C and Ki67. In wild-
type tissue, a weak nucleoplasmic lamin staining was detectable in 70% of 
proliferating, Ki67-positive keratinocytes (Fig. 4a, arrows), whereas the 
staining was strongly reduced in non-proliferating, Ki67-negative cells 
(arrowheads). In contrast, 80% of proliferating LAP2α-deficient transit 
amplifier cells were negative for nucleoplasmic lamins. Thus, LAP2α loss 
is tightly linked to lower levels of nucleoplasmic lamins A and C in the 
context of an intact tissue.
If the LAP2α-loss-mediated delocalization of lamins A and C and the 
hyperproliferation of progenitor cells are functionally linked, one would 
expect a similar phenotype in A-type lamin-deficient tissues. Indeed, we 
found a subtle, but statistically significant, increase in Ki67-positive tran-
sit amplifier cells in the paw epidermis of Lmna−/− mice, causing a mild 
tissue hyperplasia (Fig. 4b). Thus, the absence of A-type lamins partly 
phenocopies the effects seen in LAP2α-deficient tissues and supports 
a common role for A-type lamin–LAP2α complexes in pRb-mediated 
cell-cycle control.
Our data indicate a dependence of the LAP2α loss phenotype on 
regenerative activity. We therefore tested the haematopoietic system, 
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Figure 3 LAP2α-deficient paw epidermis contains a higher number of 
proliferating progenitor cells causing epidermal hyperplasia. (a) Right: 
haematoxylin/eosin-stained paraffin sections of epidermis from different 
paw regions (plantar or dorsal paw epidermis) of eight-week-old Lap2α+/+ 
and Lap2α−/− mice. Scale bar, 50 µm. Left: the thickness of the different 
epidermal regions (excluding stratum corneum) was quantified using 
Axiovision imaging software and plotted in a bar graph (n = 4). (b, c) 
Paraffin sections of paw epidermis were analysed by immunofluorescence 
microscopy with antibodies against the indicated antigens. DNA was 
stained with Hoechst. Confocal images are shown. Scale bar, 50 µm. 
(b) Ki67-positive cells from paw epidermis were counted, normalized 
to skin length and plotted in a bar graph (n = 7). (c) The thickness of 
the K5-expressing and K10-expressing layer was quantified with LSM 
imaging software and plotted in a bar graph (n = 3). Results are shown 
as means ± s.e.m. P values are indicated as follows: two asterisks, highly 
significant; asterisk, significant.
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which has a high regenerative capacity and expresses LAP2α at high 
level (Supplementary Information, Fig. S6a). Because flow cytometry 
revealed no alterations in lineage-marker-negative Sca-1/c-Kit-positive 
cells (LSK cells, comprising haematopoietic stem cells and primitive 
multipotent progenitors) in the bone marrow of Lap2α−/− versus con-
trol mice (Supplementary Information, Fig. S6b), we tested erythro-
poiesis, which requires pRb (refs 12, 13). Four cell populations (R1–R4; 
Fig. 5a) with different expression levels of cell-surface markers Ter119 
and CD71 (Ter119medCD71high, Ter119highCD71high, Ter119highCD71med 
and Ter119high CD71low) represent consecutive stages of erythroid dif-
ferentiation14. Flow cytometry revealed an up to fourfold increase in 
erythroid progenitors (R1 and R2) in spleens from Lap2α−/− versus 
control mice and a more subtle, but significant, increase in bone mar-
row erythroid progenitors (Fig. 5a). The number of mature erythroid 
cells (R3 and R4) was barely affected, indicating that LAP2α-null 
erythroblasts can differentiate. Spleen size and architecture were not 
affected (Supplementary Information, Fig. S4a). Haematocrit levels, 
reflecting erythrocyte numbers in peripheral blood, were slightly but 
significantly increased in Lap2α−/− (56.5 ± 0.8% (s.e.m); n = 8) versus 
wild-type littermates (52.8 ± 1.0% (s.e.m.); n = 9; P = 0.014). Thus, the 
increase in progenitor cell numbers leads to a net increase in mature 
erythrocytes in peripheral blood. To investigate the cell-cycle phe-
notype of early erythroblasts, we analysed lysates of Ter119-positive 
spleen cells by immunoblotting: Lap2α−/− lysates had increased levels of 
the proliferation markers PCNA and phospho-pRb in comparison with 
wild-type samples (Fig. 5b), whereas the apoptotic marker poly(ADP-
ribose) polymerase (PARP) p85 fragment was unchanged. Thus, the 
increase of early erythroblasts in Lap2α−/− mice is caused by inefficient 
exit from the cell cycle and a deregulated pRb pathway rather than by 
decreased apoptosis.
Because the skin phenotype was most pronounced in stressed tis-
sue, we tested how Lap2α−/− mice responded to severe erythroid stress, 
caused by phenylhydrazine (PHZ)-induced haemolysis. Three days 
after PHZ injection, spleen size was increased fourfold compared with 
mock-treated animals, and haematocrit values were decreased from 
about 50% to about 30%. Flow cytometry of spleen cells from PHZ-
treated mice revealed a significant increase in all erythroid cell types 
in both Lap2α−/− and control littermates, reflecting the response to 
haemolytic stress. However, erythroid progenitor cells in PHZ-treated 
Lap2α−/− spleens were significantly increased in comparison with those 
in the PHZ-treated controls (Fig. 5d). Haematocrit levels were rescued 
to almost the pre-treatment levels within seven days after treatment, 
but red blood cell levels recovered more efficiently in Lap2α−/− versus 
wild-type littermates within the first five days (Fig. 5c).
It has previously been suggested that pRb loss may affect erythropoi-
esis indirectly by inhibiting the differentiation of macrophages, which 
provide the niche for erythropoiesis15. However, LAP2α-deficient bone 
marrow cells readily differentiated into macrophages in vitro, and, 
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Figure 4 Loss of nucleoplasmic lamins A and C is linked to epidermal 
hyperproliferation. (a, b) Paraffin sections of paw epidermis from 
Lap2α−/− (a) or Lmna−/− (b) mice and wild-type controls were analysed by 
immunofluorescence microscopy with antibodies against Ki67 and lamins A 
and C. Confocal images are shown. Scale bar, 50 µm. Rectangles in a mark 
the regions shown as insets. Arrows indicate Ki67-positive cells; arrowheads 
indicate Ki67-negative cells. (a) The percentages of Ki67-positive cells 
either positive or negative for nucleoplasmic lamin A/C staining in Lap2α 
knockout (−/−) and wild-type (+/+) paw epidermis are shown (n = 4).  
(b) Left: the thickness of the different epidermal regions (excluding stratum 
corneum) in the paw (plantar or dorsal epidermis) of Lmna−/− (−/−) or Lmna+/− 
and Lmna+/+ (Control) mice was quantified with Axiovision imaging software 
and plotted in a bar graph (n = 3). Right: Ki67-positive cells were counted, 
normalized to skin length and the results are shown in a bar graph (n = 3). 
Results are shown as means ± s.e.m. P values are indicated as follows: bold, 
one-tailed; two asterisks, highly significant; asterisk, significant.
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unlike pRb-deficient macrophages15, showed normal expression of the 
late macrophage differentiation markers CSF-1R (colony stimulating 
factor-1 receptor), SR-A (scavenger receptor A) and Cd11b (data not 
shown). We therefore concluded that the effects of LAP2α are intrinsic 
to erythroblasts and are not caused indirectly by affecting the niche of 
erythroid progenitors.
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Figure 5 Absence of LAP2α leads to elevated levels of erythroid progenitors. 
(a) Representative flow cytometric profiles of spleen or bone marrow cells 
from eight-week-old wild-type (+/+) or Lap2α knockout (−/−) mice. Cells were 
labelled with antibodies against Ter119 and CD71. Regions 1–4 (R1–R4) 
represent four erythroid maturation stages. Bar graphs show the percentage 
of labelled erythroid progenitors (R1 and R2) and mature erythroid cells (R3 
and R4) in spleen and bone marrow. Results are shown as means ± s.e.m. 
(n = 3). (b) Ter119+ spleen cells obtained by magnetic cell sorting from 
Lap2α knockout and wild-type control mice were lysed and processed for 
immunoblotting with antibodies against the indicated antigens. Numbers 
indicate the molecular masses of marker proteins in kDa. Quantifications 
of band intensities normalized to actin levels are shown on the right. 
Knockout values are depicted as fold difference from the wild-type. (c, d) 
Lap2α−/− mice (−/−) and wild-type littermate controls (+/+) were injected 
with PHZ; after two days, spleen cells were analysed by flow cytometry with 
antibodies against Ter119 and CD71 (d). Regions 1–4 are as in a. The bar 
graph shows values of Lap2α−/− mice and wild-type littermates. Knockout 
values are depicted as fold difference from the wild-type. Results are shown 
as means ± s.e.m. (n = 3). (c) Haematocrit levels in peripheral blood from 
LAP2α knockout (−/−) and wild-type (+/+) mice were determined over a 
time course of seven days after PHZ injection at day 0 and day 1. Horizontal 
lines indicate mean values (n = 4). P values are indicated as follows: two 
asterisks, highly significant; asterisk, significant. Uncropped images of blots 
in b are shown in Supplementary Information, Fig. S7.
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Taken together, our results reveal two major functions of LAP2α in 
vivo. First, it is required for localizing a subfraction of A-type lamins in 
the nuclear interior (Supplementary Information, Fig. S1). The existence 
of a nucleoplasmic pool of lamin A, as opposed to the stable lamina-
forming pool at the nuclear periphery, has been described before16, 
but the molecular mechanisms of lamin A targeting were unclear. Our 
hypothesis is consistent with earlier findings showing that the loss of 
nucleoplasmic A-type lamins during myoblast differentiation in vitro17 
and on entering senescence5 is linked to a downregulation or loss of 
LAP2α. Second, our study provides strong evidence for a function of 
the nucleoplasmic, LAP2α-associated A-type lamins in regulating early 
progenitor cell proliferation in regenerative tissues in vivo. Several obser-
vations indicate a role of A-type lamin–LAP2α complexes in the pRb 
pathway: first, pRb was deregulated (hyperphosphorylated) and E2F–
pRb target genes were upregulated in LAP2α-deficient cells on contact-
inhibition-mediated growth arrest and in affected tissues; second, the 
effects of LAP2α on cell-cycle progression depend on its pRb-binding 
and lamin-binding domains and on the presence of pocket proteins; and 
third, the set of tissues affected in Lap2α−/− mice was similar to that in 
pRb-deficient animals. LAP2α and pRb18 are dispensable for self-renewal 
of lin−Sca-1+c-Kithigh haematopoietic cells, but they affect the cell-cycle 
exit of early erythroid progenitors during erythropoiesis12,13. LAP2α-
deficient and pRb-deficient epidermis19 and intestine20 show an impaired 
balance between proliferation and differentiation of transit amplifier 
cells. However, LAP2α-linked phenotypes are milder than those caused 
by pRb deficiency, because pRb is not absent from Lap2α−/− cells but 
functionally impaired, and LAP2α deficiency may affect only a subset 
of pRb functions. Although at present we do not have any experimental 
evidence for an interaction of LAP2α with the closest relatives of pRb, 
namely p107 and p130, we cannot completely rule out possible effects 
of LAP2α on other pocket proteins.
Loss of p16, which may also cause hyperphosphorylation of pRb, 
could have consequences similar to those of LAP2α loss in mice. Indeed, 
hyperproliferation of haematopoietic21 and neural stem cells22 and of 
pancreatic island cells23 was described in aged p16-deficient mice. The 
different cell types affected in LAP2α-deficient and p16-deficient mice 
may be explained by the different expression profiles of these proteins.
Our data suggest that LAP2α-mediated targeting of A-type lamins 
to the nucleoplasm regulates pRb activity in early progenitor cells to 
maintain a proper balance between proliferation and differentiation 
(Supplementary Information, Fig. S1). Whereas multipotent stem cells 
(for example haematopoietic stem cells), which express little LAP2α and 
no lamin A/C (refs 24, 25), are not affected by LAP2α loss, this mecha-
nism may be highly relevant for stem-cell-derived, lineage-committed 
progenitors, which start to express lamin A/C and have high levels of 
LAP2α. We consider our findings to be highly relevant for laminopathic 
diseases in humans3, suggesting that mutations in LMNA or LAP2 may 
impair early progenitor cells in tissue regeneration6. This hypothesis is 
supported by recent studies showing impaired function of adult stem 
cells on expression of progeria-linked lamin variants26–28. 
MeTHOds
Targeted disruption of the Lap2α gene. To generate LAP2α-isoform-deficient 
mice, we made a targeting construct allowing conditional deletion of the LAP2α-
specific exon 4 in the mouse Lap2 gene on chromosome 10, which encodes six 
isoforms7. The targeting vector contained a neomycin resistance cassette, flanked 
by flipase recognition target recombination sites, upstream of exon 4, as well as 
Cre-recombinase-specific loxP sites at the 5´ end of the neo gene and the 3´ end of 
exon 4 (Supplementary Information, Fig. S2a). The targeting construct comprised 
a 6.5-kilobase (kb) 5´ homologous region including exons 2 and 3, and a 3.2-kb 3´ 
homologous region including exon 5, derived from genomic Lap2-containing bac-
terial artificial chromosome (BAC) clones from Genome Systems (Lap2-genomic 
22427). It also contained a diphtheria toxin gene after the 3´ homology arm as a 
negative selection marker for random insertion. For cloning of the targeting con-
struct, see Supplementary Information. The targeting construct was introduced into 
embryonic stem cells, and clones were tested for homologous recombination by 
Southern blot analyses (Supplementary Information, Fig. S2c). Heterozygous clones 
were used for blastocyst injection, and chimaeric offspring were derived with sub-
sequent germline transmission of the floxed allele. Heterozygotes were intercrossed 
to obtain viable homozygous offspring, which were crossed with transgenic mice 
ubiquitously expressing the Cre recombinase10. Homozygous Lap2α knockout mice 
were further crossed with wild-type C57BL/6 mice to remove the Cre recombinase 
gene. Mice were maintained in accordance with the procedures outlined in the Guide 
for the Care and Use of Laboratory Animals. Animal experiments were performed 
in accordance with permission from the Austrian authorities and under National 
Institutes of Health guidelines. Adult mice were analysed between 3 and 12 weeks 
after birth. PHZ (Sigma-Aldrich, St Louis, MO, USA) was dissolved in PBS and 
injected intraperitoneally at 60 mg kg−1. Haematocrit was determined from tail-vein 
blood with the Vet animal blood count (Scil Animal Care). Genotyping of mice was 
performed as described in Supplementary Information.
Isolation and analyses of primary fibroblasts. Primary fibroblasts were isolated 
one to three days postnatally from back skin as described29. Cells were cultivated in 
high-glucose DMEM medium, 10% fetal calf serum, 50 U ml−1 penicillin, 50 µg ml−1 
streptomycin and 0.2 µM l-glutamine (all from Invitrogen, Carlsbad, CA, USA) at 
37 °C and 5% CO2. Experiments were performed between passages 1 and 3. For anal-
ysis of cell growth, 105 cells were seeded on six-well plates and cell numbers and cell 
volume were determined daily with a CASY counter Model TTC (Schärfe System, 
Reutlingen, Germany). For transfection experiments, modified pEGFP-C1 (Clontech 
Laboratories, Palo Alto, CA, USA) encoding full-length LAP2α (amino-acid residues 
1–693, derived from pTD15 (ref. 30)) or a LAP2α deletion mutant (residues 1–414, 
derived from pSV12 (ref. 30)) with amino-terminal GFP tags, or empty pEGFP-C1 
were transiently transfected into primary skin fibroblasts with Lipofectamine LTX 
(Invitrogen). Labelling with BrdU was performed with the 5-bromo-2´-deoxyuridine 
labelling and detection kit I (Roche, Mannheim, Germany). Apoptosis was analysed 
by TdT-mediated dUTP nick end labelling (TUNEL) reaction, using the in situ cell 
death detection kit/TMR red (Roche). Positive cells were analysed with an Axiovert 
200M microscope (Zeiss, Jena, Germany).
For subcellular fractionation31, isolated nuclei were resuspended in 500 µl of 
hypotonic buffer per 107 cells (10 mM HEPES pH 7.4, 10 mM NaCl, 5 mM MgCl2, 
1 mM EGTA, 1 mM dithiothreitol, and protease inhibitor cocktail from Roche) 
and 8.5% sucrose. Suspensions were mixed with NaCl to 50 or 200 mM, and solu-
ble and insoluble fractions were separated by centrifugation for 30 min at 16,000g 
at 4 °C, and analysed by immunoblotting. SDS–PAGE and immunoblotting were 
performed as described31.
Reverse transcription (RT–) PCR. Poly(A)+ mRNAs were isolated and reverse 
transcribed as described4. Complementary DNAs were normalized to actin expres-
sion levels. PCR amplification was performed with GoTaq Green Master Mix 
(Promega, Madison, WI, USA) using primers specific for mouse LAP2α, LAP2, 
lamin A/C, PCNA, cyclin E and E2F1. For primer sequences see Supplementary 
Information. Ethidium bromide-stained bands on agarose gels were quantified 
with Adobe Photoshop version 8.0.
Haematoxylin/eosin staining and immunofluorescence microscopy. Tissues 
were dipped into prechilled 2-methylbutane and snap-frozen in liquid nitro-
gen. Cryosections were obtained with the Cryostat HM500 OM at −23 °C. 
Alternatively, tissues were fixed in 4% formaldehyde (Rotifix; Roth, Karlsruhe, 
Germany), dehydrated, embedded in paraffin and sectioned with a Leica RM 
2155 microtome. Staining with haematoxylin/eosin was performed using the 
tissue-processing system Pat Histo ASS-1.
For immunofluorescence microscopy, cryosections were fixed in 3.7% for-
maldehyde (Merck) in PBS. Paraffin sections were rehydrated and incubated for 
60 min in citrate buffer (1.8 mM citric acid solution, 8.2 mM sodium citrate) at 
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100 °C. Sections were incubated for 30 min in 0.1% Triton X-100 in PBS, blocked 
with goat serum (Vectastain; Vector Labs, Burlingame, CA, USA), and incubated 
with antibodies and Hoechst dye as described32. Immunofluorescence micro-
scopy of cells was performed as described32. Where indicated, fibroblasts were 
synchronized in G1 by the addition of 5 µg ml−1 aphidicolin (Sigma-Aldrich) 
overnight before staining. Fluorescence intensity measurement was performed 
with LSM Imaging software (Zeiss). To determine the intensity ratio of nucleo-
plasm to rim, nucleoplasmic and peripheral intensity values were determined 
along a nuclear axis and averaged (ratio = average intensity of nucleoplasm/
average intensity of rim).
Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting 
(MACS). Spleen and bone marrow were squashed through a 70-µm cell strainer, 
washed with PBS, centrifuged and resuspended in 1–2 ml of PBS/0.2% BSA. Of 
this suspension, 50 µl was mixed with Fc block (CD16/CD32, BD Biosciences, 
Franklin Lakes, NJ, USA) and stained with primary antibodies for 30 min on 
ice. Samples were washed, resuspended in PBS/0.2% BSA and analysed with the 
BD FACSCalibur system. Data were quantified with FlowJo software (Tree Star). 
For MACS, 2 × 107 spleen cells were stained with phycoerythrin (PE)-labelled 
Ter119 antibody (BD Biosciences) for 30 min on ice, washed, resuspended in 
PBS/0.2% BSA and incubated with anti-PE MicroBeads (Miltenyi Biotec, Auburn, 
CA, USA). Cells were resuspended in PBS/0.2% BSA and Ter119-positive cells 
were collected with the autoMACS separator (Miltenyi Biotec).
Antibodies. The following antibodies were used: monoclonal antibodies against 
LAP2 and LAP2β (ref. 31), lamin A/C (1E4, a gift from Frank McKeon)33, p27 
(F8; Santa Cruz Biotechnology, Santa Cruz, CA, USA), cytokeratin 10 (MAB3230, 
Chemicon, Temecula, USA), desmoplakins 1 and 2 (Progen Biotechnik, Heidelberg, 
Germany), total Rb (G3-245; BD Biosciences) and PCNA (BD Biosciences); 
and polyclonal antibodies against LAP2α (ref. 32), lamin A/C (N18; Santa Cruz 
Biotechnology), Ki67 (Novocastra Laboratories, Newcastle, UK), p16 (M156; Santa 
Cruz Biotechnology), p107 (C18; Santa Cruz), cytokeratin 5 (AF138; Covance, 
Berkeley, CA, USA), plectin (provided by Gerhard Wiche), involucrin (Covance), 
RbS780 and RbS807/811 (Cell Signaling Technologies, Beverly, MA, USA), anti-
PARP p85 fragment (Promega) and actin (A-2066; Sigma-Aldrich). For FACS 
analyses we used biotin-labelled anti-CD71, PE-labelled anti-Ter119, PE-labelled 
anti-c-Kit, fluorescein isothiocyanate-labelled anti-Sca-1 and biotin-labelled line-
age cocktail (all from BD Biosciences).
Statistical analyses. Statistical analyses were performed with Microsoft Office 
Excel 2003. Student’s t-test was used to calculate P values (two-tailed unless stated 
otherwise, α level 0.05). Percentages were converted to arcsin values before sta-
tistical analysis.
Note: Supplementary Information is available on the Nature Cell Biology website.
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Figure S1 Model depicting the function of LAP2α. LAP2α targets a subfraction 
of lamin AC from the peripheral lamina to the nucleoplasm, where the complex 
interacts with pRb and represses the expression of pRb/E2F-dependent 
cell cycle regulatory genes. In the absence of LAP2α nucleoplasmic lamin 
A/C is lost and pRb’s repressor activity is impaired. While cell proliferation 
and differentiation of early progenitor cells in regenerating tissues is 
balanced in wild-type tissues, LAP2α-deficient cells hyperproliferate due 
to the deregulated pRb pathway. Despite hyperproliferation, differentiation 
appears normal, but several control mechanisms (?) may keep the number of 
differentiated cells within a narrow window.
Figure S1  Model depicting the function of LAP2?? LAP2? 
targets a subfraction of lamin AC from the peripheral 
lamina t  the nucleopl sm, where the co plex int racts 
with pRb and represse  the expr ssion of 
pRb/E2F-dependent c ll cycl  regulatory genes. In the 
absence of LAP2? nucleoplasmic lamin A/C is lost and 
pRb’s repressor activity is impaired. While cell proliferation 
and differentiation of early progenitor cells in regenerating 
tissues is balanced in wild-type tissues, LAP2?-deficient 
cells hyperproliferate due to the deregulated pRb pathway. 
Despit  hyperproliferation, differentiation appears norm l, 
but several control me hanis s (?) ay keep the number 
of differentiated cells within a narrow window. xxxxxxxxxxx 
x x x x x x x x x x x x x x x x x x x x x  
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Figure S2 Targeted inactivation of Lap2α. (a) Schematic representation of the 
Lap2 gene locus, the targeting vector, and the targeted allele. NcoI restriction 
sites, FRT (yellow triangles) and loxP (blue triangles) recombination sites, exons 
(boxes), the Pgk-neo and the diphtheria toxin cassette (DT) are shown. The 
position of the probe used for Southern blotting and the expected fragments 
are indicated. (b) PCR analysis of genomic DNA prepared from tail biopsies 
of wild-type (wt), heterozygous floxed (wt/floxed), homozygous floxed (floxed), 
heterozygous (wt/ko) and homozygous knockout (ko) mice. A schematic drawing 
of the wild-type, floxed and deleted Lap2 alleles is shown and positions of 
primers are indicated. (c) Southern blot analysis of NcoI-digested genomic DNA 
from wild-type (+/+) and heterozygous floxed (+/floxed) ES cell clones, using 
the probe shown in (a). (d, e) Immunoblot analyses of lysates from primary 
fibroblasts (d) isolated from newborn wild-type (+/+), heterozygous (+/−) and 
homozygous knockout (−/−) mice, and from heart and intestine tissue (e) 
prepared from 2 months old mice, using pan LAP2 antibody, detecting all LAP2 
isoforms. Actin was stained as a loading control. Numbers indicate molecular 
masses of marker proteins in kDa. (f) Immunofluorescence of wild-type (+/+) 
or LAP2α knockout (−/−) fibroblasts stained with antibodies to LAP2β or LAP2. 
Confocal images are shown. Bar, 10 μm. (g) Reverse transcriptase (RT-) PCR 
of mRNA from primary fibroblasts using primers for LAP2α, LAP2 isoforms 
(indicated on the right), lamin A/C, and actin to normalize for mRNA amounts. 
Numbers denote corresponding marker bands and their length in bp.
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Figure S2  Targeted inactivation of Lap2?. (a) Schematic 
representation of the Lap2 gene locus, the targeting 
vector, and the targeted allele. NcoI restriction sites, FRT 
(yellow triangles) and loxP (blue triangles) recombination 
sites, exon  (boxes), the Pgk-n o and the diphtheria toxin 
cassette (DT) are shown. The position of the probe used 
for So thern blotting and the expected fragments are 
indicated. (b) PCR analysis of genomic DNA prepared 
from tail bi p ies of ild-type (wt), heterozygous floxed 
( t/floxe ), h mozygous floxed (floxed), heterozygous 
(wt/ko) and homozygous knockout (ko) mice. A schematic 
rawing of the wild-type, floxed and delet d Lap2 alleles is 
shown and positions of primers ar  indicated. (c) Southern 
blot analysis of NcoI-digested genomic DNA from wild-type 
(+/+) and heterozygous floxed (+/floxed) ES cell clones, 
using the probe shown in (a). (d, e) Immunoblot analyses 
of lysates from primary fibroblasts (d) isolated from 
newborn wild-type (+/+), heterozygous   (+/?) and 
homozygous knockout (???) mice, and from heart and 
intestine tissue (e) prepared from 2 months old mice, using 
pan LAP2 antibody, detecting all LAP2 isoforms. Actin was 
stained as a loading control. Numbers indicate molecular 
masses of marker proteins in kDa. (f) Immunofluorescence 
of wild-type (+/+) or LAP2? knockout (???? fibroblasts 
stained with antibodies to LAP2? or LAP2. Confocal 
images are shown. Bar, 10 ?m. (g) Reverse transcriptase 
(RT-) PCR of mRNA from primary fibroblasts using primers 
for LAP2?, LAP2 isoforms (indicated on the right), lamin 
A/C, and actin to normalize for mRNA amounts. Numbers 
denote corresponding marker bands and their length in bp.
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Figure S3 Immortalized LAP2α knockout fibroblasts show impaired cell cycle 
arrest upon contact inhibition. Immortalized skin fibroblasts from LAP2α 
knockout mice and wild-type littermates were seeded at equal cell numbers 
and grown to confluency. Proliferating (Day 4 and 5) or contact inhibited 
(Day 7 and 8) cells were either lysed and processed for immunoblotting 
using antibodies to the indicated antigens (a) or used for BrdU-labeling 
assays (c). Numbers in (a) indicate molecular masses of marker proteins in 
kDa. (b) Mean cell volumes of primary and immortalized fibroblasts were 
determined using a Casy cell counter and plotted in a bar graph. Means ± 
s. d. from 3 independent experiments are shown in (b) and (c). (d) Pictures 
of cells from the indicated time points (see a) were obtained using a Zeiss 
microscope equipped with a Canon digital camera; Magnification: 100x.
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Figure S3  Immortalized LAP2? knockout fibroblasts show 
impaired cell cycle arrest upon contact inhibition. 
Imm rtalized skin fibroblasts from LAP2? knockout mice 
a wild-type litt rmates wer  seeded at equal cell 
number  and grown to confluency. Proliferating (Day 4 and 
5) or contact inhibited (Day 7 and 8) cells were either lysed 
and processed for immunoblotting using antibodies to the 
indicated antigens (a) or used for BrdU-labeling  assays 
(c). Numbers in (a) indicate molecular masses of marker 
proteins in kDa. (b) Mean cell volumes of primary and 
immortalized fibroblasts were determined using a Casy 
ll c unter and plotted in a bar graph. Me s ± . d. from 
3 indep ndent experiments are shown in (b) nd (c). (d) 
Pictures of cells from the indicated time points (see a) were 
obtained using a Zeiss microscope equipped with a Canon 
digital camera; Magnification: 100x.xxxxxxxxxxxxxxxxxxxx
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Figure S4 LAP2α-null mice show no overt pathologies in muscle, heart and 
liver, but enhanced proliferation of progenitors in intestinal tissue.  
(a) Paraffin- or cryosections of indicated tissues isolated from wild-type (+/+) 
and LAP2 α knockout (−/−) mice were stained with haematoxylin/eosin. Bar, 
50 μm. (b) Cryosections of colon were stained with haematoxylin/eosin (upper 
panels) or processed for immunohistochemistry using an antibody to Ki67 
(lower panels). Bar, 50 μm. Bar graphs show the length of the crypt axis (n = 
10) as determined by Axiovision imaging software (left graphs) or the number 
of Ki67-positive cells per crypt (right graphs; n = 8). Means ± s. e. m. are 
shown; p-values are indicated; ** highly significant; * significant. 
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Figure S4  LAP2?-null mice show no overt pathologies in 
muscle, heart and liver, but enhanced proliferation of 
progenitors in intestinal tissue. (a) Paraffin- or cryosections 
of indicated tissues isolated from wild-type (+/+) and LAP2
? knockout (???? mice were stained with 
haematoxylin/eosin. Bar, 50 µm. (b) Cryosect ons of colon 
were stained with haematoxylin/eosin (upper panels) or 
processed for immunohistochemistry using an antibody to 
Ki67 (lower panels). Bar, 50 ?m.  Bar graphs show the 
length of the crypt axis (n = 10) as determined by 
Axiovision imaging software (left graphs) or the number of 
Ki67-positive cells per crypt (right graphs; n = 8). Means ± 
s. e. m. are shown; p-values are indic ted; ** highly 
significant; * significant. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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Figure S5 Lap2α−/− epidermal progenitors have hyperphosphorylated pRb, 
but differentiate normally. (a) Total pRb was immunoprecipitated from 
whole lysates of paw skin and back skin of LAP2α knockout (−/−) or wild-
type control mice (+/+). Precipitates were processed for immunoblotting 
using antibodies to total pRb or LAP2. Arrow denotes phosphorylated pRb. 
Numbers indicate molecular masses of marker proteins in kDa. (b, c) Tissue 
sections of paw epidermis from Lap2+/+ and −/− mice were analyzed by 
immunofluorescence microscopy using antibodies to desmoplakin (DP) 1 
and 2, plectin, involucrin, keratin 10 (K10) or Ki67 as indicated. DNA was 
stained with Hoechst. Confocal images are shown. Bar, 50 μm.
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Figure S5  Lap2???? epidermal progenitors have 
hyperphosphorylated pRb, but differentiate normally. (a) 
Total pRb was immunoprecipitated from whole lysates of 
paw skin and back skin of LAP2? knockout (???? or 
wild-type control mice (+/+). Precipitates were processed 
for immunoblotting using antibodies to total pRb or LAP2. 
Arrow denotes phosphorylated pRb. Numbers indicate 
molecular masses of marker proteins in kDa. (b, c) Tissue 
sections of paw epidermis from L p2+/+ and ??? mice were 
analyzed by im unofluorescence icroscopy using 
antibodies to desmoplakin (DP) 1 and 2, plectin, involucrin, 
keratin 10 (K10) or Ki67 as indicated. DNA was stained 
with Hoechst. Confocal images are shown. Bar, 50 µm. 
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Figure S6 The haematopoietic stem and multipotent progenitor cell 
compartment is not affected in LAP2α knockout mice. (a) Quantitative 
realtime PCR of cDNAs obtained from mRNA of bone-marrow derived 
macrophages (MPs), whole bone marrow (BM), thymus (Thy), spleen (Spl), 
lin-Sca-1+c-Kithigh hematopoietic stem and progenitor cells (LSK), skin 
fibroblasts (Fbl) and heart. Values are depicted as fold difference to heart 
expression levels and represent means ± s. d. from 3 biological replicates. 
(b) Representative flow cytometric profiles of lineage marker negative, 
Sca-1/c-Kit double positive (lin- Sca-1+c-Kithigh) haematopoietic stem and 
progenitor cells in bone marrow of Lap2α−/− mice and wild-type littermate 
controls. LSK fraction of total lineage negative bone marrow cells in % is 
depicted. Values represent means ± s.e.m. (n = 3).
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Figure S6  The haematopoietic stem and multipotent 
progenitor cell compartment is not affected in LAP2? 
knockout mice. (a) Quantitative realtime PCR of cDNAs 
obtained from mRNA of bone-marrow derived macropha-
ges (MPs), hole bone marrow (BM), thymus (Thy), 
spleen (Spl), lin-Sca-1+c-Kithigh hematopoietic stem and 
progenitor cells (LSK), skin fibroblasts (Fbl) and heart. 
Values are depicted as fold difference to heart expression 
levels and represent means ± s. d. from 3 biological 
replicates. (b) Representative flow cytometric profiles of 
lineage marker negative, Sca-1/c-Kit double positive (lin- 
Sca-1+c-Kithigh) haematopoietic stem and progenitor cells in 
bone marrow f Lap2???? mice and wil -type littermate 
controls. LSK fraction of total lineag  negative bone 
marrow cell  in % is d picted. Values represent means ± 
s.e.m. (n = 3). xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
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Figure S7 Full scans of key Western data. (a, b) Full scans of 
immunoblot gels presented in Figure 2b (a) and 5b (b) of the 
manuscript are shown. (a) Primary skin fibroblasts from LAP2α 
knockout mice (−/−) and wild-type (+/+) littermates were seeded at 
equal cell numbers and grown to confluency. Lysates were prepared at 
the indicated time points (see also Figure 2a). (b) Ter119+ spleen cells 
obtained by magnetic cell sorting from LAP2α knockout and wild-type 
control mice were lysed and processed for immunoblotting. Antibodies 
are indicated on the left (a) or below (b) gels. Red parentheses denote 
bands shown in the Figures of the manuscript, if other unspecific bands 
are detectable. Numbers indicate molecular masses of marker proteins 
in kDa. + Ctrl: positive control.
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Figure S7  Full scans of key Western data. (a, b) Full 
scans of immunoblot gels presented in Figure 2b (a) and 
5b (b) of the manuscript are shown. (a) Primary skin 
fibro la ts from LAP2? knockout mice (?????and wild-type 
(+/+) littermate  were seeded at equal cell numb rs and 
grown to confluency. Lysates were prepared at the indica-
ted time points (see also Figure 2a). (b) Ter119+ spleen 
cells obtained by magnetic cell sorting from LAP2? knock-
out and wild-type c ntrol mice were lysed and processed 
for immunoblotting. Antibodie  are indicated on the left (a) 
or below (b) g l . Red parentheses denote b nds shown in 
the Figures of the manuscript, if other unspecific bands are 
detectable. Numbers indicate molecular masses of marker 
proteins in kDa. + Ctrl: positive control. XXXXXXXXXXXX
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SUPPLEMENTARY METHODS 
Cloning of the LAP2α targeting construct 
For construction of the targeting vector we used a BAC clone (Genome Systems, LAP2-
genomic 22427, accession #g238), derived from strain 129 DNA. Oligonucleotide pair  5’-
CCCCCGCGGATAACTTCGTATAATGTAAGCTATACGAAGTTATCCATGGCCC-3’, 5-
GGGCCATGGARAACTTCGTATAGCATACATTATACGAAGTTATCCGCGGGGG-3’ 
containing a loxP site, and 5’-CCCCCATGGAGATCTGATATCCCCGGATCCCCCGGG 
GGG-3’, 5’-CCCCCCGGGGGATCCGGGGATATCAGATCTCCATGGGGG-3’, containing 
required restriction sites were cloned into pBSKS+ (Stratagene, La Jolla, USA) via 
SacII/KpnI, and 5’-CCCGAGCTCGCGGCCGCGAATTCGGGGGTACCGGGCCGCG 
GCCC-3’, 5’-GGGCCGCGGCCCGGTACCCCCGAATTCGCGGCCGCGAGCTCGGG-3’ 
inserted into the generated construct via SacI/SacII resulting in pBK9. Plasmid pDTα 
containing the diphtheria toxin (DT) gene was cut with EcoRI, treated with Klenow enzyme, 
cut with BamHI and the DT gene was inserted into pBK9 via EcoRV/BamHI generating 
intermediate construct 1. A BglII-cut genomic DNA fragment containing exon 5 was inserted 
at the BglII site of intermediate 1 yielding intermediate construct 2. A fragment containing 
exon 3, obtained from a genomic clone by PCR using primer pair 5’-
ACTGGCCGTCGTTTTAC-3’ and 5’-CCCGGTACCAGATCTCACATAAACATGTAAT 
ATGGACC-3’,  and cut with PstI and KpnI was ligated together with an EcoRI/PstI genomic 
DNA fragment containing exon 2 into intermediate 2 resulting in intermediate construct 3. An 
EcoRI fragment of genomic DNA containing intron sequences downstream of exon 1 was 
inserted into this construct yielding intermediate construct 4. Plasmid pK-11 was digested 
with KpnI and SacII to yield a fragment containing the neomycin resistance cassette flanked 
with FRT sites and an upstream loxP site, which was inserted into intermediate construct 4 via 
KpnI/SacII to yield intermediate construct 5.  
© 2008 Macmillan Publishers Limited.  All rights reserved. 
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A PCR fragment containing parts of exon 4, obtained from genomic DNA with the primer 
pair 5’-GGAAACAGCTATGACCATG-3’ and 5’-CCCGGTACCAGATCTCACATAAACA 
TGTAATATGGACC-3’ and cut with ApaI was ligated with an EcoRI/ApaI-digested 
genomic DNA fragment containing exon 4 into pBKS+ via SacII/EcoRI. Next a BsmI/EcoRI 
and a BsmI/BglII fragment containing intron sequences downstream of exon 4 were inserted 
into pBSKS+ via EcoRI/NotI. This and the latter pBSKS+ derived construct were cut with 
SacII/EcoRI and inserted into pBSKS+ via SacII. The SacII fragment of this construct was 
cloned into intermediate construct 5 yielding the targeting construct. 
The targeting vector was linearised with NotI and electroporated into W9.5 ES cells. Clones 
were picked, expanded, and screened for homologous recombinants by Southern blot 
analyses. Genomic DNA of ES cells was digested with NcoI and hybridized with a probe (see 
Fig. S1) containing intron sequences downstream of exon 5 and outside of the homology 
domain of the targeting construct. Southern blot analysis was performed according to standard 
protocols using the AlkPhos Direct CDP-Star System (GE Healthcare Biosciences, NJ, USA) 
for hybridization. Positive clones were injected into C57Bl/6 blastocysts, chimeras were 
derived and bred to produce recombinant offspring as described. 
 
Genotyping of LAP2α knockout mice 
For genotyping, genomic DNA was prepared from tail tips and PCR analyses were performed 
using puRETaq Ready-To-Go PCR beads (GE Healthcare Biosciences, NJ, USA) in a PTC-
200 Peltier Thermo Cycler (TJ Research). Primers used were: 
Exon 4 as: 5’-CACAATCCCTAGAGGACTTCACTT-3’ 
Intron after Exon 4 as: 5’-CTGTGACTTTGCTGGCCTTCCAGTCTA-3’ 
Exon 3 s: 5’-CAGGGAACTGAATCGAGATCCTCTAC-3’ 
TN5-3: 5’-GCCCTGAATGAACTGCAGGACG-3’  
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Primers used for expression analysis 
LAP2α/LAP2: 
LAP2f: 5’-GTGGGAACAACCAGGAAGCTATATGA-3’ 
LAP2αr: 5’-TGAGTGCCTGCTGTGCATCACTA-3’  
LAP2r: 5’-TTCTGACTTGACATCTGCCAAGG-3’ 
Lamin A/C: 
LACf: 5’-CATCAAGCTGGCCCTGGACATGGAG-3’ 
LACr: 5’-TGCGCCTTCCACACCAAGTCAGTAG-3’ 
PCNA: 
PCNAf: 5’-GATGCCGTCGGGTGAATTTG-3’ 
PCNAr: 5’-TGGTTACCGCCTCCTCTT CT-3’ 
E2F1: 
E2F1f: 5’-ACGCTATGAAACCTCACTAAA-3’ 
E2F1r: 5’-AGGACATTGGTGATGTCATA-3’ 
 
Immunohistochemistry of tissues 
For immunohistochemistry, frozen sections were fixed in 3.7% formaldehyde (Merck, NJ, 
USA) in PBS, washed, permeabilised and treated with 2% H2O2 in PBS plus 0.3% goat serum 
for 15 minutes. After blocking with goat serum (Vectastain; Vector Labs, Burlingame, CA, 
USA), primary antibodies diluted in 0.1% gelatine/0.1% Triton-X 100 in PBS were applied 
either 1 hour at room temperature or overnight at 4°C. Samples were then washed and 
incubated in biotinylated secondary antibodies (Vector Laboratories). Sections were washed 
in PBS and Elite ABC Reagent (Vectastain Elite ABC Kit from Vector Laboratories) was 
applied for 30 minutes. Sections were treated for 2-10 minutes with DAB staining solution 
(DAB substrate kit for peroxidase from Vector Laboratories), counterstained in haematoxylin 
(Sigma), washed thoroughly, dehydrated and mounted in Entellan (Merck). 
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Quantitative PCR analyses 
For quantitative PCR of LAP2α expression levels, cDNAs from different tissues were 
produced as described in the Methods section. PCR amplification was performed using the 
MESA GREEN qPCR MasterMix Plus for SYBR Assay I TTP (Eurogentec, Seraing, 
Belgium) and primers specific for mouse LAP2α (see above) on the MasterCycler ep realplex 
(Eppendorf, Hamburg, Germany). 
 
Immunoprecipitation of pRb from skin lysates 
Paw and back skin from LAP2α-deficient mice and wild-type littermates was isolated and 
homogenised in mouse lysis buffer (25 mM HEPES pH 7.5, 25 mM Tris-HCl pH 7.5, 100 
mM NaCl, 5 mM MgCl2, 10 mM EGTA, 0.1% Tween-20, 0.5% NP-40, 0.4% Triton X-100, 1 
mM PMSF, 1 mM DTT, 20 µm cytochalasin B, 0.25 mg/ml DNAse I, 0.05 mg/ml RNAse A, 
protease inhibitor cocktail from Roche, 0.5 mM β-glycerol phosphate, 1 mM sodium-
orthovanadate) using the precellys 24 homogenizer with 2.8 mm ceramic beads (Peqlab, 
Erlangen, Germany). 2 mg protein from total lysates were imunoprecipitated using antibodies 
to pRb (G3-245 from BD Biosciences, Franklin Lakes, NJ, USA) and fast flow sepharose G 
(Sigma, Munich, Germany) according to standard protocols. Immunoprecipitates were 
washed three times in lysis buffer and processed for Western blotting. 
 
Microscopy equipment and settings 
Microscopy of haematoxylin/eosin stained sections was done on a Zeiss Axio Imager.M1 
equipped with a Zeiss AxioCam MRc5 and Axiovision LE software, version 4.5. All 
immunofluorescence microscopy samples were viewed in a Zeiss Axiovert 200M microscope 
equipped with a Zeiss LSM510META confocal laser-scanning unit, an alpha Plan-Fluor 
100x/1,45 Oil (a=0,11mm) and a Plan-Apochromat 63x/1.40 Oil DIC MC27 (a=0.19mm) 
objective (Zeiss) using LSM imaging software (Zeiss). Images were prepared with Adobe 
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Photoshop software. Fluorochromes used were either Texas Red (Jackson Immuno Research, 
West-Grove, USA) or Alexa Fluor 488 (Molecular Probes, Inc., Eugene, OR, USA), coupled 
to appropriate secondary antibodies. 
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• Title of qualification awarded  Diploma in Molecular Biology
   
Additional Certificates “Deutsches Sprachdiplom, zweite Stufe”, an international diploma of German language 
acquired in 1999, recognized as fulfilling German language entry requirements by German 
universities.
“First certificate in English” grade A – certificate of competence in English awarded by 
university of Cambridge for candidates whose mother tongue is not English, acquired in 1999. 
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SCIENTIFIC PUBLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC ORAL 
PRESENTATIONS 
 
 
 
 
 
 
 
 
 
SCIENTIFIC POSTER 
PRESENTATIONS 
 
 ? Ivana Gotic, Michael Leschnik, Ursula Kolm, Mato Markovic, Bernhard J. Haubner, 
Katarzyna Biadasiewicz, Bernhard Metzler, Colin L. Stewart and Roland Foisner:. 
       LAP2α loss impairs heart function and stress response in mice. Submitted manuscript 
  
? Ivana Gotic, Wolfgang M. Schmidt, Katarzyna Biadasiewicz, Michael Leschnik, Rita Spilka, 
Juliane Braun, Colin L. Stewart and Roland Foisner 
        Loss of LAP2α Delays Satellite Cell Differentiation and Affects Postnatal Fibre Type 
        Determination. Submitted manuscript 
 
? Naetar, Nana; Korbei, Barbara; Kozlov, Serguei; Dorner, Daniela;Kerenyi, Marc; Kral, 
Rosana; Gotic, Ivana; Fuchs, Peter; Cohen Tanya; Bittner Reginald; Stewart, Colin L. and 
Foisner, Roland. 
       Loss of nucleoplasmic LAP2α–lamin A complexescauses erythroid and epidermal 
        progenitor hyperproliferation. Nat Cell Biol. 2008 Nov;10 (11):1341-8  
 
? Ćukušić, Andrea; Ivanković, Milena; Škrobot, Nikolina; Ferenac, Marina; Gotić, Ivana; 
Matijašić, Mario; Polančec, Denis; Rubelj, Ivica. 
Spontaneous senescence in MDA-MB-231 cell line. Cell proliferation. 39 (2006): 205-
216. 
? Ivanković, Milena; Ćukušić, Andrea; Gotić, Ivana; Škrobot, Nikolina; Matijašić, Mario; 
Polančec, Denis; Rubelj, Ivica. 
Telomerase activity in HeLa cervical carcinoma cell line proliferation. Biogerontology. 
8(2) (2007): 163-172. 
 
 
? Role of Lamina-associated polypeptide 2α in striated muscle differentiation and 
regeneration 
        The Multiple Faces of Lamins in Aging & Disease, EMBO Workshop, January 6-9, 2009, 
         Vienna Austria 
? Role of Lap2α – Lamin A complexes in muscle differentiation and regeneration. 
Annual Euro-laminopathies Meeting, March 22-24, 2007, Rome, Italy. 
? Role of Lap2α – Lamin A complexes in muscle differentiation and regeneration. 
        Anatomy and Embryology of the Mouse, EMBO Practical Course, September 9-17, 2006, 
        Zagreb, Croatia.  
 
 
? Ivana Gotic and Roland Foisner: Role of Lap2α – Lamin A complexes in muscle 
differentiation and regeneration. 
Advances in Stem Cell Research, EMBO Conference Series, October 12-14, 2007, 
Stockholm, Sweden. 
? Ivana Gotic and Roland Foisner: Role of Lap2α – Lamin A complexes in muscle 
differentiation and regeneration. 
Muscle Development and Regeneration Workshop, Myores Network of Excellence, 
September 19-22, 2007, Berlin, Germany. 
? Ivana Gotic and Roland Foisner: Role of Lap2α – Lamin A complexes in muscle 
differentiation and regeneration. 
International PhD conference, June 24-26, 2007, Cambridge, UK. 
? Ivana Gotic and Roland Foisner: Role of Lap2α – Lamin A complexes in muscle 
differentiation and regeneration. 
3. PhD-Symposium of the Medical University of Vienna, June 21-22, 2007, Vienna, Austria. 
? Andrea Ćukušić, Milena Ivanković, Ivana Gotić, Ivica Rubelj: Isolation and 
characterization of senescent cells from immortal human cell line MDA-MB-231. 
Second congress of Croatian geneticists. September 24-27, 2005, Supetar, Brač, Croatia. 
? Milena Ivanković, Ivana Gotić, Andrea Ćukušić, Ivica Rubelj: Telomerase activity during 
growth of HeLa cells. Second conress of Croatian geneticists. September 24-27, 2005, 
Supetar, Brač, Croatia.  
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SCIENTIFIC WORKSHOPS 
 
 ? EMBO Practical Course Anatomy and Embryology of the Mouse, September 9-17, 2006, 
        Zagreb, Croatia.  
 
? EMBO Workshop The Multiple Faces of Lamins in Aging & Disease, January 6-9, 2009, 
        Vienna Austria 
 
 
SCIENTIFIC SYMPOSIA  Participated in organization of 2 Vienna Biocenter PhD student symposia: 
? Timing age, 4th VBC PhD Student Symposium, Vienna, Austria, November 2-3, 2006 
? Molecules to Mind, 5th VBC PhD Student Symposium, Vienna, Austria, November 15-16, 
2007 
 
 
MOTHER TONGUE  Croatian 
 
OTHER LANGUAGES 
 
  English 
• Reading skills  excellent 
• Writing skills  excellent 
• Verbal skills  excellent 
 
  German 
• Reading skills  excellent 
• Writing skills  excellent 
• Verbal skills  excellent 
 
  French 
• Reading skills  basic 
• Writing skills  basic 
• Verbal skills  basic 
 
  Spanish 
• Reading skills  basic 
• Writing skills  basic 
• Verbal skills  basic 
 
 
TECHNICAL SKILLS  
AND COMPETENCES 
 
 COMPETENT WITH MOST MICROSOFT OFFICE AND ADOBE PC APPLICATIONS 
 
DRIVING LICENCE  Category B 
 
SOCIAL SKILLS 
AND COMPETENCES 
 
 TEAM WORK, TOLERANCE, FLEXIBILITY, PATIENCE, DISCIPLINE, COMMUNICATION, RESPONSIBILITY 
 
 
